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pulmonary particulate transport requires related biofluid physicochemical properties.
Aims included measuring the effects of common aerosol drugs on artificial saliva and
diffusivities of asthma medications in mucus. Artificial saliva solutions doped with
asthma medications were characterized by pH, interfacial tension, and rheology. To
measure diffusion, drug concentration was monitored by time-dependent FTIR spectra,
and diffusivity obtained using Fick’s second law. Measured theophylline and albuterol
diffusivities were ca. 10-6 cm2/s.
Surface Modification of Polymer Films with Light-Emitting Chemicals. To
develop a polymer film system that changed color in response to radiation, acid groups of
poly(ethylene-co-acrylic acid) were used to attach two light-emitting polymers: 4(octyloxy)-4-biphenylcarboxylic acid and 2,7-bis(bromomethyl)-9,9-dihexyl-9Hfluorene. Each reaction step was confirmed using static contact angle goniometry, FTIR
spectroscopy, and X-ray photoelectron spectroscopy. UV-Vis and fluorescence
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spectroscopy measured the absorption spectra. Modified films were irradiated (=254
nm) and produced blue emissions.

DEDICATION
This thesis is dedicated to my fiancé and best friend, Zach Wynne, who never lets
me give up on myself and cheers me on in every aspect of life, my parents, Mark and
Linda Cornell, for always encouraging me and supporting every one of my adventures,
and to my sister Chelsea, for always making me laugh when I need it most.

ii

ACKNOWLEDGEMENTS
These research efforts could not have been completed without the help and
assistance of many people. Most importantly, I’d like to thank my advisor Dr. Keisha
Walters. Without her giving me a chance to prove myself, I would never have achieved
as much as I did or really learned my true potential. Her academic and personal guidance
has transformed a graduate degree from a dream to a reality, and I’m grateful to have had
such an excellent advisor during this process. I’d also like to thank the members of my
committee, Dr. Bill Elmore and Dr. Priscilla Hill, for their time and feedback both in the
classroom and in my research throughout my time at MSU.
The other graduate students in the PolySEL group have contributed in so many
ways to my research as well as my overall experience at Mississippi State. They have not
only helped in endless ways in the lab and in the classroom, but I truly value their
friendship as well. Thank you Caitlin Naske, Zach Wynne, Erick Vasquez, Ersan Eyiler,
Mat Rowe, and Maryam Dadgarmoghaddam!
I’d also like to thank my family, who have supported me in every endeavor, have
offered advice whenever needed, and can always make me laugh. I learned my work ethic
from my dad, perseverance from my mom, and sense of humor and optimism from my
sister. The love and encouragement of my fiancé and best friend Zach has also been
essential to my achievements in graduate school. Without them, I would not be where I
am today.

iii

I greatly appreciate all of the help from Dr. Jonathan Frisch with the UV-Vis and
fluorescence spectroscopy on the light-sensitive films project, as well as Maria CebadaRicalde for her help with UV illumination of the films. Thank you to Ersan Eyiler for
running XPS on my samples, and to Dr. Mark Bricka for use of the rheometer. Also,
thank you to Jennifer Miller with help running samples. Thank you to Entergy and the
National Science Foundation [EPS-0903787], through the Mississippi EPSCoR program,
for funding this research.

iv

TABLE OF CONTENTS
Page
DEDICATION.................................................................................................................... ii
ACKNOWLEDGEMENTS............................................................................................... iii
LIST OF TABLES...............................................................................................................x
LIST OF FIGURES ........................................................................................................... xi
CHAPTER
I.

INTRODUCTION TO ARTIFICIAL SALIVA, AEROSOL DRUGS,
AND MODELING DIFFUSION OF DRUGS THROUGH
PULMONARY MUCUS ...................................................................................1
1.1
1.2
1.3
1.4
1.5
1.6
1.7

II.

Background ............................................................................................1
Types of Asthma Treatments .................................................................3
Saliva......................................................................................................5
Mucus.....................................................................................................6
Drug Inhalation, Deposition, and Diffusion ..........................................8
Research Objectives.............................................................................10
References............................................................................................11

CHARACTERIZATION OF THE PHYSICOCHEMICAL
PROPERTIES OF NEAT AND DRUG-DOPED ARTIFICIAL
SALIVA...........................................................................................................13
2.1
2.2
2.3

Abstract ................................................................................................13
Introduction..........................................................................................14
Materials and Methods.........................................................................17
2.3.1 Drugs..............................................................................................17
2.3.2 Artificial Saliva Components and Modifying Substances .............17
2.3.3 Preparation of Standard Artificial Saliva Solutions.......................18
2.3.4 Preparation of Altered Artificial Saliva Solutions .........................19
2.3.5 pH Measurements of Neat and Drug-Doped Artificial
Salivas ............................................................................................20
2.3.6 Interfacial Tension Measurements.................................................20
2.3.7 Shear Rate and Viscosity Measurements .......................................21
v

2.4

Results..................................................................................................21
2.4.1 pH of Neat Saliva Solutions and Drug-Doped Saliva
Solutions ........................................................................................21
2.4.2 Interfacial Tension .........................................................................23
2.4.3 Rheology ........................................................................................30
2.5
Conclusions..........................................................................................35
2.6
References............................................................................................37
III.

DIFFUSION OF THEOPHYLLINE AND ALBUTEROL THROUGH
ARTIFICIAL MUCUS ....................................................................................39
3.1
3.2

Abstract ................................................................................................39
Introduction..........................................................................................39
3.2.1 Mucus Diffusion using ATR-FTIR................................................43
3.3
Materials and Methods.........................................................................46
3.3.1 Materials ........................................................................................46
3.3.1.1
Diffusants...........................................................................46
3.3.1.2
Preparation of Artificial Mucus .........................................47
3.3.2 Methods: FTIR Spectroscopy ........................................................47
3.4
Results and Discussion ........................................................................48
3.4.1 Data Collection ..............................................................................48
3.4.2 Data Analysis .................................................................................51
3.5
Conclusions..........................................................................................58
3.6
References............................................................................................59

IV.

INTRODUCTION TO POLYMER SURFACE MODIFICATION
USING LIGHT-EMITTING POLYMERS .....................................................61
4.1
4.2
4.3
4.4
4.5
4.6

V.

Background: Polymer Surface Modification .......................................61
Uses of Light-Emitting Polymers ........................................................64
Classes of Light-Emitting Polymers ....................................................66
Research Objectives.............................................................................70
Approach..............................................................................................71
References............................................................................................72

MODIFICATION AND CHEMICAL GRAFTING OF
POLY(ETHYLENE-CO-ACRYLIC ACID) FILMS ......................................75
5.1
5.2
5.3

Abstract ................................................................................................75
Introduction..........................................................................................75
Materials and Methods.........................................................................79
5.3.1 Materials ........................................................................................79
5.3.2 FTIR Spectroscopy ........................................................................79
5.3.3 Contact Angle Goniometry ............................................................80
5.4
Results and Discussion ........................................................................80
5.4.1 Preliminary Reactions of EAA Film..............................................80
vi

5.4.2 Primary Reactions of EAA Films ..................................................82
5.4.2.1
Reaction Path “A”: Grafting of OBC.................................82
5.4.2.2
Reaction Path “B”: Grafting of BDMF..............................85
5.4.3 Static Contact Angle Results .........................................................90
5.5
Conclusions..........................................................................................93
5.6
References............................................................................................94
VI.

OPTICAL PROPERTY CHARACTERIZATION OF EAA-OBC
AND EAA-BDMF POLYMER FILMS ..........................................................96
6.1
6.2
6.3

Abstract ................................................................................................96
Introduction..........................................................................................97
Materials and Methods.........................................................................99
6.3.1 Materials ........................................................................................99
6.3.2 Methods........................................................................................100
6.3.2.1
UV-Vis Spectroscopy ......................................................100
6.3.2.2
Fluorescence Spectroscopy..............................................100
6.3.2.3
UV Lamp Illumination.....................................................100
6.3.2.4
FTIR Spectroscopy ..........................................................100
6.4
Results and Discussion ......................................................................101
6.4.1 UV-Vis Spectroscopy ..................................................................101
6.4.2 Fluorescence Spectroscopy..........................................................102
6.4.3 UV Lamp Illumination.................................................................105
6.4.4 FTIR and Fluorescence Spectroscopy of 6 Month Old
Films ............................................................................................106
6.5
Conclusions........................................................................................111
6.6
References..........................................................................................112

VII.

RECOMMENDATIONS...............................................................................113
7.1
7.2

Recommendations for Artificial Saliva .............................................113
Recommendations for Light-sensitive Polymer Films ......................114

APPENDIX
A

FTIR METHODS: ATR, TRANSMISSION, AND DRIFTS .......................116
A.1
A.2
A.3
A.4

FTIR Methods: ATR, Transmission, and DRIFTS............................117
FTIR Set-Up.......................................................................................117
Data Collection and Use of OMNIC Software ..................................121
Sample Set-Up ...................................................................................128
A.4.1 Veemax II ATR............................................................................128
A.4.2 MIRacle ATR...............................................................................131
A.4.3 DRIFTS........................................................................................132
A.4.4 Transmission FTIR ......................................................................134
vii

B

SURFACE ANALYSIS AND DEPTH OF PENETRATION: A
COMPARISON OF DIFFERENT SURFACE-SENSITIVE FTIR
TECHNIQUES ..............................................................................................136
B.1
B.2
B.3
B.4
B.5

C

COMPRESSION MOLDER OPERATIONAL GUIDELINES AND
PRODUCTION OF EVOH FILMS USING COMPRESSION
MOLDING.....................................................................................................146
C.1
C.2

D

E.2

Determination of Optimal Reaction Times for Preliminary
EAA Surface Modification Steps.......................................................160
References..........................................................................................165

GRATING OF POLY(ETHYLENE GLYCOL DIACRYLATE) TO
AMINE SURFACE-MODIFIED EAA FILMS.............................................166
F.1
F.2
F.3

G

Instrument Specifications...................................................................153
Instrument Set-Up..............................................................................153
Static Contact Angle ..........................................................................155
Pendant Drop .....................................................................................156
References..........................................................................................158

DETERMINATION OF OPTIMAL REACTION TIMES FOR
PRELIMINARY EAA SURFACE MODIFICATION STEPS .....................159
E.1

F

Compression Molder Operational Guidelines ...................................147
Using the Compression Molder to Make EVOH Films.....................150

CONTACT ANGLE GONIOMETRY OPERATIONAL
GUIDELINES FOR DATA COLLECTION AND ANALYSIS ..................152
D.1
D.2
D.3
D.4
D.5

E

Introduction to Surface Chemistry Characterization Methods ..........137
Depth of Penetration ..........................................................................141
Depth of Penetration: Comparing ATR Techniques..........................142
Comparing spectra of ATR Techniques ............................................143
References..........................................................................................145

Introduction........................................................................................167
Results................................................................................................167
References..........................................................................................171

NANOPARTICLES IN DRUG DIFFUSION ...............................................172
G.1
G.2
G.3
G.4
G.5

Introduction........................................................................................173
Characteristics of Nanoparticles ........................................................173
Fate of Nanoparticles in the Lung......................................................175
Nanoparticles in Inhalation Medicine................................................176
Toxicity of Nanoparticles ..................................................................179
viii

G.6
G.7

Conclusions........................................................................................180
References..........................................................................................182

ix

LIST OF TABLES
TABLE

Page

2.1

Artificial Saliva Compositions [Preetha and Banerjee, 2005]. ..........................19

3.1

Summary of measured diffusivity coefficients for theophylline and
albuterol in artificial mucus................................................................................57

5.1

Summary of average contact angle values for surface-modified EAA
films at each reaction step. .................................................................................92

B.1

Tabulated Summary of Commonly used ATR-FTIR Crystal Properties
Important for Crystal Selection [Pike Technologies, 2011].............................139

B.2

Table of Refractive Indices [Kazarian and Chan, 2010], Incidence
Angles, and Calculated Depth of penetration (dp) ranges for an EAA
film sample (n2=1.408) for the four ATR crystal options available in our
laboratories. ......................................................................................................143

D.1

Reference static contact angles for standard materials.....................................157

E.1

Carbonyl peak height values for the transformation from carboxylic acid
(1700 cm-1) to acid chloride (1795 cm-1) during the reaction of EAA
with PCl5 to form EAA-Cl. ..............................................................................162

E.2

Peak height values for functional groups of interest in the reaction of
EAA-Cl to EAA-NH2.......................................................................................164

x

LIST OF FIGURES
FIGURE

Page

1.1

Chemical structures of the asthma treatments used in this study:
albuterol, theophylline, KI, and fluticasone propionate and salmeterol
xinafoate, respectively, which in combination constitute Advair®. ....................5

1.2

Depiction of gel and sol mucus layers above the pulmonary epithelial
cells with cilia penetrating the sol layer. ..............................................................7

1.3

Depiction of human lung generations. .................................................................9

2.1

Chemical structures of asthma drugs used in this study.....................................17

2.2

pH data for neat and drug-doped artificial saliva solutions. ..............................22

2.3

Average interfacial tension values for three artificial salivas (X1, X2,
and Saliveze) and natural saliva [A: Preetha and Banerjee, 2005; B:
Kasakov, 2009]. Error bars represent 95% confidence intervals. ......................25

2.4

Comparison of IFT for artificial saliva solutions with and without the
addition of mucus and/or phosphatidylserine (PS), compounds
representative of those found in natural saliva...................................................26

2.5

Interfacial tension of drug-doped X1 saliva solution. IFT of neat X1
(67.24 mN/m) indicated by blue dashed line. ....................................................27

2.6

Interfacial tension of drug-doped X2 saliva solution. IFT of neat X2
(69.31 mN/m) indicated by blue dashed line. ....................................................28

2.7

Interfacial tension of drug-doped saliveze saliva solution. IFT of neat
saliveze (IFT 67.05 mN/m) indicated by blue dashed line.................................29

2.8

Viscosity versus shear rate for neat artificial saliva solutions and natural
saliva [*Preetha and Banerjee, 2005, ^Vissink et al., 1984]. .............................32

2.9

Plot of viscosity versus shear rate for comparison of neat xialine 1 to
drug-doped xialine 1...........................................................................................33

xi

2.10

Plot of viscosity versus shear rate for comparison of neat xialine 2 to
drug-doped xialine 2...........................................................................................34

2.11

Plot of viscosity versus shear rate comparing neat (unmodified) saliveze
to drug doped saliveze........................................................................................35

3.1

Illustration of gel-sol mucus structure above the pulmonary epithelial
cells with beating cilia penetrating the sol layer. ...............................................41

3.2

Chemical Structures of theophylline (left) and albuterol (right)........................46

3.3

Schematic of the experimental FTIR diffusion set-up. The artificial
mucus layer is sandwiched between a layer of the drug-doped solution
and the ATR-FTIR crystal. Not to scale. ..........................................................48

3.4

ATR-FTIR spectra for a concentration series of theophylline in IPA. ..............49

3.5

Time-resolved ATR-FTIR spectra collected over 600 sec for the
diffusion of a 25 mg/mL theophylline/IPA solution through a 3.5 mm
artificial mucus layer. .........................................................................................50

3.6

Stacked spectra of the artificial mucus components. Boxed peaks around
~1640 cm-1 are of interest due to the overshadowing the peaks have on
secondary amine peaks in the drugs. ..................................................................51

3.7

Theophylline concentration profile based on measured FTIR peak
height fitted to a linear function. ........................................................................52

3.8

Schematic representation of boundary conditions applied to the mucusdrug diffusion system. ........................................................................................54

3.9

Comparison of experimental and calculated concentrations for a 10mg/mL theophylline-IPA solution diffusing through an artificial mucus
layer. ...................................................................................................................56

4.1

Chemical structure of poly(p-phenylenevinylene) (PPV). .................................67

4.2

Chemical structure of polyacetylene (PA). ........................................................68

4.3

Chemical structure of polyfluorene (PF)............................................................69

4.4

Chemical structure of the repeat unit for polydiacetylene (PD).........................70

4.5

Chemical structure of 4-(octyloxy)-4-biphenyl carboxylic acid (OBC). ..........71

4.6

Chemical structure of 2,7-bis (bromomethyl)-9,9-dihexyl-9H-fluorene
(BDMF). .............................................................................................................71
xii

5.1

Chemical structures of OBC (a) and BDMF (b). ...............................................78

5.2

Reaction schematic of the preliminary reaction steps of EAA prior to
reactions with light-sensitive chemicals.............................................................81

5.3

ATR-FTIR spectra of preliminary film reactions steps: (a) EAA-Neat,
(b) EAA-Cl, (c) and EAA-NH2. .........................................................................81

5.4

Conversion of carboxylic acid of OBC chemical to acid chloride.....................83

5.5

Reaction schematic of the reaction steps of EAA-NH2 with acid chloride
converted OBC chemical to EAA-OBC.............................................................83

5.6

ATR-FTIR spectra of preliminary film reactions steps: EAA-Neat (a),
EAA-Cl (b), EAA-NH2 (c), and EAA-OBC (d).................................................84

5.7

FTIR spectral comparison of OBC chemical and EAA-OBC reacted
film. The peaks used to identify OBC on the surface of EAA-OBC are
boxed around both spectra..................................................................................85

5.8

Reaction schematic of the reaction steps of EAA-NH2 with BDMF
chemical to form EAA-BDMF...........................................................................86

5.9

ATR-FTIR spectra of preliminary film reactions steps: EAA-Neat (a),
EAA-Cl (b), EAA-NH2 (c), and EAA-BDMF (d). ............................................87

5.10

FTIR spectral comparison of BDMF chemical and EAA-BDMF reacted
film. The peaks used to identify BDMF on the surface of EAA-BDMF
are boxed around both spectra............................................................................88

5.11

Transmission FTIR spectra of the preliminary step reaction films, as
well as the final reaction products, EAA-OBC and EAA-BDMF. ....................89

5.12

Representative image of a sessile droplet showing the intermolecular
forces used to calculate the static contact angle. ................................................91

5.13

From left, EAA-Neat, EAA-Cl, EAA-NH2, and EAA-OBC static
contact angle images. .........................................................................................93

5.14

From left, EAA-Neat, EAA-Cl, EAA-NH2, and EAA-BDMF static
contact angle images. .........................................................................................93

6.1

Chemical structures of OBC (a) and BDMF (b). ...............................................98

6.2

Visible spectrum with wavelengths for each color range [Madigan,
2011]...................................................................................................................99

6.3

UV-Vis spectra for EAA-Neat, EAA-Cl, EAA-NH2, and EAA-OBC.............101
xiii

6.4

UV-Vis spectra for EAA-Neat, EAA-Cl, EAA-NH2, and EAA-BDMF..........102

6.5

FS spectra for EAA-Neat, EAA-Cl, EAA-NH2, and EAA-OBC.....................103

6.6

FS spectra for EAA-Neat, EAA-Cl, EAA-NH2, and EAA-BDMF..................104

6.7

Films prior to UV irradiation (a) and during irradiation (b). ...........................105

6.8

MIRacle-ATR FTIR spectral comparison of newly made EAA-OBC
film with EAA-OBC film after 6 months.........................................................106

6.9

MIRacle ATR FTIR spectral comparison of newly made EAA-BDMF
film with EAA-BDMF film after 6 months. ....................................................107

6.10

FS spectra of EAA-OBC film after six months and newly made EAAOBC film for comparison.................................................................................108

6.11

FS spectra of EAA-BDMF film after six months and newly made EAABDMF film for comparison..............................................................................109

6.12

UV illumination of six month old EAA-BDMF (left) and EAA-OBC
(right) at a wavelength of 254 nm. ...................................................................110

A.1

Airline valve setup in PolySEL Lab 180..........................................................118

B.1

Spectra collection using a single-bounce attenuated total reflectance
(ATR) FTIR accessory. ....................................................................................141

B.2

Comparison of MIRacle and Veemax ATR spectra for an EAA-NH2
film with absorbance presented on a common scale. .......................................144

C.1

Main power source switch................................................................................147

C.2

Picture indicating red switch for powering compression molder.....................148

C.3

Instrument control panel...................................................................................148

C.4

Carver, Inc. compression molder (model 3893.4PR1A00). .............................149

C.5

EVOH film produced at 190 C and 4000 lbf without drying pellets. .............151

C.6

EVOH film produced at 190 C 4000 lbs. with dried pellets...........................151

D.1

Kruss EasyDrop Contact Angle Goniometer with syringe loaded...................153

D.2

Images depicting the proper syringe (left) and syringe plunger (right)
placement on the Kruss EasyDrop Contact Angle Goniometer. ......................154
xiv

E.1

Primary reaction steps for surface modification of EAA film: conversion
of carboxylic acid to acid chloride using PCl5 and subsequent
conversion to primary amines using ethylene diamine. ...................................160

E.2

ATR-FTIR spectra of EAA-Cl films at reaction times of 0, 5, 15, 35,
and 45 minutes showing progressive decrease in the acid carbonyl (at
~1700 cm-1) and increase in the acid chloride carbonyl (at ~1795 cm-1).........161

E.3

ATR-FTIR spectra of EAA-NH2 films at reaction times of 0, 60, 90, and
150 min and 24 hours—with and without sonication. Sonicated films
had complete surface reaction with the ethylene diamine, while
unsonicated films contained some unreacted surface –Cl groups
(presence of peak at ~1800 cm-1). ....................................................................163

F.1

Chemical structure of poly(ethylene glycol diacrylate) (PEGD). ....................167

F.2

Reaction scheme for the reaction of PEGD with EAA-NH2............................169

F.3

ATR-FTIR spectra of EAA-NH2 (2), EAA-PEGD575-Acetone (3a),
EAA-PEGD575-Toluene (3b), EAA-PEGD258-Acetone (4a) and EAAPEGD258-Toluene (4b). Spectral peaks of interest are boxed. .......................170

xv

CHAPTER I
INTRODUCTION TO ARTIFICIAL SALIVA, AEROSOL DRUGS, AND MODELING
DIFFUSION OF DRUGS THROUGH PULMONARY MUCUS
1.1

Background
The implementation of inhalation aerosol drugs has been one of the most

successful and effective treatments for respiratory illnesses. This delivery mechanism has
allowed for the direct application of therapeutic drugs to damaged, diseased, or distressed
lungs needing immediate treatment. Asthma is one of the most common respiratory
illnesses treated by aerosol drugs. Studies of the various types of inhalation drugs have
led to improvements in the treatment of asthma and how they can promote reversal of
bronchoconstriction (immediate response treatment) or act as preventative agents to
provide continuous systemic therapy against the emergence of bronchoconstriction
[Volsko and Reed, 2000].
Aerosols are also being investigated as treatments for other ailments, such as
diabetes. An inhalation form of insulin called Oralin®, a high-velocity fine particle
aerosol, was developed as an alternate delivery method for insulin for diabetic patients.
The invasiveness of current diabetes treatments provoked the interest in using aerosols to
control the disease. The small particle size and direct deposition into the lungs resulted in
more rapid absorption and metabolic control than the previous methods of subcutaneous
injection [Modi, 2005]. Insulin bioavailability can reach 37% with inhalation
administration as opposed to 1% via oral, sublingual nasal or transdermal administration
1

[Todoroff and Vanbever, 2011]. Infection in the lungs of cystic fibrosis (CF) patients is
also an ailment for which the use of aerosol drugs is being investigated. Pseudomonas
aeruginosa is an infection that is nearly impossible to cure with antibiotics and is a
leading cause of death in CF patients. Due to the denser, more highly glycosylated
pulmonary mucus of CF patients, it is increasingly difficult to diffuse any treatments
through these layers to treat the P. aeruginosa. Photodynamic antimicrobial therapy was
found to be a successful treatment by delivering photosensitizers to the lungs through
inhalation. Delivery of red light at 635 nm and two photosensitizers across artificial CF
mucus was successful, validating the theory of using aerosols as treatments for CF
complications [Donnelly et al., 2007, Khanvilkar et al., 2001]. Recent research has also
investigated the use of nanoparticle agglomerate suspensions composed of asthma
treatments fluticasone and/or albuterol. The resulting aerosols contained an ideal watersoluble nanostructure as well as a range of particle diameters from 1-5 micron, which can
be tailored for localized treatments. This method would be a solution to the recurring
issue of drug particle size, exhalation of nanoparticle (>0.5-1 micron in diameter) sized
drugs, and poor water solubility by some drugs in saliva and pulmonary mucus. A
tailored drug particle size avoids the physiological barriers of the lung physiology and
delivers the drug to the desired lung region [El-Gendy et al., 2011, Todoroff and
Vanbever, 2011].
Along with research on current and developing treatments for asthma, other
factors affecting the efficiency of aerosol treatments need to be investigated to result in
the most effective treatment for lung inflammation. Saliva, being the ultimate carrier of
the aerosols to the lungs, needs to be considered when engineering aerosol drugs, as well
as the pulmonary mucus that serves as a protective barrier for the lungs while obstructing
2

the diffusion of the drugs to the lung surface. Drugs need to be designed to diffuse
through the viscous mucus layer quickly while retaining their medicinal properties.
Model mucus membranes have been developed, as well as mathematic simulation models
for the diffusion of the drugs through mucus. Lipophilicity has been found to be one of
the most influential characteristics of the ability of drug diffusion, as well as particle size
[Larhed et al., 1997].
The deposition patterns and diffusion mechanisms of the drugs are also under
intense investigation. Understanding drug properties, deposition patterns, drug-mucus
interactions, and drug diffusion will ultimately lead to the development of the least
invasive, most effective drug that will diffuse the lung mucus at the highest concentration
and in the fastest manner. Developments in this field could contribute to an even wider
range of illnesses being treated with aerosol drugs.
1.2

Types of Asthma Treatments
Aerosols are frequently used as a delivery mechanism in the lungs for the

treatment of respiratory and systemic illnesses. Compared to other drug delivery
methods, smaller dosages, low cost and minimal side effects, bypassing of the digestive
system, non-invasiveness, chemical stability, patient compliance, and faster action make
inhalation drug delivery worth further investigation and development [Chan, 2006].
Significant advances have been made, especially in the past decade, for the
treatment of respiratory illnesses via pulmonary drug delivery [Chan, 2006]. Treatments
range from fast acting rescue 2-receptor agonists and systemic corticosteroids to longterm medications that prevent lung inflammation and control of diseases such as asthma
[Chan, 2006; Volsko and Reed, 2000]. Aerosol fast-acting 2-receptor agonists are
3

typically the treatment of choice of most physicians due to their effectiveness in relaxing
the bronchoconstriction by binding to the 2-receptors of the bronchial smooth muscle.
Fast acting 2-receptor agonists also have minimal systemic absorption and side effects.
Corticosteroids, when administered short-term and in high doses, can speed the resolution
of bronchoconstriction as well as lessen the likeliness of relapse. Systemic effects limit
this treatment to short term for acute attacks [Volsko and Reed, 2000]. Long-term
treatments are administered to patients to provide continuous therapy and eliminate or
lessen the frequency and severity of attacks. These drugs prevent the
bronchoconstriction that cause asthma attacks as well as control acute symptoms.
Treatment types include long-acting 2-receptors, corticosteroids, and leukotriene
modifiers, which block the immune system chemicals that cause asthma symptoms,
leukotrienes, from affecting the body [Mayo Clinic, 2010].
Some of the most common drugs used in the treatments of asthma include
albuterol/salbutamol, a short-acting 2-receptor agonist, prednisone, a systemic
corticosteroid, salmeterol and theophylline, both long-acting 2-receptor agonists, or an
anti-inflammatory corticosteroid, such as fluticasone [Volsko and Reed, 2000]. Other
long-term treatments include drugs such as Advair®, a salmeterol-fluticasone propionate
mixture and Singulair®, a leukotriene modifier comprised of montelukast sodium.
Theophylline was one of the most widely used treatments for asthma for decades as both
a fast-acting and long-acting treatment, however, due to misuse, abuse, toxicity with high
doses, and difficulty determining the optimal dosage [Volsko and Reed, 2000], albuterol
surpassed theophylline as the leading treatment for fast-acting asthmatic management.
Theophylline is still used as a long-term treatment, but with increased patient monitoring.
Albuterol/salbutamol, on the other hand, is most commonly used in rescue situations as a
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response to an asthma attack. Albuterol is one of the most effective immediate treatments
when inhaled via aerosol inhaler, since it provides direct effect to the inflamed bronchial
smooth muscle. Potassium iodide (KI), an expectorant, is another treatment that thins
mucus secretions in the respiratory tract, making it easier for patients to clear the airway
by coughing. KI is not a commonly used treatment for asthma. This research focuses on
four asthma treatments: albuterol/salbutamol, theophylline, KI, and Advair®. The
chemical structures of these drugs can be seen in Figure 1.1.

Figure 1.1

1.3

Chemical structures of the asthma treatments used in this study: albuterol,
theophylline, KI, and fluticasone propionate and salmeterol xinafoate,
respectively, which in combination constitute Advair®.

Saliva
Saliva is a complex biological fluid that first contacts the inhaled pharmaceuticals.

The three human salivary glands, parotid, submandibular, and sublingual glands [Rossetti
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et al., 2008], secret saliva at a rate of approximately 1.5 liters per day [Preetha and
Banerjee, 2005, Juniper et al., 1995]. It is an aqueous non-Newtonian slightly alkaline
fluid comprised primarily of water, lipids, glycoproteins, and digestive enzymes [Preetha
and Banerjee, 2005]. Saliva has many functions that contribute to mouth lubrication,
digestion, management of oral microbes [Rossetti et al., 2008], and has recently been
investigated as a biomarker for diseases and the detection of systemic illnesses [Schipper
et al., 2007].
Artificial saliva can act as a close replicate for patients who lack an adequate
amount of natural saliva to satisfy the body’s functions. Artificial salivas must be as close
as possible in a biophysical capacity to the physiological properties of natural saliva. For
research purposes, artificial salivas must model natural saliva accurately for the validity
of any conclusions. Properties such as viscosity, wettability, interfacial and viscoelastic
tension, and uniformity must be closely replicated [Levine, 1993].
1.4

Mucus
Mucus is a viscous secreted fluid that is produced by goblet cells and sub-mucosa

glands of mucous membranes as a protective barrier [Todoroff and Vanbever, 2011,
Hombach and Bernkop-Schnurch, 2010]. It is secreted at a rate of approximately one liter
per day in the human body [Hombach and Bernkop-Schnurch, 2010]. Mucus contains
antiseptic enzymes, immunoglobulins, proteins, and glycoproteins (mucins). It covers the
entire airway and protects the membrane against bacteria and other foreign agents that
enter the lung. Mucus exists in two layers: an upper gel phase and a lower sol phase. The
upper gel phase is 95% water, 2% mucin, and the remainder salts, proteins, and lipids.
The lower sol layer is less viscous, which allows for cilia beating [Todoroff and
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Vanbever, 2011]. Figure 1.2 illustrates the setup of the gel-sol mucus layer on top of the
pulmonary epithelial cells and beating cilia.

Figure 1.2

Depiction of gel and sol mucus layers above the pulmonary epithelial cells
with cilia penetrating the sol layer.

In the respiratory system, the mucus protects the lungs by trapping foreign
particles that enter the respiratory tract and lungs. By protecting the lungs from foreign
particles, the lung mucus also acts as a barrier that impedes the diffusion of drug
particulates. The structure of the mucosal barrier is one of the most influential factors
against the diffusion of particles. Mucin causes the viscoelastic property of mucus and is
the backbone of the cross-linked network structure of mucus. [Khanvilkar et al, 2001].
The crosslinking phenomenon is caused by disulfide bridges and hydrophobic bonds of
polymerized mucin aggregate rods [Khanvilkar et al, 2001]. In addition, mucus is
hydrophobic due to the presence of several phospholipids [Khanvilkar et al, 2001].
When making artificial mucus, several factors must be considered. The artificial
mucus must be close in viscosity to natural mucus in order to accurately mimic the
viscosity differences between mucus and saliva. In using a more complex artificial mucus
network, any resulting conclusions regarding useful diffusion and air-liquid interface
behavior observations will be increasingly accurate. Valid conclusions can be made for
7

inhaled drug behavior when the artificial system is a close to natural physiologic
characteristics as possible.
1.5

Drug Inhalation, Deposition, and Diffusion
Understanding the fate of aerosol drugs in the lungs is essential to the therapeutic

properties of treatments provided by the drugs. Chemical interaction is an important
characteristic to consider, since the pharmacodynamic response is determined by these
interactions [Todoroff and Vanbever, 2011]. Drugs that are quickly uptaken by
pulmonary macrophages provide rapid response to ailing lungs, while uptake by other
cell types may redirect the drugs to another pathway, deeming them ineffective to their
desired pathway [Todoroff and Vanbever, 2011]. Drugs must also be small enough to
avoid being swept away by cilia in the lung epithelial cells (mucociliary clearance), but
large enough to avoid being exhaled. In order to minimize the amount of exhaled
particles and dose variability, particles should be greater than 0.5-1 m. These particles
will settle in the central and distal tracts of the lung by gravitational settling [Todoroff
and Vanbever, 2011]. Particles less than 1 m are most likely to be exhaled [El-Gendy et
al., 2011]. Ultrafine particles less than 100 nm can reach the alveolar region, where
systemic drug absorption occurs, by Brownian motion [Todoroff and Vanbever, 2011].
Particles in the range of 1-3 m also reach the alveolar region, while particles 3-10 m
deposit in the tracheo-bronchial tree for airway treatment [Todoroff and Vanbever, 2011].
The structure of the lung tissue that interacts with the inhaled particles is largely
dependent on the airway generation where the particle deposits. The particle deposition
location is based on the aerodynamic diameter of the aerosol particle, and is a function of
particle density, particle diameter and particle dynamic shape factor [Todoroff and
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Vanbever, 2011]. Drug behavior at the air-liquid interfaces also needs to be evaluated.
Proteins, protein aggregation, and particle immersion must also be considered [Todoroff
and Vanbever, 2011].
Lung geometry is the last important factor to consider when modeling particle fate
with inhalation drugs. Lungs are similar to inverted trees, with a large trunk (the trachea)
and branches that are bifurcated into many generations, with the largest generations
branching off the trachea and becoming increasingly smaller with thicker lung walls
[Gehr et al., 1990]. The thinner, larger generations, where drugs are most likely
deposited, have more ideal properties such as larger surface area and thinner lung walls
for drug diffusion [Martonen and Katz, 1993, Gehr et al., 1990]. A depiction of lung
geometry can be seen in Figure 1.3.

Figure 1.3

Depiction of human lung generations.
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1.6

Research Objectives
Using the information provided from previous sections, a comprehensive

understanding of asthma, treatments of the disease, the geometry of the lung, and mucus
and saliva properties has been formed. This study investigates the physicochemical
properties of saliva and mucus that impact the ultimate fate of the drug being
administered and its bioavailability. Three artificial salivas were made and evaluated for
pH, interfacial tension and rheological properties in both the neat and drug-doped forms.
It is also important to understand the path of the particulates that exist in these inhalation
drugs through the respiratory tracts, deposition patterns, and the ultimate bioavailability
of these medications. By using representative drug-doped solutions and an artificial
mucus layer, materials and transport parameters can be measured for modeling the
behavior of drug particles in the human lung.
Once the evaluation of the data demonstrated how the drugs affect the physical
properties of saliva, the diffusivity properties of the drugs were then tested. Two drugs,
theophylline and albuterol, were then selected for diffusion experimentation using an
artificial mucus. Using Fick’s second law of diffusion, the diffusivity coefficients of the
drugs through the mucus were determined.
This research is part of a larger project that models the deposition pattern of drug
particulates on the surface, and then follows the drug particulates through the mucus layer
to the lung surface. The mucus layer compositions are also being investigated. This part
of the research focuses on the effects of the drugs on the properties of saliva and
pulmonary mucus, as well as the diffusion of the drug particles though the mucus layer.
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CHAPTER II
CHARACTERIZATION OF THE PHYSICOCHEMICAL PROPERTIES OF NEAT
AND DRUG-DOPED ARTIFICIAL SALIVA
2.1

Abstract
Three artificial saliva solutions, xialine 1, xialine 2, and saliveze, were prepared

and their properties compared to natural/physiological saliva. The interfacial tensions of
the saliva solutions were evaluated in addition to rheological properties. All three
artificial saliva solutions varied minimally (1.62-8.46%) from the interfacial tension
values given for natural saliva in the literature [Preetha and Banerjee, 2005; Kasakov,
2009]. The artificial salivas were more viscous than natural saliva at all shear rates
evaluated by rheology. Each saliva solution was then doped with four drugs used in the
treatment of asthma: albuterol/salbutamol, theophylline, potassium iodide (KI), and
Advair®. KI, salbutamol and Advair® consistently increased the interfacial tension
measurements. Albuterol and theophylline gave inconsistent interfacial tension results
showing both increased and decreased values. The salbutamol- and Advair®-doped
salivas consistently demonstrated lower viscosities over the shear rate ranges examined
(0.1-100 s-1) as compared to the neat salivas. Theophylline had minimal impact on the
viscosity of the saliva solutions. At lower shear rates, KI-doped salivas were more
viscous than the neat salivas, but varied minimally from the neat solutions at higher shear
rates. pH data was also collected for the neat and drug doped saliva solutions. Albuterol
and theophylline produced minimal changes in the saliva solutions, as well as producing
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both increases and decreases in pH levels. KI and Advair® produced consistent increases
in pH levels for all three saliva solutions.
2.2

Introduction
Drugs can be aerosolized using a propellant as a pulmonary drug delivery

mechanism for the treatment of respiratory and systemic illnesses. Inhalation drugs have
been researched as treatment options for conditions such as asthma [Chan, 2006; Volsko
and Reed, 2000], diabetes [Modi, 2005; Todoroff and Vanbever, 2011], and cystic
fibrosis [Donnelly et al., 2007; Khanvilkar et al., 2001], among others. Chemical
stability, patient compliance, low cost, and small dosages [Chan, 2006] make inhalation
drug delivery systems worth further investigation and development.
With inhalation drugs, the drug particles are typically either dry powder or
dissolved in an aqueous solution dispensed as small droplets. Regardless of the medium
used to carry the drug to the lung, the drug arrives to the lung with some saliva that gets
inhaled with each breath. It is therefore important to consider the properties of saliva
when researching and modeling drug interactions with the lung. In addition,
understanding the complexity of salivary composition and biological function could lead
to the development of new salivary substitutes that can combat a number of oral diseases
and disorders. Saliva is multifunctional and contributes to not only general health, but
also plays major roles in mouth lubrication [Preetha and Banerjee, 2005; Schipper et al.,
2007], the management of oral microbes [Rossetti et al., 2008] and digestion [Preetha and
Banerjee, 2005; Schipper et al., 2007]. Additionally, saliva has been recently investigated
as a provider of biomarkers for diseases and the detection of systemic illnesses [Schipper
et al., 2007].
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Saliva is a complex natural fluid secreted by human salivary glands (parotid,
submandibular and sublingual glands, and minor salivary glands on the tongue [Schipper
et al., 2007]) at about 1.5 liters per day [Juniper et al., 1995]. Saliva is an aqueous nonNewtonian fluid [Juniper et al., 1995] comprised mostly of water (99.5%), proteins
(0.3%), and inorganic and trace constituents (0.2%) [Schipper et al., 2007]. The proteins
that are found in saliva are mostly glycoproteins [Schipper et al., 2007; Juniper et al.,
1995], enzymes, immunoglobulins, antimicrobial peptides [Schipper et al., 2007], and
lipids [Juniper et al., 1995]. The inorganic portion of saliva contains the standard
electrolytes found in bodily fluid but at different concentrations, which causes saliva to
be a hypotonic fluid [Schipper et al., 2007].
Saliva has many functions in the body, and artificial saliva acts as a close
replicate for patients who lack enough natural saliva for the body’s lubrication,
mucoadhesive, and protective needs [Juniper et al., 1995]. The artificial saliva used to
model natural saliva for experimental purposes must be as close as possible in a
biophysical capacity for the accuracy and validity of any conclusions. Asthmatic patients
deal not only with inflamed and constricted airways, but also more viscous saliva
[Shimura et al., 1988; Keal, 1971]. Studying the effects of pharmaceutical treatments
have on the viscosity and interfacial tension of saliva is crucial to understanding the
impact these drugs can have on the physiological properties of saliva.
Since initial investigations into asthma inhalation drugs in the early 1900s
[Volsko and Reed, 2000], many subtypes of inhalation treatments have been developed.
Currently, inhalation-based asthma treatments range from fast-acting “rescue” 2receptor agonists to long-acting 2-receptor agonists that prevent lung inflammation and
control the disease [Ullman and Svedmyr, 1998; Volsko and Reed, 2000]. This study
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investigates four drugs (albuterol/salbutamol, theophylline, potassium iodide, and a
fluticasone/salmeterol mixture) that are used in the treatment of asthma.
Albuterol (salbutamol) is a fast-acting bronchodilator that can be administered
through an inhaler or a nebulizer. It is the most commonly used fast-acting treatment for
acute asthmatic symptoms. Albuterol can be applied as either a fast-acting rescue
treatment or a long-acting treatment [Chan, 2006, Juniper et al., 1995], and is typically
administered in solution with saline. Theophylline is a methylxanthine drug initially used
in the 1920s [Hendel and Weinberger, 1983]. It is a bronchodilator and respiratory
stimulant that can be used as a fast-acting treatment for acute symptoms or can be
administered for long-acting relief as well. Potassium iodide (KI) is an expectorant that
works by thinning mucous secretions and reduces chest congestion [Hendel and
Weinberger, 1983]. The fourth drug is a 2:1 mixture of fluticasone propionate and
salmeterol xinafoate marketed commercially as Advair. Fluticasone is a corticosteroid
and is used for anti-inflammatory purposes, and salmeterol, which has also been used by
itself as a treatment for asthma, is used to treat the constriction of the airways
[GlaxoSmithKline, 2010]. Figure 2.1 shows the chemical structures of all the drugs
being investigated. The work presented compares some physicochemical characteristics
of three artificial salivas, and examines how the addition of asthma medications affects
the saliva properties.
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Fi g ur e 2. 1
2. 3
2. 3. 1

C h e mi c al str u ct ur es of ast h m a dr u gs us e d i n t his st u d y.

M at e ri als a n d M et h o ds
D r u gs
T h e f oll o wi n g dr u gs w er e us e d as t h e i n h al ati o n a er os ol tr e at m e nts i n t his st u d y:

t h e o p h ylli n e ( > 9 8 %, T CI A m eri c a, C A S 5 8- 5 5- 9), al b ut er ol s ulf at e ( 0. 0 8 3 % al b ut er ol i n
s ol uti o n, N e p hr o n P h ar m a c e uti c al C or p or ati o n, C A S 5 1 0 2 2- 7 0- 9), s al b ut a m ol ( M P
Bi o m e di c als, C A S 1 8 5 5 9- 9 4- 9), p ot assi u m i o di d e ( ³ 9 9 %, Fis h er S ci e ntifi c, C A S 7 6 8 1 1 1- 0) a n d fl uti c as o n e pr o pi o n at e/s al m et er ol xi n af o at e 1 0 0 m c g/ 5 0 m c g ( c o m m er ci al n a m e
A d v air ® , Gl a x o S mit h Kli n e).
2. 3. 2

A rtifi ci al S ali v a C o m p o n e nts a n d M o dif yi n g S u bst a n c es
T h e c h e mi c als us e d t o m a k e t h e artifi ci al s ali v as, as w ell as t h e c h e mi c als us e d t o

alt er t h e n e at s ol uti o ns, w er e o bt ai n e d fr o m Si g m a Al dri c h ( St. L o uis, M O, U S A), V W R
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( W est C h est er, P A, U S A) a n d Fis h er S ci e ntifi c ( H a m pt o n, N H, U S A). T h e artifi ci al
s ali v a c o m p o n e nts ar e x a nt h a n g u m ( 9 0- 1 0 0 %, M P Bi o m e di c al, C A S 1 1 1 3 8- 6 6- 2),
c al ci u m c hl ori d e ( A C S R e a g e nt Gr a d e, 9 0- 1 0 0 %, M P Bi o m e di c al, 1 0 0 4 3- 5 2 - 4),
m a g n esi u m c hl ori d e ( M P Bi o m e di c al), s o di u m c hl ori d e ( ³ 9 9 %, Fis h er S ci e ntifi c, C A S
7 6 4 7- 1 4- 5), di- p ot assi u m h y dr o g e n ort h o p h os p h at e ( 9 8 %, A cr os Or g a ni cs, C A S 7 7 5 8 1 1- 4), p ot assi u m di- h y dr o g e n ort h o p h os p h at e ( ³ 9 9 %, A cr os Or g a ni cs, C A S 7 7 7 8- 7 7- 0),
D-s or bit ol ( 9 7 %, A cr os Or g a ni cs, C A S 5 0- 7 0- 4), s o di u m c ar b o x y m et h yl c ell ul os e ( 9 9 %,
T CI A m eri c a, C A S 9 0 0 4- 3 2- 4), m et h yl- p- h y dr o x y b e n z o at e ( N F gr a d e, Pf alt z a n d B a u er,
I n c., C A S 9 9- 7 6- 3), s o di u m fl u ori d e ( 9 9 %, Alf a A es ar, C A S 7 6 8 1- 4 9- 4), p ot assi u m
c hl ori d e, a n d f o o d gr a d e s pirit of l e m o n ( M c C or mi c k br a n d “ p ur e l e m o n e xtr a ct). H P L C
gr a d e w at er ( Fis h er S ci e ntifi c, C A S 7 7 3 2- 1 8- 5) w as us e d i n t h e pr e p ar ati o n of all
a q u e o us s ol uti o ns. S o m e m o difi c ati o ns w er e m a d e t o t h e artifi ci al s ali v a s ol uti o ns b y
a d di n g c o m p o n e nts, m u ci n ( b o vi n e s u b m a xill ar y gl a n ds T y p e 1- S, Si g m a), a n d/ or
p h os p h ati d yls eri n e ( P S, > 9 8 %, Fl u k a Bi o c h e mi k a, C A S 5 1 4 4 6- 6 2- 9).
2. 3. 3

P r e p a r ati o n of St a n d a r d A rtifi ci al S ali v a S ol uti o ns
T hr e e artifi ci al s ali v a s ol uti o ns w er e us e d f or all e x p eri m e nt al p ur p os es. Xi ali n e 1

( X 1) a n d xi ali n e 2 ( X 2) ar e m ai nl y c o m p os e d of x a nt h a n g u m, w hil e s ali v e z e is b as e d o n
s o di u m c ar b o x y m et h yl c ell ul os e a n d s or bit ol. T h e c o m p ositi o ns a n d c o n c e ntr ati o ns of t h e
c o m p o n e nts of t h es e s ali v a s ol uti o ns w er e o bt ai n e d fr o m Pr e et h a a n d B a n erj e e [ 2 0 0 5]
a n d ar e s h o w n i n T a bl e 2. 1.
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Table 2.1

Artificial Saliva Compositions [Preetha and Banerjee, 2005].

Artificial Saliva Components
Xialine 1 (g/L) Xialine 2 (g/L) Saliveze (g/L)
Xanthan gum
0.92
0.18
----Sodium carboxymethylcellulose
--------10.00
Potassium chloride
1.20
1.20
0.62
Sodium chloride
0.85
0.85
0.87
Magnesium chloride
0.05
0.05
0.06
Calcium chloride
0.13
0.13
0.17
Di-potassium hydrogen orthophosphate
0.13
0.13
0.80
Potassium di-hydrogen orthophosphate
--------0.30
Sodium fluoride
--------0.0044
Sorbitol
--------29.95
Methyl p-hydroxybenzoate
0.35
0.35
1.00
Spirit of lemon
--------3.785
2.3.4

Preparation of Altered Artificial Saliva Solutions
In an effort to closer resemble natural saliva, components such as mucin (from the

bovine submaxillary gland) and phosphatidylserine (PS) were added according to
concentrations found in literature. Mucin was added in the concentration 2 mg/mL of
saliva solution, a concentration similar to that found in natural saliva [Vissink et al.,
1984]. PS was added to the saliva solutions based on the known concentration of the
phospholipid phosphatidylethanolamine (PE) present in natural saliva [Levine, 1993]. PS
was used instead of PE due to the availability of PS and the higher cost of PE. While the
lipid concentration in natural saliva has been found to be 4.4 g/mL [Preetha and
Banerjee, 2005], PS was added to the artificial saliva solutions at 44 g/mL due to
material constraints of other saliva components and to prevent human error with
measuring such a small amount of PS.
Other alterations made to the saliva recipes found in the literature included the
addition of drugs targeted for the inhalation treatment of bronchial disorders. Albuterol
was obtained from the manufacturer pre-mixed at a concentration 0.083% (2.5 mg
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albuterol/3 mL isotonic saline). For consistency, this same concentration was used for the
addition of theophylline, potassium iodide, salbutamol, and fluticasone
propionate/salmeterol to the saliva solutions. It is important to note that salbutamol and
albuterol are structurally identical. The reason both materials are included in the study is
because the salbutamol was in powder form while albuterol was in solution, and the
differences in phase was of interest to examine uniformity between the delivery phases.
2.3.5

pH Measurements of Neat and Drug-Doped Artificial Salivas
pH measurements were collected for the neat saliva solutions (unmodified), as

well as the drug doped saliva solutions. The data was collected using an Accumet Basic
AB15 pH meter (Fisher Scientific). Prior to data collection, the pH meter was calibrated
using buffer solutions of pH 2,4,7,10, and 12. Sample pH values were collected a
minimum of three times and averaged.
2.3.6

Interfacial Tension Measurements
Interfacial tension data was collected using a Kruss Easydrop contact angle

goniometer with a Teli CCD camera. To contain and dispense the solution droplets,
Kendall Monojet tuberlin 1 mL syringes with 1.83 mm inner diameter EFD Ultra
Dispense needles were used. Kruss' Drop Shape Analysis (DSA) software (version
1.90.0.14) was used to collect and analyze drop images. Pendant drops with 10 L
volume were formed at ambient temperature using a dispensing rate of 700 L/min.
Images of the pendant drops were then captured and the drop shape evaluated using the
DSA software to determine interfacial tension values. For each solution, a minimum of
ten interfacial tension points was collected to obtain averages, standard deviation and
95% confidence intervals.
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2.3.7

Shear Rate and Viscosity Measurements
Shear rate and viscosity data were collected and analyzed on the saliva solutions

using a TA Instruments AR 1500x rheometer with a 60 mm aluminum parallel plate
accessory, Rheology Advantage Instrument Control AR software (version V5.7.0), and
Rheology Advantage Data Analysis software (version V5.7.0) . Step-flow shear data
were collected at 37 C (maintained by a Peltier plate) over a shear rate range of 0.1 to
100 s-1, with 10 points per decade.
2.4

Results
It is important that these artificial saliva solutions have similar properties to

natural saliva so that the effects of drug addition on saliva properties can be understood.
Surface coverage and surface wettability are crucial behaviors key to understanding and
predicting the path of the particulates in droplet formation and deposition on the lung.
The following section discusses the pH, interfacial tension and viscosity of the neat
artificial saliva solutions in comparison to natural saliva as well as the interfacial tensions
and viscosities of the drug-doped solutions to see the effects of the drug on the
viscoelastic properties of saliva.
2.4.1

pH of Neat Saliva Solutions and Drug-Doped Saliva Solutions
pH is one of many factors that affect the diffusion of particles through the

pulmonary mucus. It has been reported that an increase in pH produces an increase in
diffusion coefficient and a decrease in lag time of the drug particle in the mucus[Shaw et
al., 2005]. With this information, the drug-doped saliva solutions, as well as the neat
saliva solutions for comparison, were evaluated for pH levels. The effects of drug
addition on pH of the neat saliva solutions can be seen in Figure 2.2.
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Figure 2.2

pH data for neat and drug-doped artificial saliva solutions.

The addition of drugs produced both increases and decreases in pH of the saliva
solutions. Theophylline had the least effect on pH, producing only a 0.46 % decrease in
pH for the X1 solution, 0.00% change for X2, and a 2.53% decrease in saliveze. Advair®
had the greatest effect on pH of the saliva solutions, resulting in 7.43%, 8.33%, and
2.82% increases for X1, X2, and saliveze, respectively. Albuterol produced decreases in
pH for X1 (2.64%) and X2 (1.07%), and a slight increase in saliveze (1.43%). KI
produced consistent, although slight, increases in pH with all three solutions, resulting in
1.05%, 1.93%, and 0.00% increases for X1, X2, and saliveze, respectively. Of the four
drugs, KI and Advair were the only two drugs to produce consistent increases in pH.
The molecular structures of the drugs influenced the effect of the drug addition to
the saliva solutions. The molecular structure of Advair®, which produced consistent
increases in pH in all three solutions, contains several C-F bonds, which are
electronegative and the dissociation of the fluorine is the likely cause of the increase in
pH. Based on the results of the addition of Advair® to the saliva solutions, the fluorine
acted as a Lewis acid and accepted a pair of electrons, therefore increasing the pH of the
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solution. KI, which also consistently increased the pH of all three solutions, likely
dissociated into K+ and I-. The I- acted as a Lewis acid, accepting a pair of electrons and
increasing the pH of the solution. However, due to the presence of K+, which likely acted
as a Lewis base and donated a pair of electrons and raising the pH of the solution, the
effects of KI on the pH of the solutions are not significant, which is reflected by the very
slight solution pH increases. Theophylline also had a minimal effect on pH of the saliva
solutions. The structure of theophylline is very stable due to the double ring structure and
presence of double bonds. Also, theophylline is a poorly water-soluble molecule [Colinet
et al., 2009]. Since theophylline did produce decreases in X1 and saliveze, the
dissociation of H+ from the secondary amine or a breakage of an O=C double bond were
the location(s) of the electron pair donation, therefore acting as a Lewis base and
subsequently causing the decrease in pH. Albuterol produced consistent decreases in pH
in X1 and X2. Albuterol has several –OH present that are known Lewis bases, donating a
pair of electrons and decreasing the pH of those solutions. Albuterol did produce a slight
increase in pH in saliveze, which could be due to the different composition of saliveze
compared to X1 and X2. It is important to large range of the 95% confidence interval
error bars, which encompass values of neat saliveze and indicate that the slight increase
in pH of saliveze with the albuterol addition is not significant.
2.4.2

Interfacial Tension
The interfacial tension (IFT) of the unmodified saliva solutions was first

compared to literature values of similar artificial salivas [Preetha and Banerjee, 2005] for
validation purposes. The average xialine 1 (X1) IFT value was 67.59 mN/m, 2.0% higher
than the literature value of 66.15 mN/m. xialine 2 (X2) had an average IFT value of 69.31
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mN/m, which is 6.8% higher than the 64.89 mN/m literature value. The average saliveze
IFT value was 67.05 mN/m, 4.9 % higher than the literature value of 64.17 mN/m. The
IFT values for the salivas prepared in this studied varied less than 3.03 % between one
another, despite the difference in recipes. They were consistently 2.0 to 6.8 % higher
than the literature-reported IFT values for these salivas. This is thought to be due to the
differences in collection methods. Pendant drop using a contact angle goniometer was the
collection method for this study, while a Langmuir Blodgett instrument was used for the
data collection of the literature-reported IFT values [Preetha and Banerjee, 2005].
A comparison of interfacial tension for artificial and natural saliva solutions is
presented in Figure 2.3. The artificial salivas varied only minimally from interfacial
tensions of natural saliva [Preetha and Banerjee, 2005; Kasakov, 2009]. The IFTs of the
artificial salivas varied 1.62-4.57% from natural saliva A [Preetha and Banerjee, 2005]
and 5.63-8.46% from natural saliva B [Kasakov, 2009]. The IFT data support the use of
these solutions as valid model substitutes for natural saliva.
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Figure 2.3

Average interfacial tension values for three artificial salivas (X1, X2, and
Saliveze) and natural saliva [A: Preetha and Banerjee, 2005; B: Kasakov,
2009]. Error bars represent 95% confidence intervals.

In an effort to make the saliva solutions closer resemble the properties of natural
saliva, two types of additives found in natural saliva were added—either separately or in
combination—at concentrations found in natural saliva: phosphatidylserine (PS), a
phospholipid representative of those found in natural saliva; and mucin, a glycoprotein
[Preetha and Banerjee, 2005; Vissink et al., 1984]. PS was added at a concentration of 44
g/100 mL [Preetha and Banerjee, 2005] and mucin was added at a concentration of 2%
w/v [Vissink et al., 1984]. Interfacial tension data for these modified artificial saliva
solutions can be seen in Figure 2.4.
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Figure 2.4

Comparison of IFT for artificial saliva solutions with and without the
addition of mucus and/or phosphatidylserine (PS), compounds
representative of those found in natural saliva.

Preetha and Banerjee (2005) found that the addition of a phospholipid
(phosphatidylethanolamine, PE) and mucin caused an increase in IFT in all three of the
saliva solutions (X1, X2 and saliveze). Although PS was used in our formulations instead
of PE, the addition of mucin and/or PS to the saliva solutions in this study, X1, X2 and
saliveze, increased the IFT (Figure 2.3). For X1, the addition of mucin, PS, and
mucin+PS resulted 5.61%, 6.64%, and 7.22% increases in IFT, respectively. For X2,
which has an identical composition to X1 with the exception of a less amount of xanthan
gum, the addition of mucin, PS, and mucin+PS resulted in 6.50%, 16.90%, and 4.43%
increases in interfacial tension values, respectively. Lastly, the addition of mucin, PS, and
mucin + PS to saliveze resulted in 1.70%, 1.85%, and 2.75% increases in interfacial
tension values, respectively. Due to the significant variations in the interfacial tension
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property within the artificial salivas (large range of variation from 1.70-16.90%), any
further experiments were conducted using only neat saliva solutions without PS or mucin.
IFT was then measured for the three saliva solutions, X1, X2, and saliveze, with
and without the addition of the four bronchial drugs (albuterol/salbutamol, theophylline
[theo], potassium iodide [KI], and Advair®). IFT data for these neat and doped saliva
solutions are shown in Figures 2.5-2.7. For these figures, the blue dashed line represents
the average IFT for the corresponding neat saliva solution.

Figure 2.5

Interfacial tension of drug-doped X1 saliva solution. IFT of neat X1 (67.24
mN/m) indicated by blue dashed line.

Figure 2.5 contains the IFT data for X1 saliva solution containing 0.083% w/v of
four asthma drugs showing that drug addition resulted in elevated IFT values for X1. The
IFT increase ranged from 2.05% (albuterol) to 19.26% (theophylline). The IFT values of
albuterol and salbutamol varied a higher than expected amount. Despite the shared
structure and equivalent concentration levels in the saliva solutions, the form of the drug
(solution versus powder) seems to affect the surface tension in X1.
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The other two saliva solutions did not show the same general trend for all of the
drugs. KI, salbutamol, and Advair increased the IFT for X2 (Figure 2.6), and these
same three—plus albuterol—resulted in increased IFT for saliveze (Figure 2.7). For X2,
albuterol caused a 10.17% decrease and theophylline produced a 6.78% decrease in
average IFT. KI, salbutamol, and Advair® raised the IFT of X1 from 0.51% (KI) to
8.15% (salbutamol). Of the four drugs tested, saliveze showed a decreased IFT (1.2%)
only with the addition of theophylline. The other four drugs caused increased IFT ranging
from 2.0 % (Advair®) to 5.9 % (salbutamol).

Figure 2.6

Interfacial tension of drug-doped X2 saliva solution. IFT of neat X2 (69.31
mN/m) indicated by blue dashed line.

It is uncertain the exact reasons for the inconsistency regarding the impact of drug
addition on the IFT of the artificial saliva solutions. It was expected that the addition of a
given drug would result in similar IFT deviation trends, particularly with X1 and X2
since the two solutions have only small differences in composition. Regardless of the lack
of general trends, drug addition to the artificial saliva solutions, even at a low
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concentration (0.083% w/v), resulted in marked deviations in IFT, a key parameter in
aerosol droplet formation and deposition in the lung. To improve deposition performance,
the addition of these drugs would ideally result in decreased IFT. Surface tension affects
wettability of the fluid, which impact surface coverage and therefore diffusion and
ultimate fate of the fluid and the particulates in the fluid. Drug additions resulting in
lower surface tensions increase wettability and therefore increase surface coverage. A
larger surface coverage would allow a larger amount of drug arriving on the lung surface
to diffuse through the pulmonary mucus layer and into the tissue for the fastest possible
drug efficiency.

Figure 2.7

Interfacial tension of drug-doped saliveze saliva solution. IFT of neat
saliveze (IFT 67.05 mN/m) indicated by blue dashed line.

The range of changes in IFT with the addition of drugs can be better explained
with understanding of the hydrophobicity of the drugs. An increase in IFT indicates the
drop of the solution (referring to the drop suspended from the needle in pendant drop
goniometry) is becoming more hydrophilic. Theophylline is a poorly water-soluble drug
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[Colinet et al., 2009], so the increase in IFT of the theophylline-doped X1 solution can be
justified with that information. The slight decreases in IFT of theophylline-doped X2 and
saliveze may be due to theophylline not dissolving fully in that solution. The other drugs
produced consistent IFT increases in all other solutions, with the exception of the
decrease in albuterol-doped X2. Advair® contains several CF bonds, which are
hydrophobic and the likely cause for the increase in IFT of the saliva solutions.
Albuterol/salbutamol is water soluble, and it was expected that both solutes would
produce decreases in IFT. KI produced consistent increases, indicating the solubility in
saliva was minimal. The solubility of KI is affected by solvent temperature in pure water.
Since the saliva solutions are very concentrated with materials other than water, KI had
limited solubility.
It is also important to refer to the error bars as well as the values of the average
IFT values for each drug addition for each solution. The changes in IFT with the addition
of drugs are very slight at the low drug concentration. Analysis of a stronger
concentration of drug on the changes in IFT with the drug addition would be required to
fully determine the effect the drugs have on IFT of saliva.
2.4.3

Rheology
The viscoelastic properties of the artificial saliva solutions were also examined

using rheology. Viscosity data was collected as a function of shear rate to identify any
shear thinning or shear thickening behaviors. All samples were run in triplicate. Figure
2.8 displays shear rate versus viscosity data for the neat (unmodified) saliva solutions and
natural saliva [Preetha and Banerjee, 2005]. All three of the artificial solutions were
found to be more viscous than natural saliva over the shear rate range tested. This higher
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viscosity may be due to the relative low number of components in the artificial solutions
(13) versus natural saliva and/or it could be a result of the limited data for natural saliva
viscosity found in the literature. Another issue may lie with the variation in the measured
values for natural saliva, which is not unexpected considering the inherent variation in
samples collected from human donors [Preetha and Banerjee, 2005; Vissink, et al. 1984].
All three neat artificial saliva solutions were found to be non-Newtonian and
exhibited shear thinning behavior, similar to the viscoelastic behavior observed for
natural saliva. Visually saliveze appeared to be much thicker and viscous than either
xialine solution. The rheology data collected on these samples confirms this observation.
Xialine 1 and xialine 2 are both less viscous than saliveze over the entire shear rate range
tested (Fig. 2.8). Due to the only slight differences in composition between xialine 1 and
xialine 2, it was expected that the two solutions would not exhibit significantly different
rheological properties. However, the one difference in composition between xialine 1 and
xialine 2, the concentration of xanthan gum, is the likely reason for this variation.
Xanthan gum is a well-known and commonly used thickening agent. A slightly more
viscous xialine 1 would result in a higher viscosity at lower shear rates, but this slight
variation in composition is less notable at higher shear rates.
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Figure 2.8

Viscosity versus shear rate for neat artificial saliva solutions and natural
saliva [*Preetha and Banerjee, 2005, ^Vissink et al., 1984].

Rheological characterization was also performed on the saliva solutions doped
with Advair, KI, salbutamol, or theophylline. Due to material constraints, rheology data
was not collected for albuterol-doped solutions. Figures 2.9, 2.10, and 2.11 display the
rheological data for drug doped xialine 1, xialine 2, and saliveze, respectively.
Figure 2.9 shows a plot of shear rate versus viscosity for neat xialine 1 and its
drug-doped derivatives. The solutions tested all exhibited shear thinning, non-Newtonian
viscoelastic behavior. All five solutions show decreased viscosity as shear rate increased
and appeared to approach common viscosity levels at the highest shear rates tested (100
s-1). Neat xialine 1 had the highest viscosity values at low shear rates.

32

Figure 2.9

Plot of viscosity versus shear rate for comparison of neat xialine 1 to drugdoped xialine 1.

A plot of rheological data for neat and drug-doped xialine 2 is shown in Figure
2.10. Neat and drug-doped xialine 2 solutions exhibited non-Newtonian, shear thinning
behavior. The KI-doped solution had the highest viscosity at the lower shear rates, even
higher than the neat solution.
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Figure 2.10

Plot of viscosity versus shear rate for comparison of neat xialine 2 to drugdoped xialine 2.

Each of the saliveze solutions, neat and doped (Fig. 2.11), showed nonNewtonian, shear thinning behavior, similar to xialine 1, xialine 2 and natural saliva.
Saliveze doped with KI was the only solution to show higher viscosities than the neat
solution over the entire shear rate range tested. Theophylline-doped saliveze also had a
higher viscosity than the neat saliveze at lower shear rates, but then its viscosity
decreased slightly below that of the neat saliveze as the shear rate was increased.
Salbutamol and Advair® doped solutions followed the same trends observed for the
xialine solutions and were less viscous than the neat solution over all the shear rate range
tested.
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Figure 2.11

2.5

Plot of viscosity versus shear rate comparing neat (unmodified) saliveze to
drug doped saliveze.

Conclusions
The neat artificial saliva solutions generated as part of this study varied minimally

from literature interfacial tension values for natural saliva, thus supporting the use of
these artificial solutions as valid substitutes for natural saliva. The artificial salivas were
more viscous than natural saliva at all shear rates; this could be due to the extreme range
of possible properties of natural saliva, which vary between specimens and are affected
by factors such as age of the patient, diet of the patient, general health, and natural
composition that are never identical between specimens.
Drug addition to the artificial saliva solutions at a relatively low concentration
resulted in measurable deviations in the interfacial tension, a key parameter in aerosol
droplet formation and deposition in the lung. KI, salbutamol, and Advair consistently
produced increases in the average interfacial tension measurements that were collected.
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Albuterol and theophylline were inconsistent with both increases and decreases in
average interfacial tension measurements observed depending on the specific drug. Ideal
results would have shown consistent decreases in interfacial tension with the drug
additions. Lower surface tensions would result in increased wettability and subsequently
increased surface coverage. A larger surface coverage would allow a larger amount of
drug arriving on the lung surface to permeate through the mucus layer present on the lung
and into the tissue for the quickest possible effectiveness of the drug. The impact of drug
addition on droplet formation, deposition, and wettability are important factors in
predicting the behavior of aerosol drugs on the lung surface.
Salbutamol and Advair consistently showed lower viscosities over all shear rate
ranges when compared to the neat saliva for all saliva types. Since salbutamol and
albuterol are structurally identical, it can be reasonably assumed that albuterol would
have produced similar data to salbutamol and also result in lower viscosity trends.
Theophylline had minimal effect on the viscosity of the saliva solutions, and has little to
no variations from the neat solutions. KI appeared to have higher viscosities at lower
shear rates than the neat solutions, but varied minimally from the neat solutions at higher
shear rates. Decreases in viscosity with the addition of drugs were the desired result. Less
viscous fluids have increased surface wettability and coverage and therefore would allow
a larger area of drug-doped saliva to deposit on the lung with a greater amount of drug
available to treat the applicable condition.
Additionally, pH data was collected for the neat and drug doped saliva solutions.
Albuterol and theophylline produced minimal changes in the saliva solutions, as well as
producing both increases and decreases in pH levels. KI and Advair® produced consistent
increases in pH levels for all three saliva solutions.
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CHAPTER III
DIFFUSION OF THEOPHYLLINE AND ALBUTEROL THROUGH ARTIFICIAL
MUCUS
3.1

Abstract
Two drugs used in the treatment of asthma, theophylline and albuterol, were

diffused through an artificial mucus layer for the purpose of evaluating their diffusion
coefficients. To monitor the diffusion process, one side of the mucus layer was placed in
contact with the drug-doped isopropanol solution and the other side of the layer was in
contact with a zinc selenide crystal to allow for time-resolved attenuated total reflectance
Fourier transform infrared spectroscopy (ATR-FTIR) measurements. Spectra were
collected at constant time intervals and monitored for quantitative changes in spectral
peaks corresponding to the functional groups of the drugs. Analysis of the data resulted in
diffusivity coefficients of 5.5-7.0 x 10-6 cm2/s for theophylline (as dissolved in
isopropanol [IPA]) through artificial mucus and 4.9-9.6 x 10-6 cm2/s for albuterol
(dissolved in IPA) through artificial mucus.
3.2

Introduction
Significant advancements in delivery method and drug efficiency have been made

in the treatment of respiratory illnesses such as asthma. Treatments are most commonly
aerosol inhalation pharmaceuticals that range from fast-acting rescue drugs to long-term
medications that prevent lung inflammation and allow for control of the disease [Volsko
and Reed, 2000]. Inhalation drugs have many characteristics that make them worth
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further investigation and development, including good patient compliance, chemical
stability, small dosages, and bypassing the digestive system [Chan, 2006].
It is important to understand the path of particulates—including inhalation
drugs—through the respiratory tract, deposition patterns, and the ultimate bioavailability
of these medications. Upon inhalation, drug particles travel through the bronchiole lung
generations and ultimately land on the mucus layer that coats the alveolar pulmonary
membrane. Inhaled drugs must then diffuse through the mucus layer in order to reach the
lung surface and treat the inflammation.
The complexity of the mucus is a major contributing factor to the path of the drug
particulates and the composition of the pulmonary mucus layer. Mucus is hydrophobic
[Khanvilkar et al., 2001], exists in two layers, and is arranged in crosslinked and
entangled mucin fiber networks [Lai et al., 2009]. The gel, which is the upper more
viscous phase, is composed of 95% water, 2% mucus and 3% salts, proteins and lipids
[Todoroff and Vanbever, 2011; Khanvilkar et al., 2001]. The sol is the bottom, less
viscous layer that sits atop the pulmonary epithelial cells and beating cilia. The primary
function of pulmonary mucus is to protect the lung surface and trap foreign matter that
enters the lungs. Figure 3.1 illustrates the structure of the gel-sol mucus layer on top of
the pulmonary epithelial cells and beating cilia.
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Figure 3.1

Illustration of gel-sol mucus structure above the pulmonary epithelial cells
with beating cilia penetrating the sol layer.

The trapped particles are swept away by beating cilia or exhalation unless they are
able to transport through the mucus faster than the effective velocity transport of the
upper layer. The gel layer of the mucus is replenished approximately every twenty
minutes due to the mucus flow rate of about 5 mm per minute [Lai et al., 2009]. This
rapid transformation is responsible for the effective clearance of any trapped particles.
The sol layer is renewed much slower. Aside from mucociliary clearance, particles may
also become trapped in the dense fiber mesh of the mucus layer formed by the mucin
macromolecules [Khanvilkar et al., 2001], further obstructing the permeability of the
particle [Lai et al., 2009]. In order for particles to diffuse through the complex mucus
network, the drugs must penetrate the mucus layer faster than the rate of mucus renewal
and clearance [Lai et al., 2009].
Aerosol drugs are designed to retain medicinal properties while diffusing through
the mucus. It is possible to design particles to overcome the obstruction of the mucus
layer. Mucus-inert polymers or hydrophilic coatings can be used to increase the rate of
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particle diffusion as well as further customize the drug release and improve drug
effectiveness [Lai et al., 2009]. Another technique being researched is mucoadhesion,
where particles are coated with a polymeric material designed to cling to the mucus layer,
slowing the particle transfer time and improving drug absorption [Lai et al., 2009].
One of the most influential characteristics of a material to diffuse is size.
Nanoparticles (>100 nm) can remain in the lungs for weeks due to their small size, while
larger particles of ideal aerodynamic diameter for treating airways (1-5 μm) [El-Gendy et
al., 2011] are cleared from the lung within 24 h [Todoroff and Vanbever, 2011]. Particles
that are small enough to be diffused are cleared through the mucus layer and into the
pulmonary membrane, eventually becoming systemic. Larger particles are swept away by
cilia or exhaled. By using representative drug-doped solutions and an artificial mucus
layer, materials and transport parameters can be measured for modeling the behavior of
drug particles in the human lung.
Drug diffusion is also affected by other drug characteristics such as surface charge
[Khanvilkar et al., 2001, Larhed et al., 1997], molecular weight, and lipophilicity [Larhed
et al., 1997]. It has also been found that hydrophobic particles have lower permeabilities
due to the hydrophobic nature of the mucus [Khanvilkar et al., 2001; Norris and Sinko,
1997]. Strong lipophilic particles have lower diffusion coefficients than less lipophilic
particles [Larhed et al., 1997]. Molecular weights have been investigated for their
influence on particle diffusion. Larhed el al. found that drugs with higher molecular
weights had lower diffusion coefficients than the particles with lower molecular weights
[Larhed et al., 1997], and this inverse relationship between molecular weight and
diffusion coefficient has been regularly reported [Khanvilkar et al., 2001]. Additionally,
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particle charge has been found to influence drug diffusion since mucus components are
negatively charged. Khanvilkar et al. reported that positively charged low-molecular
weight drugs bind to the mucus electrostatically [Khanvilkar et al., 2001]. It has also been
reported that particles with a negative charge is not affected by the mucus barrier
[Khanvilkar et al., 2001; Norris and Sinko, 1997]. It has also been reported that hydrogen
bonding and hydrophobic interactions bind polar and non-polar drugs to mucus
[Khanvilkar et al., 2001]. Additionally, pH was found to influence the diffusion of drugs
across the membrane. An increase in pH produced an increase in diffusion coefficient and
a decrease in lag time [Shaw et al., 2005].

3.2.1

Mucus Diffusion using ATR-FTIR
Typically, more conventional methods of transport experiments such as

permeation cells or dynamic gravimetric sorption have been used to measure diffusion
[Hallinan et al., 2007; Hallinan et al., 2010]. However, ATR-FTIR as a method for
measuring diffusion has been used with increasing frequency over the past two decades
[Elabd et al., 2003]. ATR-FTIR allows for time-resolved analysis of diffusion systems on
a molecular level during the diffusion process, as well as quantification of molecular
interactions between the diffusants and diffusing medium through shifts in IR spectra
[Hallinan et al., 2007; Hallinan et al., 2010]. Several systems have obtained successful
results using time-solved ATR-FTIR spectra for measuring diffusion. Hallinan et al.
measured diffusion of methanol and water in nafion using the ATR-FTIR method, as well
as relating the spectral information to concentration and subsequently Fick’s second law,
similar to the method used in this study. The results of the methanol and water diffusion
in nafion matched results determined from a permeation cell, validating this technique for
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that system [Hallinan et al., 2007; Hallinan et al., 2010]. Additionally, systems such as
water in polymers like poly(vinyl chloride) or poly(ethylene terephthalate) [Elabd et al.,
2003] and even biological systems such as the permeation of acetonitrile and pcyanophenol in polyethylene glycol through silastic membranes representative of skin
[Watkinson et al., 1994] have been successfully evaluated using the ATR-FTIR method
of data collection and Fickian diffusion model. Elabd et al. highlights several more
systems for which this technique has worked, primarily diffusants/solutes through
polymers [Elabd et al., 2003]. Each of the systems he mentions have many references,
signifying the abundant amounts of data to validate this method in over fifty diffusing
systems [Elabd et al., 2003].
Despite the success of using ATR-FTIR as a method for characterizing diffusion
coefficients, this technique has scarcely been used for analyzing mucosal diffusion
systems. Larhed et al. determined the diffusion coefficients of lipophilic drugs mannitol,
metoprolol, propranolol, hydrocortisone, and testosterone through native pig intestinal
mucus, but did so using a radiolabeled drug tracer technique. Plastic syringes (1 mL) with
the tips cut off were used as diffusion chambers. The syringes were filled with a mucus
gel solution stabilized with glass bead packing, and the radiolabeled drug solution is
added over the gel and allowed to diffuse through the gel [Khanvilkar et al., 2001; Larhed
et al., 1998; Larhed et al., 1997]. The gel is then pushed out of the tube and cut into
pieces, and the radioactivity in each piece of gel is determined. Using the syringe tube
geometry, weighted least square fits of normalized theoretically determined radioactivity
values and normalized experimental radioactivity values, the diffusion coefficients are
obtained [Khanvilkar et al., 2001; Larhed et al., 1998; Larhed et al., 1997]. Owen et al.
used a UV spectrophotometric technique where two quartz capillary cells, one loaded
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with Nonoxynol-9-doped alginate delivery gel and the other with bovine cervical mucus,
are brought in contact with one another and a quantifiable concentration profile is
achieved [Khanvilkar et al., 2001; Owen et al.,1999]. The cell holder is then scanned
using the sample transport drive of a UV spectrophotometer [Khanvilkar et al., 2001;
Owen et al., 1999].
Despite the developments that have been made in the efficiency of inhalation
drugs and the improvements in the drug delivery systems, little research has been done on
following the path of the drug particles from inhalation through the diffusion of the
mucus layer to the lung epithelium. The work presented here involves the development of
methods for measuring the diffusion coefficients in artificial mucus, and is part of a
larger project that involves modeling transport within the lung airways, deposition, and
then fate within the lung. While particulate removal from the lung can occur via
exhalation and/or cilial movement into the gastrointestinal tract, these drugs can also
diffuse across the mucus layers and be taken up by the macrophages and epithelial cells
lining the lung alveoli. The specific objectives of this effort are to (1) compare the
composition and the physicochemical properties of artificial mucus with native mucus,
(2) develop a method to measure diffusivities using FTIR, and (3) measure the diffusion
coefficients of solvent and drug-doped solutions though artificial mucus layers.
An artificial mucus, representative of human pulmonary mucus, was prepared to
act as a surrogate for the native mucus layer present on the lung surface. The composition
of this artificial mucus solution is available in Section 3.3.1. Due to variations between
specimens and properties that change with time since harvesting, artificial mucus was
used for a more well-controlled system. Two commonly used drugs in asthma treatments,
theophylline and albuterol, were dissolved in isopropanol and the solutions served as a
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model for drug-solvent mixture that would be deposited on the mucus surface after
inhalation treatments (e.g. nebulized drug solutions) are administered. Drugs are typically
delivered to the in either dry powder form or dissolved in saline solution. Due to the lack
of spectral variation between water-based mucus and water-based saline, isopropanol was
used as the solvent for ease of tracing the progress of the diffusion.
3.3

Materials and Methods

3.3.1

Materials

3.3.1.1

Diffusants
Theophylline (>98 %, TCI America, CAS 58-55-9, M.W. 180.17 g/mol) and

albuterol (Spectrum, CAS 18559-94-9, M.W. 239.31 g/mol) solutions were prepared at
various concentrations using isopropanol (IPA, Ricca Chemical, 70 % v/v aqueous
solution, CAS 67-63-0). The chemical structures of theophylline and albuterol are shown
in Figure 3.2. Each solution was sonicated using a Branson 3510 sonicator with heat until
completely dissolved. Solutions with concentrations higher than 50-mg/mL experienced
dissolution when cooled at ambient temperature for times greater than thirty minutes.

Figure 3.2

Chemical Structures of theophylline (left) and albuterol (right).
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3.3.1.2

Preparation of Artificial Mucus
The artificial mucus was made by heating HPLC water (HPLC grade, CAS 7732-

18-5, Fisher Scientific) on a hot plate to 80 °C while stirring with a magnetic stir bar. An
isotonic saline solution was prepared by adding 1.57 g NaCl/NaHCO3 mixture (Minimum
of 70% NaCl, Ayr saline nasal rinse packet; B.F. Ascher and Co., Inc.; Lenexa, KS) to
177 mL 80 C HPLC water. To increase the surface tension, sodium dodecyl sulfate
surfactant (BioXtra, >99.0 %, CAS 151-21-3, Sigma Aldrich) was added to the saline
solution in the amount of 5 mM and mixed thoroughly. Next, 1 wt.% locust bean gum
(LBG, from Ceratonia siliqua seeds, CAS 9000-40-2, Sigma Aldrich) was added drop by
drop to the saline solution until the LBG was fully dissolved [Anwarul Hasan et al.,
2010]. The artificial mucus gel became more viscous with cooling, ultimately solidifying
into a semi-solid gel.
3.3.2

Methods: FTIR Spectroscopy
Fourier transform infrared spectroscopy was performed using a Nicolet 6700

spectrometer (Thermo Electron Corporation) and Omnic software (version 8.1.10,
Thermo Fisher Scientific). Attenuated total reflectance (ATR-FTIR) spectra were
collected with a 60 zinc selenide crystal with a liquid nitrogen cooled MCT-A*
(mercury-cadmium-telluride) detector and a Pike Technologies Veemax II accessory,
with the angle of incidence set to 60. Pike Technologies also produced the liquid
retainer, used to contain liquid samples on top of the ATR crystal.
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3.4
3.4.1

Results and Discussion
Data Collection
Drug solution diffusion in mucus was collected and evaluated using FTIR

spectroscopy. The artificial mucus layer was placed in a reservoir and a spectrum was
collected to serve as a baseline standard for comparison to time-resolved spectra. Then a
layer of drug-doped IPA is placed on top of the mucus layer. A schematic of this setup
can be seen in Figure 3.3.

Figure 3.3

Schematic of the experimental FTIR diffusion set-up. The artificial mucus
layer is sandwiched between a layer of the drug-doped solution and the
ATR-FTIR crystal. Not to scale.

Figure 3.4 shows a comparison of neat IPA with the drug-doped IPA solution to
show the peaks specific to theophylline. Several peaks are clearly seen in the 1750-1500
cm-1 range for the theophylline-doped IPA solutions that are not present in neat IPA. Data
collection concentrations ranged from 5-25 mg/mL.
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Figure 3.4

ATR-FTIR spectra for a concentration series of theophylline in IPA.

Spectra were collected at constant time intervals of sixty seconds and monitored
for changes in spectral peaks corresponding to the functional groups of the drugs. With
time, peaks corresponding to the drug-doped solution appeared and increased in
absorbance as the concentration increased at the crystal surface. Eventually the peak
heights for the solvent and drug became constant indicating an equilibrium state was
achieved. An example of these time-resolved ATR-FTIR spectra for a 25 mg/mL
theophylline/IPA solution diffusing through mucus is provided in Figure 3.5. The
baseline spectrum (t = 0 min) is a scan of the neat mucus.
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Figure 3.5

Time-resolved ATR-FTIR spectra collected over 600 sec for the diffusion
of a 25 mg/mL theophylline/IPA solution through a 3.5 mm artificial
mucus layer.

Examining Figure 3.5, the peaks that appear and subsequently increase in height
with time correspond to the solvent (IPA) and to the drug (theophylline), with the
majority of these peaks corresponding to IPA. While theophylline is present in the
solution, the concentration and relatively low absorption make it difficult to differentiate
from the IPA peaks. In addition, the peak at ~1645 cm-1 corresponding to the secondary
amines in theophylline [Pretsch et al., 2000] is overshadowed by the large peak at ~1640
cm-1 corresponding to ring stretching of galactose and mannose [Wang and
Somasundaran, 2007] in the LBG-based mucus. Stacked ATR-FTIR spectra of the
mucus components can be seen in Figure 3.6.
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Figure 3.6

Stacked spectra of the artificial mucus components. Boxed peaks around
~1640 cm-1 are of interest due to the overshadowing the peaks have on
secondary amine peaks in the drugs.

Albuterol-doped IPA solutions also contained the ~1645 cm-1 peak. Peaks in this
wavenumber range correspond to secondary amines [Bruno and Svoronos, 2006;
Silverstein and Webster, 1998] that are present in both chemical structures. Theophylline
contains primary, secondary and tertiary amines and albuterol contains secondary amines.
(Refer to the structures in Figure 3.2). The peak height tool was then used to calculate the
peak height of the drug peaks at ~1645 cm-1. These peak heights were then converted to
concentration using a calibration curve, and these concentrations could be used to
determine an average diffusivity coefficient, which is explained in further detail in
section 3.4.2
3.4.2

Data Analysis
To prepare a peak height-concentration calibration curves for the drug-doped IPA

solutions, first the height of the 1645 cm-1 peak was found for each solution ranging in
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from concentration from 0 to75 mg/mL. Measured peak heights for the drug were plotted
versus the corresponding concentration, and the data set was fitted to a linear function, as
predicted by Beer’s Law [Hallinan et al., 2010]. An example of a fitted concentration
profile can be seen in Figure 3.7.

Figure 3.7

Theophylline concentration profile based on measured FTIR peak height
fitted to a linear function.

Next, the peak heights of the drugs were measured for each of the time-resolved
spectra. In order to evaluate the time-resolved spectra for increasing concentrations of
drug-doped solutions, the neat mucus solution was subtracted from the time-resolved
spectra. Using the subtraction processing method available within the Omnic software,
one spectrum can be subtracted from another to more clearly identify differences; the
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dr u g- d o p e d I P A s ol uti o n c o n c e ntr ati o n c o ul d b e cl e arl y s e e n i n t h e s u btr a cti o n s p e ctr a.
F or e x a m pl e, a s p e ctr u m f or t h e o p h ylli n e-I P A s ol uti o n t hr o u g h m u c us at a ti m e of 4 0 0 0
s e c o n ds w o ul d l o o k li k e t h e n e at m u c us s ol uti o n wit h s e v er al I P A p e a ks a p p e ari n g. Si n c e
it is k n o w n t h at t h e o p h ylli n e is i n t h e I P A s ol uti o n a n d t h at a str o n g p e a k of m u c us
o v ers h a d o ws t h e tr a c e a bl e p e a k f or t h e o p h ylli n e t h at is pr es e nt, it is n e c ess ar y t o r e m o v e
a n y p e a ks c orr es p o n di n g t o m u c us i n or d er t o s e e t h e t h e o p h ylli n e p e a k. T h e s u btr a cti o n
t o ol us es t h e n e at m u c us s p e ctr u m t o i d e ntif y t h e p e a ks c orr es p o n di n g t o m u c us a n d
r e m o v e t h e m fr o m t h e ti m e r es ol v e d s p e ctr u m, r es ulti n g i n a s p e ctr u m t h at c orr es p o n ds t o
t h e t h e o p h ylli n e-I P A s ol uti o n t h at h as pr es e ntl y diff us e d t hr o u g h t h e m u c us t o t h e s urf a c e
of t h e A T R cr yst al. Fr o m h er e, t h e p e a k h ei g ht of t h e t h e o p h ylli n e p e a k c a n b e e v al u at e d
a n d s u bs e q u e ntl y us e d f or f urt h er c al c ul ati o ns. T his e v al u ati o n m et h o d w as us e d t o fi n d
t h e p e a k h ei g ht of t h e dr u g at e a c h ti m e i nt er v al, a n d t h e d at a w as or g a ni z e d as p e a k
h ei g ht v ers us ti m e. T h e n, usi n g t h e f u n cti o n f o u n d b y fitti n g t h e c o n c e ntr ati o n pr ofil e
d at a, t h e p e a k h ei g ht v ers us ti m e d at a w as c o n v ert e d t o c o n c e ntr ati o n v ers us ti m e b y
s ol vi n g f or t h e “ x ” v ari a bl e of t h e fitt e d c ali br ati o n c ur v e f u n cti o n.
Fi c k’s s e c o n d l a w of diff usi o n, a o n e- di m e nsi o n al c o nti n uit y e q u ati o n [ H alli n a n
et al., 2 0 0 7; El a b d et al., 2 0 0 3], w as us e d t o a n al y z e t h e eff e cti v e diff usi vit y ( n e gl e cti n g
m ulti c o m p o n e nt eff e cts) of t h e dr u gs t hr o u g h t h e m u c us l a y er. T h e e q u ati o n f or Fi c k’s
s e c o n d l a w of diff usi o n i n t er ms of c o n c e ntr ati o n c a n b e s e e n i n E q u ati o n 3. 1 [ H alli n a n et
al., 2 0 0 7].

¶C
¶ 2C
= D
¶t
dx 2

E q. 3. 1

w h er e C is c o n c e ntr ati o n p er u nit v ol u m e of t h e diff us a nt, t is ti m e, x is p ositi o n, a n d D is
t h e eff e cti v e diff usi o n c o effi ci e nt. Cr a n k's s ol uti o n of Fi c k’s s e c o n d l a w diff er e nti al
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equation [Crank, 1975; Watkinson et al., 1994] was used to make solving for the
diffusion coefficient using experimental data easier. Assuming a planar geometry with a
fixed thickness, h, for the mucus layer on the lung and the two boundary conditions
shown in Eqns. 3.2 and 3.3, a simplified, quantitatively solvable version of the equation
is obtained (Eqn. 3.4). A schematic representation of the boundary conditions can be seen
in Figure 3.8. Crank, using a Laplace Transform method, determined an approximation
using trigonometric series, which was used to solve the differential equation [Crank,
1975; Hallinan et al, 2007; Elabd et al., 2003].

Figure 3.8

Schematic representation of boundary conditions applied to the mucus-drug
diffusion system.

Boundary Condition 1:

(1) 𝐶 = 𝐶𝑜 𝑎𝑡 𝑥 = ℎ, 𝑡 ≥ 0

Eq. 3.2

Boundary Condition 2:
Eq. 3.3

54

𝐶

𝐶

∑

E q. 3. 4

Usi n g C O , t h e k n o w n r es er v oir c o n c e ntr ati o n, C , a c o n c e ntr ati o n m e as ur e d at t h e
m u c us- dr u g s ol uti o n i nt erf a c e, n, t h e s eri es s ol uti o n t o t h e e q u ati o n ( n u m b er of
it er ati o ns), a n d c as t h e d e pt h of p e n etr ati o n of t h e I R s o ur c e b e a m i nt o t h e m u c us l a y er,
a s ol uti o n t o E q u ati o n 3. 5 c a n b e f o u n d. E x c el w as us e d t o s ol v e f or D , usi n g n v al u es
> 5 0 0. Si n c e all of t h e v ari a bl es w er e k n o w n v al u es wit h t h e e x c e pti o n of D , a v al u e of D
w as c h os e n as t h e i niti al g u ess a n d t h e n t h e e q u ati o n is r e gr ess e d u ntil a b est fit of t h e
e x p eri m e nt al d at a w as a c hi e v e d. I n t his m a n n er, diff usi viti es w er e f o u n d f or e a c h
diff us a nt t hr o u g h a n artifi ci al m u c us l a y er. Pl otti n g C/ C

O

v ers us ti m e f or b ot h

e x p eri m e nt al a n d c al c ul at e d ti m e-r es ol v e d c o n c e ntr ati o n d at a s er v e d as a vis u al t o ol f or
c o m p ari n g t h e c al c ul at e d a n d e x p eri m e nt al v al u es a n d t h er ef or e w as us e d t o g ui d e a n d
ass ess t h e dir e cti o n a n d pr o gr ess of t h e r e gr essi o n i n a p pr o a c hi n g t h e c orr e ct diff usi o n
c o effi ci e nt f or t h e e x p eri m e nt al d at a. It s h o ul d b e n ot e d t h at t h e diff usi o n pr o c ess will
h a v e r e a c h e d e q uili bri u m w h e n C / CO = 1.
Fi g ur e 3. 9 ill ustr at es t h e a c c ur a c y of Cr a n k’s s ol uti o n usi n g t h e c al c ul at e d
diff usi vit y as c o m p ar e d t o t h e e x p eri m e nt al d at a f or dr u g diff usi o n t hr o u g h t h e m u c us
l a y er. O v er all t h e e x p eri m e nt al d at a f oll o ws t h e s h a p e of t h e m o d el e d c ur v e a n d t h e
v al u es a gr e e w ell at t < 5 0 0 s e c a n d 3 0 0 0 s e c < t < 9 0 0 0 s e c. D e vi ati o ns c o nsist e ntl y
o c c ur b et w e e n t h e m o d el a n d e x p eri m e nt al d at a b et w e e n 5 0 0 a n d 3 0 0 0 s e c.
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Figure 3.9

Comparison of experimental and calculated concentrations for a 10mg/mL theophylline-IPA solution diffusing through an artificial mucus
layer.

Evaluation of experimental data determined the diffusivity of theophylline (in
IPA) through the mucus ranged from 5.5-7.0 x 10-6 cm2/s. Albuterol resulted in a more
rapid diffusion and produced diffusion coefficients ranging from 7.2-9.6 x 10-6 cm2/s.
The single-ring structure of albuterol may contribute to the faster diffusion as opposed to
the two-ring structure of theophylline due to steric hindrance. Molecular weight is also a
contributing factor in the diffusion; albuterol MW is 239.31 g/mol and theophylline MW
is 180.17 g/mol. This matches the trend seen in the literature; higher molecular weight
drugs have been found to diffuse more rapidly through the mucus layer [Larhed et al.,
1997; Khanvilkar et al, 2001]. Albuterol was found to diffuse faster through the mucus
layer in the experimental system used in this research, which supports the reported
correlation of higher molecular weight particles and rate of diffusion presented in
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literature. Table 3.1 summarizes the range of diffusion coefficients measured using the
FTIR diffusion method for theophylline and albuterol.
Table 3.1

Summary of measured diffusivity coefficients for theophylline and albuterol
in artificial mucus.

Drug

Mucus
Solution
Total Data
Layer
Concentration Collection
Thickness
(mg/mL)
Time (s)
(cm)

Theophylline

5-25

Albuterol

5-30

6,90010,800

Diffusivity
(10-6 cm2/s)

0.15-0.35

5.5-7.0

1,500-5,100 0.15-0.40

4.9-9.6

95%
Confidence
Interval
 0.12
 0.59

The diffusion coefficient values for aerosol drugs through mucus ranged from 4.99.6 x 10-6 cm2/s, and specific examples are given below. In the literature, homologous
carbohydrates glucuronic acid, glucosmine, and mannitol diffused through native porcine
mucus produced diffusivity values ranging from 7-9 x 10-6 cm2/s, while the lipophilic
molecule testosterone produced a diffusivity of 3 x 10-6 cm2/s [Larhed et.al., 1997].
Drugs such as isonicotinic acid hydrazide, sodium p-aminosalicylate, pentamidine,
pyrazinamide, and rifampicin produced diffusivity values ranging from 5.07-7.62 x 10-6
cm2/s when diffused through reconstituted mucus [Bhat et al., 1995]. Theophylline
diffusion coefficients have been reported as 2 x 10-6 cm2/s [Grassi et al., 2003] and 1.83 x
10-5-5.83 x 10-9 cm2/s [Alvarez-Lorenzo et al., 1999]. Based on literature findings, the
range of experimental diffusivity values measured in this work appears to be appropriate
for the materials tested thereby validating the FTIR- based data collection and analysis
methods.
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3.5

Conclusions
Based on the data that was collected and analyzed for the diffusion of

theophylline and albuterol through artificial mucus, the average diffusivity coefficients
that were calculated are accurate representations of how the drugs behave in human
pulmonary mucus. The methods of analysis employed in the evaluation of the data
resulted in expected increases in peak heights of the drug-specific peak, and followed the
expected pattern of a period of steady peak height increase with increasing time followed
by a period of unchanging peak heights, indicating equilibrium. While the diffusivities
were expected to be slightly lower, the data was consistent in the diffusivity coefficient
values that were found regardless of mucus layer thickness or the length of time data was
collected. The consistency of the data reiterates the validity of this experimental setup
and method of spectral peak and resulting quantitative data analysis.
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CHAPTER IV
INTRODUCTION TO POLYMER SURFACE MODIFICATION USING LIGHTEMITTING POLYMERS
4.1

Background: Polymer Surface Modification
Polymers are one of the most versatile and widely used materials in modern

society. They are inexpensive and have a multitude of applications from food packaging
to biomedical containment to automotive parts [Unver et al., 2011]. Polymer films are of
particular interest due to their desirable characteristics that contribute to their successful
applications. In addition to excellent bulk properties, such as high temperature stability
and strong chemical resistivity, polymer films can be processed by several different
methods and are available in a wide range of thicknesses.
For many applications, one of the most important characteristics of polymers is
the surface chemical composition. Surface composition affects the interactions of the
polymer with its surroundings and consequently the applications. Polymers can be easily
modified into a customized product for a specific use [Unver et al., 2011]. Surface
modified polymers can be designed and tailored for specific applications without altering
the bulk material. Surface modified polymers can be found in a range of products from
coatings, composites, adhesive tape, textiles [Scaffaro et al., 2011], and biomaterials
[Pasparakis et al., 2010].
Polymer surface modification can be achieved through several commonly used
techniques. Methods such as dip coating and spin coating are empirical methods of
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surface modification that are regularly employed [Tighilt et al., 2008]. Plasma treatment
is a technique used for polymeric surface modification where several activated species
(electrons, ions, free radicals, and some neutral species) [Ma et al., 2012] are used to
expose a surface of the polymer to a non-polymerizing plasma or by depositing a thin
layer of plasma polymer on the surface of the polymer [Yasuda, 1977]. Properties such
as adhesion, friction coefficient, optical reflection, surface energy, permeability, and
biocompatibility of several polymers can be controlled [Castro Vidaurre et al., 2002].
Plasma treatment alters the surface characteristics of the polymer but does not affect the
bulk properties due to the low depth of penetration [Castro Vidaurre et al., 2002]. Surface
modification via the covalent reaction of small molecules is another method used with
increasing frequency. By either creating or utilizing existing surface functionality of the
polymer, the surface functional groups can be covalently altered. By modifying the
surface only, the resultant material's surface chemistry is often achieved with increased
control over the final product as well as a more stable and permanent product compared
to those resulting from other surface modification methods [Zhang et al., 2006].
There has been extensive research into the grafting of materials onto and from
polymer surface substrates. However, only a limited amount of research has investigated
the grafting of end-functionalized polymers from a solid polymer surface [Walters and
Hirt, 2006]. Polymer films can support the grafting of a range of molecules due to their
versatile physical and chemical properties. Using covalent bonding surface modification,
very unique polymer films can result with specific properties, making them a material of
high interest due to this “custom-made” functionality [Luo et al.; 2004].
Conceptual understanding of polymer chemistry at the molecular level allows for
the development of desired functional materials. Designing functional polymer films
62

requires the knowledge not only of molecular interactions, but also the chemical reactions
the film will have with its environment. Implementing the design requires careful control.
It is also important to recognize that while some materials respond to a particular
stimulus, orientation on the grafting substrate will affect how the response will progress.
Functional groups that are present on the reacting substrate react with the responsive
functional groups. Occasionally, the spacing of the reactive functional groups on the
polymer film backbone may be too large or small and affect the degree of the response
[Scaffaro et al., 2011]. Additionally, the designer needs to choose the polymer substrate
wisely and take into account the affect some environmental factors will have on some
polymers. Exposure to high temperatures, extensive light, acids or other chemicals that
can negatively impact many properties of the polymer can cause adverse effects, such as
polymer degradation. Despite these negative performance characteristics of polymers, the
benefits of their versatility and ability to handle most extreme environments compensates
for the challenges that are encountered [Lawandy, 1982]. With this understanding,
polymer films can be designed to have a specific response to particular external stimuli.
Grafting stimuli-responsive molecules, monomers, or polymers to the polymer films will
result in a stimuli responsive polymer film, which can be affected by pH, temperature,
radiation, magnetic field, or light, among others. The responses of polymers exist in a
wide range such as a change in color, transparency, conductivity, shape (shape memory
polymers), size, refractive index, crosslinking, and chain recombination, among other
events [Lawandy, 1982]. Stimuli-responsive polymers are also referred to as “smart
polymers” and are found in everyday products as well as specialty applications
[Thomson, 2005; Luo et al., 2004].
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Light-sensitive polymer films are the application of interest in this study. Lightsensitive polymer films fluoresce a color in the visible spectrum and can be used in a
multitude of applications [Perepichka et al., 2006]. Light bulbs, computers, radiation
dosimeters, and light emitting diodes (LEDs) televisions are only a few of these
commercial uses. The concentration of this research is in light-sensitive polymer films
that change color in response to irradiation.
4.2

Uses of Light-Emitting Polymers
LEDs are one of the most common uses for light-emitting polymers since the

1990s. Some LEDs are capable of emitting light across the visible, ultraviolet and
infrared wavelengths. In the application of electroluminescence, light emission is
observed when a voltage is applied through a conductive polymer. This technique is used
in liquid crystal display (LCD) televisions as well as quantum dots, computers, and light
bulbs, among others [Perepichka et al., 2006]. LEDs are also being investigated for
prospective use in ink-jet printers due to their potential in development of the desired
primary color emissions of red-green-blue on a single substrate [Deng and Wong, 2009].
Photopolymers change properties typically in response to ultraviolet light. These
polymers have been used in fillings in dentistry as well as etching [Danesh et al., 2004].
The polymer is soft initially, formed into the desired shape, then cured with UV light.
Shape-memory plastics are a type of photopolymer that change shape in response to
temperature increase and as recently found, light [Thomson, 2005]. Researcher Robert
Langer at the Massachusetts Institute of Technology developed, with German colleagues,
programmable plastics that change shape in response to specific wavelengths of light
[Thomson, 2005]. Photosensitive groups are grafted onto a polymer film and stretched
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with an external stress. Once illuminated with specific wavelength of UV light,
crosslinking occurs within the molecular network, changing the shape of the polymer
film. When illuminated with UV light at a different wavelength, the cross-linked
molecules cleave and the polymer film reverts back to its original shape. These
researchers are hoping to use this technology for applications such as minimally invasive
surgery. For example, a polymer string could be threaded into the body through a small
incision and when activated by light would alter its physical characteristics, becoming a
corkscrew shaped stent for keeping blood vessels open [Thomson, 2005]. There could
also be possible office supply applications, such as quick release staples or paper clips
that relax when not in use [Thomson, 2005].
Another highly investigated and successful use for light emitting polymers is
radiation detection. Countless studies have been performed on light-emitting polymers
and the effects that various types of irradiation have on these materials. Polymer-based
dosimeter systems have been in use for over 60 years [Liz et al., 2011]. Self-indicating
instant radiation alert dosimeter (SIRAD) badges, developed by JPLabs Inc., are widely
used as X-ray radiation exposure prevention tools in industry. These badges contain a
diacetylene compound that is colorless until irradiated with X-ray radiation [Buston et al.,
2006]. Increasing levels of radiation result in a stronger blue color emission from the
badge [Cheung et al., 2007]. For other types of radiation, surface-modified polystyrene
films have been studied for use as reusable gamma radiation detectors. Depending on the
specific light-emitting chemicals grafted to the surface of the polystyrene film, exposure
brings a blue or red color change [Irie and Irie, 2000]. The absorption intensities of both
blue and red film types increased linearly with the absorbed dose [Irie and Irie, 2000].
Various metal-substituted phthalocyanines, such as copper phthalocyanine (CuPc), have
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also been investigated as potential gamma radiation detectors [Arshak, A. et al., 2004].
These polymers were blended into a 92% CuPc 8% poly with
diethylenglycolmonobutylether as the solvent [Arshak, K. et al., 2004] have been spin
coated onto metal oxide substrates with varying thicknesses and evaluated for their
response with gamma irradiation, with 60Co and 137Cs sources used to irradiate the
samples. It has been reported that the CuPc coated metal film emitted at ~600-690 nm
range, which is in the orange-red range of the visible spectrum [Arshak, A. et al., 2004].
In addition to diacetylene- and phthalocyanine-based dosimeters, polyester,
fluoropolymer, vinyl, and acrylate polymers have also been investigated for use in
gamma ray dosimeters [Liz et al., 2011].
4.3

Classes of Light-Emitting Polymers
Conjugated polymers are organic semiconductors [Lambeth, 2004] and have

strong fluorescent properties. These molecules, when irradiated, emit light in the visible
UV range. When the absorption maximum in the spectrum is in the UV visible range, the
polymer will fluoresce [Perepichka et al., 2006]. Several conjugated aromatic polymers
will be discussed in terms of their structure, light emitting properties, and applications.
These materials also have excellent film forming characteristics and have the ability to be
easily applied to large surfaces using simple and cost-effective techniques such as spin
coating or ink jet printing [Lambeth, 2004].
Poly(p-phenylene vinylene) (PPV) is a very commonly used green-yellowemitting conductive polymer [Wu and Chen, 2011], and its chemical structure is shown
in Figure 4.1. PPV was the first polymer to show electroluminescence [Ruddy, 2006;
Perepichka et al.; 2006]. PPVs are useful for red and green emission, but lack the ability
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to emit blue light due to the large band gap required for blue emission [Lambeth, 2004].
PPV does have the ability to crosslink the main chains by simultaneous UV irradiation
and annealing, and this technique has been investigated to achieve blue emission with
PPV [Deng and Wong, 2009]. While crosslinking can result in color variations, further
processing is required to achieve simultaneous multiple colors from a PPV derivative on
a single device. Photo-lithographical patterning through multi-step solution processing to
remove unwanted polymers or photochemical reactions of particular conjugated vinylcontaining polymers was needed to achieve multiple-color PPV products [Deng and
Wong, 2009].

Figure 4.1

Chemical structure of poly(p-phenylenevinylene) (PPV).

A second benefit of PPV is that it can be easily modified with functional side
groups. Most research has been done on modifying the benzene ring [Perepichka et al.,
2006]. The addition of these groups often changes the color the chemical fluoresces. One
example is MEH-PPV (poly [2-methoxy-5-(2-ethylhexyloxy)-p-phenylene vinylene]).
MEH-PPV is one of the most frequently used polymers in the PPV class of light-emitting
polymers and upon excitation emits in the red-orange (590 nm) range of the visible
spectrum [Zhao et al., 2007; Deng and Wong, 2009]. Other examples of functional
groups altering color emitting properties are blue-emitting diphenyl substituted structures
and green-emitted diphenylamino-substituted structures [Perepichka et al., 2006].
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PPVs were used in the first polymer based LEDs [Perepichka et al, 2006], and
continue to be used in a wide range of LED applications. Additionally, PPV derivatives
are also used as an electron-donating material in organic solar cells, despite their
tendency to photodegrade.
Polyacetylene (PA) was the first reported class of conducting polymer [Ruddy,
2006]. While not aromatic, PA does contain alternating single and double bond carbon
chain and therefore is still a conjugated system. Figure 4.2 shows the chemical structure
of polyacetylene.

Figure 4.2

Chemical structure of polyacetylene (PA).

Since PA was discovered to be electrically conductive in 1977 [Ruddy, 2006], it
has been well classified and its material characteristics thoroughly investigated. While
unsubstituted PA is non-emissive [Perepichka et al., 2006], PA has undergone successful
experimentation with disubstitution including biphenyls, which produced a violet
fluorescence (350-370 nm) [Perepichka et al., 2006]. Polyacetylenes have also been the
basis of liquid crystal applications. Neat polyacetylene is insoluble in organic solvents, so
introducing liquid crystalline substituents into the main polyacetylene chain or by
disubstitution attached to the main polymer chain using alkyl spacers results in a soluble,
fluorescing liquid [San Jose et al., 2011]. Depending on the substituents of the side
chains, the polymers exhibit blue or green photoluminescence [San Jose et al., 2011].
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Polyfluorene (PF) is another frequently used class of light emitting polymers. PFs
are a blue-emitting class of light emitting polymers and exhibit high photoluminescence
quantum yields [Zhao et al., 2009; Jhaveri et al., 2009], good solubility in common
organic solvents [Zhao et al., 2009; Perepichka et al., 2006], and thermal stability
[Perepichka at al., 2006]. The chemical structure of polyfluorene is shown in Figure 4.3.

Figure 4.3

Chemical structure of polyfluorene (PF).

PFs are most often used in light-emitting diodes (LEDs) [Zhao et al., 2009] and
photovoltaic cells [Goktas et al., 2012]. PFs are easily modified by functional group
attachment into the C-2, C-7, or C-9 positions of the fluorenes [Zhao et al., 2009; Jhaveri
et al., 2009], by copolymerization, and by functionalizing the methylene bridge for the
fine-tuning of emissive properties [Perepichka et al., 2006; Ruddy, 2006].
Yet another type of light-emitting polymer is polydiacetylene (PD). The structure
of PD is shown in Figure 4.4. These polymers emit red, blue (the most common colors of
PD crystals and films [Filhol, 2009]), or purple, depending on the delocalization of electrons on the conjugated backbone. The variations in color emission indicate the
possibility of more than two electronic structures of PD chains [Filhol, 2009]. The
emitted color from PDs is dependent on the environmental temperature, solvent polarity,
electromagnetic field [Araya, 1991], applied stress, light exposure, and changes in
chemical environment [Filhol, 2009].
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Figure 4.4
4.4

Chemical structure of the repeat unit for polydiacetylene (PD).

Research Objectives
The primary objective is to covalently graft light-sensitive polymers to polymer

films substrate in order to create light-sensitive films. (Note: This effort is a first step into
generating beta- and gamma-radiation sensitive polymers.) In order to graft lightsensitive chemicals onto the polymer film substrate, the film surface chemistry must be
modified. A survey was made of light-sensitive chemicals and their chemical structures
in order to decide on which functional groups would likely allow for facile grafting to the
surface-modified polymer films. The reaction steps were monitored using Attenuated
Total Reflectance Fourier Transform Infrared (ATR-FTIR) spectroscopy, and the
resultant light-sensitive modified films were characterized using UV-Vis spectroscopy
and fluorescence spectroscopy.
While the development and existence of radiation-responsive polymer films are
not novel, most light-sensitive polymer films are not achieved through surface grafting.
The techniques of spin coating and dip coating are more frequently used, as observed
through extensive literature research. Employing surface grafting techniques to attain
light-sensitive polymer films further develops the field and brings forth future
opportunities to develop other films sensitive to different types of radiation.
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4.5

Approach
Two light-sensitive chemicals were selected based on the interest in investigating

different classes of light-sensitive chemicals (polyphenylenes and polyfluorenes) and the
expected ease of grafting these chemicals to the selected polymer film, poly(ethylene-coacrylic acid) (EAA). The free carboxyl groups on the polymer backbone [Scaffaro, 2011]
make EAA an ideal substrate for surface modifications. Both light-emitting chemicals
contain functional groups that will allow them to be grafted to the surface-modified
polymer film structure. One of the light-sensitive chemicals investigated, 4-(octyloxy)-4biphenyl carboxylic acid (OBC), is a polyphenylene class chemical and contains a
terminal carboxylic acid group that can be used to attach it to the polymer film (Figure
4.5). OBC is expected to fluoresce in the blue-green range due to the polyphenylene and
biphenyl structure [San Jose 2011].

Figure 4.5

Chemical structure of 4-(octyloxy)-4-biphenyl carboxylic acid (OBC).

Figure 4.6 shows the structure of the other light-sensitive chemical investigated,
2,7-bis (bromomethyl)-9,9-dihexyl-9H-fluorene (BDMF), a polyfluorene class chemical.
BDMF is expected to fluoresce in the blue range of the emission spectra, since
polyfluorenes typically fluoresce blue [Zhao et al., 2009].

Figure 4.6

Chemical structure of 2,7-bis (bromomethyl)-9,9-dihexyl-9H-fluorene
(BDMF).
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CHAPTER V
MODIFICATION AND CHEMICAL GRAFTING OF POLY(ETHYLENE-COACRYLIC ACID) FILMS
5.1

Abstract
Two molecules, 4-(octyloxy)-4-biphenyl carboxylic acid (OBC) and 2,7-bis

(bromomethyl)-9,9-dihexyl-9H-fluorene (BDMF), were grafted to the surface of
poly(ethylene-co-acrylic acid) (EAA) films. OBC and BDMF were selected due to their
light sensitivity and potential for applications utilizing light-sensitive polymer films.
Carboxylic acid groups on the surface of the EAA films were converted to acid chloride
groups and then reacted with ethylene diamine to provide primary amines. The primary
amine groups served as the reactive sites to graft the OCB and BDMF molecules onto the
EAA films. The progression of each reaction was confirmed using attenuated total
reflectance Fourier transform infrared (ATR-FTIR) spectroscopy and static contact angle.
Based on the results from these analysis techniques, each reaction step can be confirmed
as well as the successful grafting of OBC and BDMF to the EAA films.
5.2

Introduction
There has been extensive research into the grafting of materials to polymer

substrates. Researchers have investigated the grafting of a range of constituents such as
acryloyl chloride to obtain liquid crystalline polymer films [Burillo et al., 1997], proteins
onto crosslinked polymer hydrogel membranes, and ethylene vinyl alcohol copolymer
films [Ikada et al., 1979]. Despite the substantial research into polymers grafted to a
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substrate, only a limited amount of research has investigated the grafting of materials
from a solid polymer film [Walters and Hirt, 2006].
The versatility of polymers films makes them a practical choice for many
applications. The bulk properties of polymers are ideal for supporting the grafting of a
range of molecules resulting in a wide variety of films. Polymer films have strong
chemical resistivity, high temperature stability, and can be processed using several
different methods such as extrusion molding or compression molding, which result in a
wide range of film thicknesses. There are numerous types of polymer films that are
available with different properties that support many types of grafted materials.
Surface modification is a method frequently employed to create polymer products
designed for specific applications without altering the bulk material and can be achieved
through several techniques. Dip coating and spin coating are frequently used empirical
methods of surface modification, as well as plasma treatment where several activated
species (electrons, ions, free radicals, and some neutral species) [Ma et al., 2012] are used
to expose a surface of the polymer to a non-polymerizing plasma or by depositing a thin
layer of plasma polymer on the surface of the polymer [Yasuda, 1977]. ]. Surface
modification via the covalent reaction of small molecules is another method used with
increasing frequency. By either creating or utilizing existing surface functionality of the
polymer, the surface functional groups can be covalently altered [Zhang et al., 2006].
Using surface modification techniques results in customized surface chemistry tailored
for specific applications. The surface composition of the polymer affects the interactions
the polymer has with its environment and subsequently, the suitable applications which
are unique to each surface modified polymer. Surface modified polymers can be found in
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a range of products from coatings, composites, adhesive tape, textiles [Scaffaro et al.,
2011], and biomaterials [Pasparakis et al., 2010].
There has been extensive research into the grafting of materials onto and from
polymer surface substrates. However, only a limited amount of research has investigated
the grafting of end-functionalized polymers from a solid polymer surface [Walters and
Hirt, 2006]. Polymer films can support the grafting of a range of molecules due to their
versatile physical and chemical properties. Designing functional polymer films requires
knowledge not only of molecular and chemical interactions of the film with the reacting
substrates, but knowledge of the interactions the film will have with its environment.
Factors such as functional group spacing, orientation, and reactivity with environmental
factors are important factors to consider when designing a surface modified polymer film.
With this understanding, polymer films can be designed to have a specific response to
particular external stimuli. Grafting stimuli-responsive molecules, monomers, or
polymers to the polymer films will result in a stimuli responsive polymer film, which can
be affected by pH, temperature, radiation, magnetic field, or light, among others. The
responses of polymers exist in a wide range such as a change in color, transparency,
conductivity, shape (shape memory polymers), size, refractive index, crosslinking, and
chain recombination, among other events [Lawandy, 1982]. Conjugated polymers are
organic semiconductors [Lambeth, 2004] and have strong fluorescent properties,
fluoresce a color in the visible spectrum, and can be used in a multitude of applications
[Perepichka et al., 2006]. Light-sensitive polymer films that change color in response to
irradiation are the application of interest in this study
The polymer film selected for this study was poly(ethylene-co-acrylic acid)
(EAA), which contains carboxylic acid groups that can serve as reactive functional group
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for grafting. EAA is a commonly used polymer film and available commercially. It is
resistant to many organic solvents and is stable in most environmental conditions. After
modification of the EAA films, 4-(octyloxy)-4-biphenyl carboxylic acid (OBC), a
polyphenylene class light-emitting chemical and 2,7-bis (bromomethyl)-9,9-dihexyl-9Hfluorene (BDMF), a polyfluorene class light-emitting chemical, are grafted onto the
surface of the EAA film.
In order to graft OBC and BDMF onto the surface of the EAA film, the
carboxylic acid groups of the neat EAA film will first undergo chemical modification.
First, accessible carboxylic acid groups (-C=OOH) on the film surface will be converted
to acid chlorides (-C=OCl) in order to allow for the quick and facile reaction of ethylene
diamine which will form an amide (-C=ON-) and leave a terminal primary amine (–NH2)
group. The primary amines are stable and suitable for grafting OBC and BDMF. The end
result is EAA film with the surface decorated with light-sensitive molecules that
fluoresce in the visible spectrum. Figure 5.1 shows the chemical structures of OBC and
BDMF. Prior to grafting, the carboxylic acid (–C=OOH) group of OBC will be converted
to acid chloride (–C=OCl), similar to the first EAA film reaction step. The acid chloride
of OBC and the bromine in BDMF can react with the primary amine available on the
EAA film surface resulting is OBC and BDMF chemisorbed to the EAA file surface.

(a)
Figure 5.1

(b)
Chemical structures of OBC (a) and BDMF (b).
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5.3
5.3.1

Materials and Methods
Materials
Poly(ethylene-co-acrylic) acid (EAA) film was extruded to an approximate

thickness of 75 μm from EAA Primacor 1410 (Dow Chemical Company, 9.5 wt% acrylic
acid) by Sealed Air Corporation in Duncan, SC. Phosphorus pentachloride (PCl5, 95%,
CAS 10026-13-8), ethylenediamine (CH2Cl2, 99%, CAS 107-15-3), chlorobenzene (99%,
CAS 108-90-7), and 2,7-bis (bromomethyl)-9,9-dihexyl-9H-fluorene (BDMF, 97%, CAS
187148-75-0) were purchased from Sigma Aldrich (St. Louis, MO, USA).
Dichloromethane (99.9%, CAS 75-09-2) and 4-(octyloxy)-4-biphenyl carboxylic acid
(OBC, 99%, CAS 59748-18-4) were purchased from VWR (West Chester, PA, USA).
HPLC grade water (Fisher Scientific, CAS 7732-18-5) and tetrahydrofuran (THF, Optima
grade, 99.9%, CAS 109-99-9) were purchased from Fisher Scientific (Hampton, NH,
USA). All chemicals were used as received.
5.3.2

FTIR Spectroscopy
Fourier Transform infrared spectroscopy was used to analyze the surface

chemistry of the films. Spectra were collected using a Nicolet 6700 spectrometer
(Thermo Electron Corporation) using Omnic software version 8.1.10 (Thermo Fisher
Scientific 1992-2009). Attenuated Total Reflectance (ATR-FTIR) spectra were collected
using a Pike Technologies Veemax II accessory with a 60 zinc selenide (ZnSe) crystal
and either a liquid nitrogen cooled MCT-A* (mercury-cadmium-telluride) detector or a
DTGS (deuterated triglycine sulfate) detector. A second method of ATR characterization
was conducted using a MIRacle-ATR (Pike Technologies) with a ZnSe/diamond crystal.
Films were also evaluated using transmission FTIR (T-FTIR) with a Thermo Electron
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universal sample holder. Spectra of the light-sensitive chemicals were collected using the
MIRacle-ATR.
5.3.3

Contact Angle Goniometry
Contact angle measurements were made using a Kruss Easydrop contact angle

goniometer with a Teli CCD camera. Drops were 10 L in volume and dispensed using a
1 mL syringe with 1.85 mm inner diameter needles. The drops were formed at ambient
temperature. A minimum of ten drops per sample was collected and analyzed using Drop
Shape Analysis software (version 1.90.0.14). Contact angles were measured using the
'Tangent 2' method; the ten data points were averaged and 95% confidence intervals
calculated.
5.4

Results and Discussion
The following section will illustrate the results and analysis of the methods used

to confirm the reaction steps from the neat (unreacted) EAA film all the way through the
final reaction steps of attaching the light-sensitive chemicals to the EAA films. The
methods of analysis to be discussed include FTIR and contact angle goniometry.
5.4.1

Preliminary Reactions of EAA Film
In order to graft the light-sensitive chemicals onto the EAA film surface, the neat

EAA film underwent two preliminary reactions (Figure 5.2). The first reaction is the
conversion of the C=OOH in EAA to C=OCl groups [EAA-Cl]. EAA films (~ 0.5-1 in2)
were placed in a 0.03 g/mL PCl5/CH2Cl2 solution for 45 min at room temperature. The
films were rinsed three times in clean CH2Cl2 and vacuum dried before proceeding to the
next step. After rinsing and drying, the films were then converted to EAA-NH2 (-C=OCl
 -C=ONHCH2CH2NH2) by sonication for 24 h in a 0.0025-g/mL
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ethylenediamine/HPLC water solution [Walters and Hirt, 2006]. The films were rinsed in
clean HPLC water three times and vacuum dried before proceeding any further. The
completion of the reactions was confirmed using ATR-FTIR.

Figure 5.2

Reaction schematic of the preliminary reaction steps of EAA prior to
reactions with light-sensitive chemicals.

Spectra were collected for neat (unreacted) EAA, EAA-Cl, and EAA-NH2 (Figure 5.3).

Figure 5.3

ATR-FTIR spectra of preliminary film reactions steps: (a) EAA-Neat, (b)
EAA-Cl, (c) and EAA-NH2.
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The ATR-FTIR spectrum for neat EAA film is shown in Figure 5.3a. The peak at
~1700 cm-1 corresponds to the carbonyl stretch of carboxylic acid. In the spectrum for
EAA-Cl (Figure 5.3b) the carbonyl peak has shifted to ~1795 cm-1 demonstrating that the
carboxylic acid was converted to acid chloride [Bruno and Svoronos, 2006; Silverstein
and Webster, 1998]. Once EAA-Cl is reacted with ethylenediamine to form EAA-NH2,
the acid chloride is converted to an amide. As can be seen in Figure 5.3c, the spectrum
for EAA-NH2 does not contain peaks corresponding to the carbonyl of the carboxylic
acid or acid chloride. Instead, two peaks can be easily identified at ~1640 cm-1 and ~1530
cm-1 that are associated with amide II bonds [Bruno and Svoronos, 2006; Silverstein and
Webster, 1998; Pretsch et al., 2000] indicating the successful conversion of the acid
chloride groups to the amide groups.
It is important to note the presence of a peak common to all spectra, regardless of
the reaction step of the film. The peak occurs at ~1465 cm-1and corresponds to the -C-Cscissor bond of the polyethylene repeat unit [Pretsch et al., 2000].
5.4.2
5.4.2.1

Primary Reactions of EAA Films
Reaction Path “A”: Grafting of OBC
EAA- NH2 film was reacted in a solution of 4-(octyloxy)-4-biphenyl carboxylic

acid (OBC) in a 2:1 molar ratio with PCl5 (both in stoichiometric excess) in THF for 72 h
at 60 C. PCl5 was present in the solution to convert the carboxylic acid of the endfunctionalized OBC chemical to an acid chloride to aid in the grafting of OBC to the
EAA-NH2 film (Figure 5.4). After completion of the reaction, the films were rinsed in
clean THF three times and vacuum dried. Figure 5.5 illustrates the grafting of OBC onto
the EAA-NH2 film surface.
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Figure 5.4

Conversion of carboxylic acid of OBC chemical to acid chloride

After completion of the reaction, the films were rinsed in clean THF three times
and vacuum dried. Figure 5.5 illustrates the grafting of OBC onto the EAA-NH2 film
surface.

Figure 5.5

Reaction schematic of the reaction steps of EAA-NH2 with acid chloride
converted OBC chemical to EAA-OBC.

The grafting reaction of OBC onto the EAA film was confirmed using ATR-FTIR
and contact angle. Figure 5.6 shows the ATR-FTIR spectra for the complete reaction
process: EAA-Neat, EAA-Cl, EAA-NH2 and EAA-OBC.
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Figure 5.6

ATR-FTIR spectra of preliminary film reactions steps: EAA-Neat (a),
EAA-Cl (b), EAA-NH2 (c), and EAA-OBC (d).

Comparing the spectra for EAA-NH2 (Fig. 5.6c) and EAA-OBC (Fig. 5.6d), it is
easily seen that there are several notable differences in the spectra for these samples
indicating that OBC grafted onto the film surface. From the EAA-OBC spectrum, there
are three peaks of interest that can be used to validate the presence of OBC on the surface
of the film. From left, a peak at ~1263 cm-1 indicates the C-N in plane bending of a
secondary amide [Bruno and Svoronos, 2006] that is present at the end of the molecule
that bonds to the –NH2 of EAA-NH2. The two peaks to the right at ~1100 cm-1 and ~1025
cm-1 are indicative of the 1-4 disubstituted benzene ring [Silverstein and Webster, 1998].
Having two peaks in this region confirms this. Also, in the region of 1300-1100 cm-1,
where two peaks are present, peaks corresponding to in-plane aromatic bending occur
[Silverstein and Webster, 1998].
Figure 5.7 depicts a comparison of the spectrum of EAA-OBC with the spectrum
of the OBC chemical. The peaks of interest are boxed around both spectra, demonstrating
the peaks used to confirm the OBC presence on the surface of EAA-OBC correspond to
the OBC chemical.
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Figure 5.7

5.4.2.2

FTIR spectral comparison of OBC chemical and EAA-OBC reacted film.
The peaks used to identify OBC on the surface of EAA-OBC are boxed
around both spectra.
Reaction Path “B”: Grafting of BDMF

EAA-NH2 film was reacted in a 5 mM solution of 2,7-bis (bromomethyl)-9,9dihexyl-9H-fluorene (BDMF) in chlorobenzene at 60 °C for 48 h. After the reaction was
complete, the films were rinsed three times in clean chlorobenzene and vacuum dried.
Figure 5.8 illustrates the grafting of BDMF onto the EAA-NH2 film. The steps to convert
EAA film to EAA-NH2 are the same as discussed previously.
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Figure 5.8

Reaction schematic of the reaction steps of EAA-NH2 with BDMF
chemical to form EAA-BDMF.

In comparing the spectra of EAA-NH2 and EAA-BDMF (Figure 5.9), BDMF was
grafted onto the film surface. The peak shoulder at ~1604 cm-1 corresponds to a
conjugated C=C bond, as is present in the benzene ring of BDMF [Bruno and Svoronos,
2006; Silverstein and Webster, 1998; Kuptsov and Zhizhin, 1988]. Two peaks in the
~1025-1050 cm-1 range at 1041 cm-1 and 1027 cm-1 (peak maxima 0.026 and 0.022,
respectively) correspond to C-H bending of a secondary amine and a 1-4 disubstituted
benzene ring, respectively [Bruno and Svoronos, 2006; Silverstein and Webster, 1998].
The peak at ~975 cm-1 (peak maxima 0.0207) corresponds to C-H aromatic in-plane
bending [Kuptsov and Zhizhin, 1988; Silverstein and Webster, 1998]. The peak at ~818
cm-1 (peak maxima 0.0253) corresponds to a 1,2,4-trisubstituted benzene ring, which is
the exact substitution of the rings in the BDMF structure [Bruno and Svoronos, 2006].
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The peaks at 551 cm-1 and 539 cm-1 (peak maxima 0.021 and 0.0166, respectively)
correspond to C-Br stretch [Bruno and Svoronos, 2006; Silverstein and Webster, 1998;
Kuptsov and Zhizhin, 1988; Pretsch et al., 2000]].

Figure 5.9

ATR-FTIR spectra of preliminary film reactions steps: EAA-Neat (a),
EAA-Cl (b), EAA-NH2 (c), and EAA-BDMF (d).

For comparison purposes, the spectrum of EAA-BDMF is compared to the
spectrum of the BDMF chemical in Figure 5.10. The peaks of interest are boxed around
both spectra, demonstrating the peaks used to confirm the BDMF presence on the surface
of EAA-BDMF do correspond to the BDMF chemical.
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Figure 5.10

FTIR spectral comparison of BDMF chemical and EAA-BDMF reacted
film. The peaks used to identify BDMF on the surface of EAA-BDMF are
boxed around both spectra.

Another important feature of the films is seen using Transmission FTIR. Figure
5.11 shows a side-by-side comparison of the transmission spectra for EAA-Neat, EAACl, EAA-NH2, EAA-OBC (on the left) and the preliminary spectra again on the right, this
time with EAA-BDMF.
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Figure 5.11

Transmission FTIR spectra of the preliminary step reaction films, as well
as the final reaction products, EAA-OBC and EAA-BDMF.

Evaluating the transmission spectra for EAA-Neat, EAA-Cl, EAA-NH2, and
EAA-OBC (on the left), particularly the peak at ~1795 cm-1 (the peak associated with the
conversion of the terminal –OH group to the acid chloride [EAA-Neat to EAA-Cl]), the
appearance of this peak is first seen with the EAA-Cl spectrum, but unlike ATR-FTIR,
this peak exists in the subsequent reaction step spectra as well. This is due to the
penetration of the –Cl into the bulk of the film and reacting with interior –OH groups as
well as the –OH groups present on the surface. With the ethylenediamine reaction, used
to produce EAA-NH2, the peak lowers in intensity because the surface –Cl are converted
to the terminal –NH2 group, but the peak is still present because the interior –Cl groups
are still present. Comparing the EAA-NH2 and the EAA-OBC film, the acid chloride
peak is again still present because of the interior –Cl groups, while the peaks at ~1640
cm-1 and ~1530 cm-1 that are associated with amide II bonds of the EAA-NH2 films are
no longer present since the OBC chemical is grafted in place of the terminal –NH2. This
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sequence is also true for the BDMF reaction series, with the acid chloride peak appearing
with the EAA-Cl film and remaining for the duration of the reaction series, as well as the
appearance of the EAA-NH2 amide II peaks and then the BDMF associated peaks
replacing the terminal –NH2 peaks.
5.4.3

Static Contact Angle Results
Static contact angle measurements were measured for the film samples after each

reaction step. Since contact angle is sensitive to the outermost surface chemistry, it can be
used to probe the efficacy of the reactions. Contact angle was determined using the
Young Equation and uses a representative photo of a sessile drop is shown in Figure 5.12,
which depicts the forces shown on a static contact angle drop The gas (ambient air),
liquid (HPLC water) and solid (EAA film) phases are in thermodynamic equilibrium.
The parameters that relate to the balance of these forces are the interfacial tension
between these three phases (SG [solid-gas], SL [solid-liquid], LG [liquid-gas]) and the
equilibrium contact angle, .
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Figure 5.12

Representative image of a sessile droplet showing the intermolecular forces
used to calculate the static contact angle.

Average static contact angles for each EAA film reaction step are given in Table
5.1. The measured water contact angle of neat EAA film was ~95.63 o  1.05, which
matches the range of contact angle values (87-99 o) found in literature for EAA [Scaffaro
et al., 2011; Janorkar et al., 2004]. The contact angle of EAA-Cl lowered only slightly to
91.44 o  1.98, similar to the findings of Scaffaro et al. [Scaffaro et al., 2011]. EAA-NH2
had an average contact angle of 72.47 o  1.01, which is also in the range of observed
static contact angle value of 77 o [Luo et al., 2004].
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Table 5.1

Summary of average contact angle values for surface-modified EAA films
at each reaction step.
Average CA

Std. Dev.

95% CI

Reference CA

EAA-Neat

95.63

1.70

1.05

87-99

EAA-Cl

91.44

2.02

1.98

EAA-NH2

72.47

1.55

1.01

EAA-OBC

80.50

2.40

1.49

EAA-BDMF

85.17

0.50

0.56

Source of
Reference
CA
Scaffaro et
al., 2011;
Janorkar et
al., 2004

Slightly lower
Scaffaro et
value than EAAal., 2011
Neat
Luo et al.,
77
2004
Li and
77-85
Marks, 2008
Jhaveri et al.,
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2009

No known contact angle ranges were known for OBC or BDMF grafted films
however, similar chemicals were found to have contact angle ranges close to those of the
contact angle averages found in this study. EAA-OBC produced an average contact angle
value of 80.25o, which is in the range of similar biphenyl-based molecules that had been
grafted to siloxane functionalized quartz and had a contact angle range of 77-85o [Li and
Marks, 2008]. EAA-BDMF had an average contact angle of 85.17o, which is close to 82o,
the average contact angle value of another brominated fluorene molecule [Jhaveri et al.,
2009].
Neat EAA was a hydrophobic solid, as was EAA-Cl. With the transition to EAANH2, the film became slightly hydrophilic (< 90). The addition of either OBC or BDMF
resulted in a slightly more hydrophobic film with the increased contact angles, even
though the films were still considered in the hydrophilic range. Figures 5.13 and 5.14
illustrate the progression of contact angles between the reaction steps.
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Figure 5.13

From left, EAA-Neat, EAA-Cl, EAA-NH2, and EAA-OBC static contact
angle images.

It can be visually observed that the drop shape changes as the film becomes
hydrophilic (EAA-NH2) and slightly more hydrophobic with either EAA-OBC or EAABDMF.

Figure 5.14

5.5

From left, EAA-Neat, EAA-Cl, EAA-NH2, and EAA-BDMF static contact
angle images.

Conclusions
Based on the ATR-FTIR and static contact angle results, EAA films were

modified to provide a terminal primary amine group that was then used to graft OBC and
BDMF. FTIR analysis confirms the presence of the expected functional groups and also
gives some indication to how the molecules may have reacted onto with films, such as the
subsurface penetration of the –Cl molecule present for all subsequent reaction spectra.
Contact angle measurements matched literature values and confirmed the preliminary
reaction steps as well as supported that OBC and BDMF were successfully grafted to the
EAA film surface.
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CHAPTER VI
OPTICAL PROPERTY CHARACTERIZATION OF EAA-OBC AND EAA-BDMF
POLYMER FILMS
6.1

Abstract
Two light-emitting molecules, 4-(octyloxy)-4-biphenyl carboxylic acid (OBC)

and 2,7-bis (bromomethyl)-9,9-dihexyl-9H-fluorene (BDMF), were grafted to the surface
of surface modified poly (ethylene co-acrylic acid) (EAA) films. Each reaction step was
confirmed previously using attenuated total reflectance Fourier transform infrared
spectroscopy (ATR-FTIR), X-ray photoelectron spectroscopy (XPS) and static contact
angle. This data is available in Chapter 5. OBC and BDMF were chosen as the grafted
molecules for their light sensitivity and use in further development of light-sensitive
polymer films. These LEP surface grafted films were evaluated using UV-Vis
spectrophotometry to determine the maximum UV absorption wavelengths. The films
were then irradiated at the maximum absorption wavelengths in a fluorescence
spectrophotometer and the emission wavelengths were found to be in the violet-blue
and/or red regions of visible light. The films were then irradiated at 254 nm with a UV
lamp to view the fluorescence of the films at all reaction stages. Both EAA-OBC and
EAA-BDMF fluoresced in the blue region of visible light. The films were reevaluated
after six months using MIRacle-ATR FTIR and fluorescence spectrophotometry. The
FTIR results confirmed that the LBC and BDMF chemicals were still in tact on the
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surface of the film, and fluorescence spectrophotometry confirmed the films still
fluoresced in the blue and red regions of visible light.
6.2

Introduction
Light-sensitive polymers (LSPs) have experienced significant commercial success

due to their wide range of applications. LSPs can be found in light-emitting diodes
(LEDs) since they are capable of emitting light across the visible, ultraviolet and infrared
wavelengths. They can also be seen in quantum dots, liquid crystal display televisions,
and light bulbs, among many more applications [Perepichka et al., 2006].
LSPs are also frequently used in the detection of radiation. They are widely
adaptable to various phases used in radiation detection dosimeters, including films
[Cheung et al., 2007] or polymer gels [Mori et al., 2005]. Typically, radiation detectors
have the light-emitting chemical grafted onto the surface for films [Cheung et al., 2007;
Walters and Hirt, 2006; Zhao et al., 2009] or are contained within the gel [Mori et al.,
2005] and change color or another property that is easily monitored for changes with
radiation exposure.
The method of grafting light-emitting chemicals to a polymer substrate to act as a
detection device has limited investigative studies. Due to the accessibility of
commercially manufactured polymers, poly(ethylene-co-acrylic acid) (EAA) was chosen
as the polymer substrate. EAA has bulk properties that make it useful for a wide range of
applications and contains reactive acid groups that can serve as the grafting sites for the
light-emitting chemicals.
Light-emitting polymers can fall into a wide variety of classifications.
Polyphenylenes and polyfluorenes are two classes of light-emitting polymers (LEPs)
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selected for use in this research. Polyphenylenes exhibit strong fluorescence in either the
blue or red visible light regions, depending on the dendrimer orientation [Liu et al., 2003]
or functional groups [Imai et al., 2003] that are attached to the main structure.
Polyfluorenes typically exhibit fluorescence in the blue visible light region [Perepichka et
al., 2006; Zhao et al., 2009; Yu et al., 2001]. The chemical structures of the two lightemitting polymers selected for use in this research, 4-(octyloxy)-4-biphenyl carboxylic
acid (OBC), which is a polyphenylene, and 2,7-bis (bromomethyl)-9,9-dihexyl-9Hfluorene (BDMF), a polyfluorene, are shown in Figure 6.1.

(a)

(b)

Figure 6.1

Chemical structures of OBC (a) and BDMF (b).

When evaluating light-emitting materials for their fluorescence properties, the
emission wavelengths are compared to the visible spectrum to determine the color of
fluorescence in the region of visible light. Figure 6.2 shows the wavelength range of
visible light in the visible spectrum. Based on what can be seen in the visible spectrum,
for EAA film grafted with OBC or BDMF to emit in the blue visible light range, the
emission wavelength must fall in the 450-475 nm range. To fluoresce red, the films must
emit in the range of 620-750 nm [Madigan 2011].
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Figure 6.2
6.3
6.3.1

Visible spectrum with wavelengths for each color range [Madigan, 2011].

Materials and Methods
Materials
The poly(ethylene co-acrylic) acid (EAA) film had an approximate thickness of

75 μm and was extruded from EAA Primacor 1410 (9.5 wt% acrylic acid) pellets (Dow
Chemical Company) by Sealed Air Corporation in Duncan, SC. Phosphorus
pentachloride (PCl5, 95%, CAS 10026-13-8), ethylenediamine (CH2Cl2, 99%, CAS 10715-3), chlorobenzene (99%, CAS 108-90-7), and 2,7-bis(bromomethyl)-9,9-dihexyl-9Hfluorene (BDMF, 97%, CAS 187148-75-0) were purchased from Sigma Aldrich (St.
Louis, MO, USA). Dichloromethane (99.9%, CAS 75-09-2) and 4-(octyloxy)-4-biphenyl
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carboxylic acid (OBC, 97%, CAS 59748-18-4) were purchased from VWR (West
Chester, PA, USA). HPLC water (HPLC grade, Fisher Scientific, CAS 7732-18-5) and
tetrahydrofuran (THF, Optima grade, 99.9%, CAS 109-99-9) were purchased from Fisher
Scientific (Hampton, NH, USA). All chemicals were used as received.
6.3.2
6.3.2.1

Methods
UV-Vis Spectroscopy
UV-Vis spectroscopy was collected using a Shimadzu UV-2550 V2.33 UV-Vis

spectrophotometer. The software used to collect and analyze data was UV Probe
(Shimadzu, version 2.33). The sample cell temperature was maintained at 25° C and the
data collection range was 900-200 nm, to cover the near infrared and ultraviolet
wavelength range.
6.3.2.2

Fluorescence Spectroscopy
Fluorescence spectroscopy data was collected using a Horiba Jobin Yvon

Fluoromax-4 spectrofluorometer. Samples were irradiated at wavelengths of 264 nm and
290 nm. Data was collected and analyzed using FluorEssence software (Horiba Jobin
Yvon, version 3.5.1.20).
6.3.2.3

UV Lamp Illumination
The films were irradiated using a 6-Watt UltraViolet Products handheld UV lamp

with wavelength options of 254 nm or 365 nm.
6.3.2.4

FTIR Spectroscopy
Fourier Transform infrared spectroscopy was used to analyze the surface

chemistry of the films. Spectra were collected using a Nicolet 6700 spectrometer
100

(Thermo Electron Corporation) using Omnic software version 8.1.10 (Thermo Fisher
Scientific 1992-2009). A MIRacle-ATR (Pike Technologies) with a ZnSe/diamond
crystal and a liquid nitrogen cooled MCT-A* (mercury-cadmium-telluride) detector.
6.4
6.4.1

Results and Discussion
UV-Vis Spectroscopy
Once the grafting of LEPs onto the EAA film surface was confirmed [see Chapter

5], these LSP-modified films can be evaluated for their fluorescent properties. The first
step was to determine at what wavelengths the films absorbed UV light. Using the UVVis spectrophotometer, samples were irradiated and data evaluated for peaks in the
absorption spectra. Figure 6.3 shows the UV-Vis spectrum for EAA-Neat, EAA-Cl,
EAA-NH2, and EAA-OBC films. It can be seen in the spectra that EAA-OBC contains a
peak that none of the other films possess. This peak is at a maximum at MAX ~ 290 nm.

Figure 6.3

UV-Vis spectra for EAA-Neat, EAA-Cl, EAA-NH2, and EAA-OBC.
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The UV-Vis spectra for EAA-Neat, EAA-Cl, EAA-NH2, and EAA-BDMF are
shown in Figure 6.4. Similar to EAA-OBC, a peak unique to EAA-BDMF can clearly be
seen in the UV-Vis spectrum. The peak for the EAA-BDMF film reaches a maximum
absorbance at MAX ~ 264 nm with a shoulder at  ~ 320 nm.

Figure 6.4
6.4.2

UV-Vis spectra for EAA-Neat, EAA-Cl, EAA-NH2, and EAA-BDMF.

Fluorescence Spectroscopy
Using the absorbance maxima wavelengths seen in the UV-Vis

spectrophotometry spectra, the films were next irradiated with UV light in a florescence
spectrophotometer to determine the wavelengths at which the films fluoresce. Since the
films had absorbance maxima values of ~264 nm and ~290 nm, all the films were
irradiated at both wavelengths. Figure 6.5 shows the florescence spectrophotometry (FS)
spectra of EAA-Neat, EAA-Cl, EAA-NH2 and EAA-OBC. The EAA-Neat, EAA-Cl,
EAA-NH2 spectra are shown for ~290 nm, since that wavelength corresponded to the
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absorbance maximum seen for EAA-OBC. The spectra of both 264 nm and 290 nm are
shown for EAA-OBC.

Figure 6.5

FS spectra for EAA-Neat, EAA-Cl, EAA-NH2, and EAA-OBC.

Examining the spectra, EAA-OBC spectra each have two peaks that indicate
fluorescence in the visible region for both wavelengths at which the film was irradiated.
A peak can be seen in the EAA-OBC-264 nm spectrum at a wavelength of ~365 nm. A
nearby peak can be seen at ~410 nm for the EAA-OBC-290 nm spectrum. Emission in
this region would fluoresce in the violet-blue region of visible light. There is also a
significant peak at ~700 nm, which corresponds to a fluorescence in the red region of
visible light. While the peak exists in both EAA-OBC spectra, the EAA-OBC-290 nm
spectrum has a peak of much higher intensity in comparison to the EAA-OBC-264 nm
spectrum. This is due to the fact that the absorbance maximum for the EAA-OBC film
was at 290 nm and not 264 nm, which would result in stronger fluorescence at the 290
nm wavelength.
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The FS spectra for EAA-Neat, EAA-Cl, EAA-NH2, and EAA-BDMF can be seen
in Figure 6.6. Like with the FS spectra for EAA-OBC, the EAA-Neat, EAA-Cl, EAANH2 spectra are shown for ~264 nm, since that wavelength corresponded to the
absorbance maximum seen for EAA-BDMF The spectra for both absorbance
wavelengths are shown for EAA-BDMF.

Figure 6.6

FS spectra for EAA-Neat, EAA-Cl, EAA-NH2, and EAA-BDMF.

Two peaks of interest can be seen in the EAA-BDMF FS spectra that indicate
fluorescence in the visible region for both irradiated wavelengths. The left peak can be
seen in the both the EAA-BDMF-264 nm and EAA-BDMF-290 nm spectra at a
wavelength of ~460 nm. While not an intense peak, it corresponds to emission in the in
the violet-blue region of visible light. There is a significant peak at ~700 nm in the EAABDMF-264 nm spectrum, which corresponds to a fluorescence in the red region of visible
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light. This peak does not appear in the EAA-BDMF-290 nm spectrum due to the fact that
the absorbance maximum for the EAA-BDMF film was at 264 nm and not 290 nm.
Florescence would have a stronger appearance at the 264 nm irradiation wavelength.
6.4.3

UV Lamp Illumination
Since the films have been shown to fluoresce using analytical techniques, the next

step was to place the films at all stages of film modification and surface grafting under a
UV lamp and observe for film fluorescence. The films were placed in a glass UVtransparent petri dish and irradiated at =254 nm. Unfortunately, the limitations of the
UV lamp only allowed for irradiation at a single UV wavelength. The films prior to
irradiation and the irradiated films can be seen in Figure 6.7. The physical appearance of
the films did not change after irradiation.

Figure 6.7

Films prior to UV irradiation (a) and during irradiation (b).

Observing Figure 6.7, it is clear that the grafting of the OBC and BDMF
chemicals caused the EAA films to fluoresce. The films did not emit visible light at any
reaction step prior to the light-sensitive chemicals being grafted to the surface-modified
EAA films. While it was expected that EAA-BDMF would have a more intense
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fluorescence at 254 nm due to the absorbance maxima of EAA-BDMF occurring at 264
nm, EAA-OBC had a stronger fluorescence at that wavelength. Since BDMF is a bulkier
molecule, it could be that OBC grafted to the EAA-NH2 film at a higher surface density
due to its more linear geometry.
6.4.4

FTIR and Fluorescence Spectroscopy of 6 Month Old Films
The stability of the EAA-OBC and EAA-BDMF films is important for further

development of the films and any future applications. The films were stored in a
desiccator for six months, then brought out to re-examine the FTIR spectra to confirm the
functional groups of the reacted films are still intact and the FS spectra to confirm the
films will still fluoresce.

Figure 6.8

MIRacle-ATR FTIR spectral comparison of newly made EAA-OBC film
with EAA-OBC film after 6 months.

A comparison of a newly made EAA-OBC film with the same film six months
later is shown in Figure 6.8. From a visual inspection of the spectra, the spectra of the
two films show no difference. To confirm the film was unchanged, the location of the
peaks and the peak heights were also evaluated. The locations of the peaks of interest
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remained unchanged after six months, however the peaks heights did have some changes.
Comparing the six-month-old film to the newly made film, the peaks experienced both
peak height increases and decreases. The maximum peak height increase was a 23.33 %
increase at ~1108 cm-1. The maximum peak decrease was 27.03 % at ~1025 cm-1. The
MIRacle-ATR data confirms the presence of the OBC chemical still intact after six
months, and that the peaks only experienced slight changes in that time period.

Figure 6.9

MIRacle ATR FTIR spectral comparison of newly made EAA-BDMF film
with EAA-BDMF film after 6 months.

MIRacle-ATR spectra were also used to evaluate the EAA-BDMF film as a newly
made film and after six months. Again, a visual inspection of the spectra reveals no
apparent differences. The locations and peak heights of the peaks of interest were
examined for any changes. The locations of the peaks experienced no changes, and the
peak heights varied only slightly. The maximum peak height increase was 7.69% and
occurred at ~1172 cm-1, and the maximum decrease in peak height happened at ~979 cm-1
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and was 3.85%. The MIRacle-ATR spectra confirmed that the light-sensitive chemicals
were both intact for both films after a time period of six months.
Next, the films were evaluated using fluorescence spectroscopy for any changes
in fluorescing activity. Figures 6.10 and 6.11 display the results of the FS spectra for the
six-month-old films, as well as the spectra of the newly made films for comparison.

Figure 6.10

FS spectra of EAA-OBC film after six months and newly made EAA-OBC
film for comparison.

The FS spectra for EAA-OBC reacted films are seen in Figure 6.10. The newly
made films are shown as dashed lines for comparison to the film spectra of the sixmonth-old films. The films were again irradiated at two wavelengths, 264 cm and 290
nm. The aged films did produce peaks in the same locations as the newly made films, but
the peak intensity was severely lower. However, this result does not indicate a
degradation of the films after six months. The fluorescence spectrophotometer has an
extremely small irradiating beam and can only collect spectra for a small spot of the film.
Due to the availability of reactive groups from the neat film from which the films are
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surface modified and subsequently reacted with the LS chemicals, only a small
percentage of the film surface will contain the LS chemical groups. The beam may have
collected spectra for an area of weak OBC presence. The important result from the FS
data is that the film still fluoresces at the same wavelengths and therefore will emit in the
blue and red regions of visible light.

Figure 6.11

FS spectra of EAA-BDMF film after six months and newly made EAABDMF film for comparison.

The EAA-BDMF film produced different results than the EAA-OBC films after
six months. It can be seen from Figure 6.11 that the FS spectra of EAA-BDMF aged film
demonstrated an increase in intensity of the peak at ~460 nm; the exact opposite of the
EAA-OBC results. This is yet another example of how the FS beam collects only a
minimal area of sample surface for data analysis and the intensity of the peaks is not a
complete indication of film fluorescence capabilities. The important fact of the existence
of the peak is most valuable. However, the newly made film produced a strong peak at
~688 nm when irradiated at 264 nm. While the aged film at 264 nm did not produce a
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distinct peak, the film did have moderate fluorescing activity in that region and is still
expected to emit in the red region of visible light, along with the blue emission as
indicated by the peak at ~460 nm.
Lastly, the films were illuminated with a UV lamp at a wavelength of 254 nm,
shown in Figure 6.12. Both films are clearly fluorescing in the blue region of visible
light. The results from MIRacle-ATR FTIR, fluorescence spectroscopy and UV
illumination indicate the presence of the LS chemicals on the surface of both films as
well as confirm the fluorescing properties of the films remain after a period of six
months.

Figure 6.12

UV illumination of six month old EAA-BDMF (left) and EAA-OBC (right)
at a wavelength of 254 nm.
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6.5

Conclusions
The observed fluorescence of the EAA-OBC and EAA-BDMF samples

demonstrates that grafting of OBC and BDMF to the surface-modified EAA films was
successful. It was also shown that the activity of these light-sensitive chemicals was not
significantly reduced by the use of the terminal functional groups in order to attach the
molecules to the EAA films, as the conjugated structures remained intact. Absorbances of
the films were measured using UV-Vis spectrophotometry. Using the absorbance maxima
values from the UV-Vis data, the OBC- and BDMF-modified EAA films were irradiated
at the absorbance maxima wavelengths. The fluorescence spectrophotometry results
showed that the films would emit visible light in the violet-blue and/or red regions. Due
to the promising data shown from these analytic techniques, the films were irradiated
using a 254 nm UV lamp, and both films fluoresced strongly in the blue range of visible
light. If films were irradiated at a higher wavelength, such as 700 nm where both films
demonstrated emission peaks, it is expected that the films would also fluoresce red. The
films were re-evaluated after six months using MIRacle-ATR FTIR, fluorescence
spectrophotometry, and UV illumination, producing data that confirmed the presence of
the OBC and BDMF chemicals still in tact on the surface of the films as well as spectra
indicating the fluorescence stability of the films over an extended period of time and
visible confirmation of fluorescing properties.
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CHAPTER VII
RECOMMENDATIONS
7.1

Recommendations for Artificial Saliva
Based on the inconsistency between drug-doped salivas in all three methods of

characterization (pH, rheology, and pendant drop), it is suggested that future studies
examine the effects of drug concentration and how varying these parameters influences
the physicochemical and viscoelastic properties. Using one representative artificial saliva
as opposed to three would eliminate the variances between saliva solutions, and the true
effects of concentration and other investigated characteristics could be examined without
having to take into effect the differences is saliva composition. Also, investigating the
effect of phospholipid phosphatidylethanolamine (PE) in the artificial saliva as opposed
to phosphatidylserine (PS) to see changes in physicochemical properties in artificial
saliva and how the properties compare to natural saliva.
Investigating the effects of other influential factors such as lipophilicity,
hydrophobicity, and particle charge would also be beneficial. A suggested method would
be using the same core particle substrate as a standard reference, and coating the particle
with varying materials with different properties, such as a hydrophilic poly(ethylene
glycol) coating versus a hydrophilic amine functional polymer coating. Studying the
lipophilicity of drugs using octanol-water partition coefficients (studies underway) is also
extremely beneficial, since lipophilicity is a key parameter in drug diffusion. A review
paper summarizing the effects of various surface chemistries and concentration
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dependence would be an asset to the field of aerosol particulate studies and biological
modeling.
Diffusion modeling would also be enhanced by modeling the gel and sol layers of
mucus as opposed to one mucus substrate. Temperature-dependent diffusion studies
using a temperature-controlled ATR-FTIR crystal would be beneficial. The temperature
of the human body, at 37 °C, would affect the diffusion of a drug particle as opposed to
25 °C ambient temperature.
7.2

Recommendations for Light-sensitive Polymer Films
The EAA-OBC and EAA-BDMF films both fluoresced blue when illuminated

with UV light at a wavelength of 254 nm. Both films also produced peaks in the red
region of visible light when characterized by fluorescence spectrophotometry (FS). It is
recommended that the films be illuminated with other UV wavelengths to see the films
fluoresce red. The films could also be illuminated a wavelength where no FS peaks were
seen to see if the films have any fluorescence in those ranges. Investigating the properties
of the films with other radiation sources such as gamma (γ) or alpha (α) would provide
insight to the potential of the films’ surface chemistry as indicators for other types of
irradiation. Grafting the film surface chemistry to other substrates with differing surface
chemistry and terminal functional groups would also be beneficial for determining the
effects of spacing on color emission.
Investigating environmental effects on the films and their aging properties would
be an interesting characterization study. The films could be characterized as newly made
films, and then stored in a variety of environmental conditions such as humid or dry
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environments, as well as hot and cold surroundings. At various time intervals, the films
could again be characterized to determine the effects of the various environments.
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APPENDIX A
FTIR METHODS: ATR, TRANSMISSION, AND DRIFTS
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A.1

FTIR Methods: ATR, Transmission, and DRIFTS
All FTIR (Fourier transform infrared) spectroscopy data was collected on a

Nicolet 6700 FTIR spectrometer (Thermo Electron Corporation) using Omnic software
(version 8.1.10, Thermo Fisher Scientific 1992-2009). In this research, either a liquid
nitrogen cooled MCT A* (mercury-cadmium-telluride) detector or a deuterated triglycine
sulfate (DTGS) detector with an extended range KBr beam splitter was used. Two
accessories were used to collect attenuated total reflection (ATR-FTIR) spectra: (1) Pike
Technologies Veemax II accessory with a 60 zinc selenide crystal for film and liquid
samples or a 65 germanium crystal for gold wafer samples; (2) Pike Technologies
MIRacle-ATR accessory with a 45 diamond/ZnSe crystal. For transmission FTIR, a
universal sample holder was used. Diffused reflectance infrared Fourier transform
spectroscopy (DRIFTS) were performed using a Pike Technologies EasyDiff accessory.
A.2

FTIR Set-Up
1. Clear the air line (Figure A.1 below depicts the airline setup)
a. Check the sink to make sure there is no glassware and make sure
everyone in the lab is wearing earplugs.
b. Carefully climb up on the counter to the right of the Waters GPC.
c. Close the yellow valve by positioning the handle perpendicular to the
airline (Labeled 1 in Fig. A.1.).
d. Open the red valve by positioning the handle parallel to the airline
(Labeled 2 in Fig. A.1).

117

e. There are two filters to the right of the yellow valve. Loosen the
screws at the bottom of each filter. Air will be released from the
bottom of the filters (Labeled 3 in Fig.A.1).

1
3

2

Figure A.1

Airline valve setup in PolySEL Lab 180
f. Watch the airflow into the sink until there is no more moisture coming
out of the hose with the compressed air that is also exiting. Once there
is no more water, close the screws of the filters, then close the red
valve, and then open the yellow valve.
g. Check the flow meter going into the FTIR to make sure there is 30 psi
flowing into the FTIR.

2. Place the accessory being used into the FTIR
a. The Veemax II ATR accessory and the MIRacle-ATR accessory both
have an air line that attaches to the FTIR at the bottom left of the FTIR
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chamber. Each accessory also comes with two “ears” that attach to the
entrance and exit of the FTIR and seals the accessory from external
air. While not in use, each of the holes on the side of either accessory
should be sealed with Parafilm to prevent anything foreign from
entering the accessory chamber.
b. The DRIFTS accessory as well as Transmission accessory are run with
the main chamber lid closed.
c. Ask for help before attempting to transition between FTIR accessories
for the first time.
3. Add liquid nitrogen to the liquid nitrogen trap to cool the MCT detector
a. The liquid nitrogen chamber is on the left side of the FTIR covered by
a circular lid.
b. Open the lid, remove the plug and place the funnel (plastic funnel with
metal stem and Styrofoam barrier) into the hole.
c. Pour liquid nitrogen into the funnel slowly, allowing enough time the
liquid nitrogen to flow into the FTIR liquid nitrogen chamber and to
not overflow the funnel. If the liquid nitrogen overflows (the excess
liquid nitrogen can be seen at the base of the funnel/entrance to the
liquid nitrogen chamber), a loud crackling noise can be heard.
Overflowing the liquid nitrogen will damage the FTIR benchtop and
accelerate the deterioration of the rubber gasket surrounding the liquid
nitrogen chamber.
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d. Remove the funnel and gently place it on a paper towel on the
benchtop. Since the funnel is frozen, it will crack if placed forcefully
or dropped.
e. Replace the plug into the liquid nitrogen chamber and close the
chamber cover slightly. Wait a few minutes before completely closing
the cover to the chamber to avoid damaging the plastic cover or rubber
gasket. These will fracture if physically forced when frozen.
f. Wait approximately 20 minutes for the detector to completely cool and
the FTIR interior to purge prior to running samples.
4. Aligning the FTIR
a. Aligning the FTIR should be done once per week in the transmission
mode. Instructions for alignment are available in the FTIR manual as
well as a supplemental manual prepared by another member of the
PolySEL research group.
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A.3

Data Collection and Use of OMNIC Software
Open the OMNIC Software and select “Collect  Experiment Setup”

121

1. The Experiment Setup window will open

In the “Collect” tab, the number of scans, resolution, and background
collection method is set. For polymer films, 128 or 256 scans are
recommended. For liquid samples, 128 scans is recommended, except for time
resolved diffusion spectra collection, where 64 or 32 scans is recommended
due to the speed with which the spectra need to be collected and the need to
not have combined/averaged (but rather discrete) spectral information. For Au
wafers with thick surface coatings, 256 scans are recommended.
2. Typically, each user has saved setup files for the types of samples and FTIR
each person uses. To access a saved setup file, click “open” on the bottom left
of the collect tab, select the folder the file is saved in, and click “open”. The
saved file with its parameters will load into the OMNIC Experiment Setup
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window.
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3. It is also important to check the “Bench” tab in the Experiment Setup window
prior to collecting the background or any samples

Here, the user can see the interferogram strength, change the type of detector
for data collection, and edit the collection range, gain, and aperture. If the
interferogram is too strong (>10) such that the detector is saturated, a physical
screen can be inserted at the FTIR beam path exit or the aperture can be
reduced.
4. Once the parameters have been confirmed in the Experiment Setup window,
click “ok” at the bottom right of the Experiment Setup window. Next, go to
the top left of the OMNIC software window and click “ColBkg” for “Collect
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Background”.

A window will open to confirm that the user is prepared to collect the
background. Make sure the crystal being used has been cleaned and allowed
to dry (no residual solvent) for Veemax or MIRacle ATR, or that the chamber
has been closed for DRIFTS or Transmission, and that the FTIR has had
enough time to purge before collecting the background for all collection
techniques. Without taking these steps, there will be strong water peaks that
appear in the background and most likely there will subsequently be negative
peaks in the sample spectra.
5. The background will begin collecting and take 1-3 minutes depending on the
number of scans the user selected.

125

6. Once the background has been collected, select “yes” in the popup window to
add the background to a window.
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Go to “File Save As” and save the background spectra in the folder of
choice.
Next, back in the OMNIC software, go to “CollectExperiment SetupUse
Specified Background” and select the background file that has previously
been saved, and click “ok”.
7. Next, load the sample. Once the sample is situated, select “ColSmp” for
“Collect Sample”. Name the sample in the first pop up window, click “ok”,
and then “ok” again in the second pop up window. Sample spectra will then
be collected.

8. Once the sample spectrum is done being collected, select “yes” to add the
spectra to a window (usually the same window of the background). However,
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be aware of which window OMNIC is adding the spectra in case any changes
need to be made.

9. Next, the sample spectra can be saved individually or as a group if there are
multiple spectra in the user's data folder.
10. Data collection using the OMNIC software follows the same procedure for
each method of FTIR data collection. Make sure that the parameters are
appropriate for the method being used.

A.4
A.4.1

Sample Set-Up
Veemax II ATR
The Veemax ATR is most commonly used for films or liquid samples with the

ZnSe crystal and wafers with the 65° germanium crystal. The incidence angle for the
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ZnSe crystal and the standard germanium crystal is 60° and 65° for the 65° germanium
crystal. Adjust the incidence angle using the knob on the front of the Veemax accessory.
To clean any of the Veemax crystals, moisten a cotton ball generously with
methanol, rub the crystal in a circular motion, dry the crystal with a new, dry cotton ball,
and then wait a few minutes for any residual methanol to evaporate prior to placing a
sample or collecting a background spectrum.
To collect sample spectra for films or wafers, place the sample on the crystal.

Set the sample in place by tightening the clamp slowly. Uniform force is
necessary for consistent contact between the sample and the crystal. Without adequate
contact, sample spectra will be noisy, inconsistent, and generally cannot be used without
analysis for ratios in order to generate semi-quantitative data.
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The sample is now ready for data collection. Once spectra collection is completed
for this sample, loosen the clamp, rotate the clamp from over the crystal and sample,
remove the sample carefully so to not scratch the crystal surface, and clean the crystal
before moving on to the next sample.
To collect sample spectra for liquid samples, clean the crystal and then attach a
previously cleaned liquid retainer, fastening the screws to the crystal plate using an Allen
wrench. To clean the liquid retainer, methanol with a cotton ball is usually adequate. It is
recommended that the user remove the rubber O-ring while cleaning to ensure there is no
residual solvent or sample trapped beneath the O-ring. Cleaning using the glassware
cleaning method can also be used. For especially difficult samples, sonication in
methanol followed by wiping with methanol cotton ball is recommended. The liquid
retainer can also be sonicated in water. Make sure the O-ring is replaced completely to
ensure the seal with the ATR crystal is good.
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Using a pipet, gently add the liquid sample to the center of the crystal until the
crystal is covered by a layer of the liquid. It is not necessary to fill the entire retainer
volume with the liquid sample in order to collect good spectra. If the sample contains any
hazardous or volatile components, cover the sample well with a clean glass slide to
prevent evaporation and/or exposure of the user to a hazardous substance. For all liquid
samples, monitor the liquid level as well as the edges of the liquid retainer to ensure no
solvent is leaking under the retainer. Once the liquid has been placed on the crystal, the
sample is ready for data collection.
Once spectra are collected, use a dry cotton ball to soak up the sample off the
crystal surface before removing the liquid retainer. With the retainer still attached, clean
the crystal with one or more methanol soaked cotton balls. Remove the retainer and clean
the retainer and crystal thoroughly with methanol before moving on to the next sample.
A.4.2

MIRacle ATR
The MIRacle-ATR can be used for liquid, solid, and powder samples. The sample

setup is very similar to the Veemax ATR setup. For solid samples such as films, there is
no need for the liquid retainer or mounting ring to be attached. Clean the crystal the same
way as with the Veemax ATR, wait for residual methanol to evaporate, collect the
background, and then place the sample on top of the crystal and secure with the pressure
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clamp and flat bottom pressure tip. For liquid or powder samples, attach the liquid
retainer and secure the retainer with the mounting ring. For powder samples, gently
“spoon” the sample into the sampling area with a spatula and use the pressure clamp with
the concave tip to secure the powder.

A.4.3

DRIFTS
DRIFTS is most commonly used to collect powder samples. To collect DRIFTS

samples, a few preparation steps are required prior to setting up the sample for collection.
First, measure out the powder sample and KBr powder in a 5:95 wt% ratio. Since only a
small amount of powder mixture is required, 0.005 grams of sample and 0.095 grams of
KBr powder is recommended. Mix the KBr powder and sample thoroughly in the mortar
and pestle. Transfer to a weighing boat for ease of sample transfer into the DRIFTS
sample cup or into a small vial for storage in the desiccator. Transfer sample into one of
the metal sample cups in the DRIFTS sample preparation kit. Using a razorblade smooth
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the surface to ensure a relatively flat sample surface from which the light will bounce.
Prepare the second metal sample cup with neat KBr powder (no sample added) that has
also been crushed and smoothed in the manner described above. Place the neat KBr
powder sample container in the first sample slot (the slot the goes into the DRIFTS
accessory first) and the Sample-KBr mixture sample container into the second sample
slot (the slot further from the end that enters the DRIFTS accessory first). Very carefully,
open the top of the FTIR hood and place the samples into the DRIFTS accessory.

Pull back on the holder gently to not disturb the smooth powder, close the lid of
the FTIR sample compartment hood and wait approximately 25-30 minutes for the FTIR
to purge. Collect the neat KBr background when an appropriate amount of time has
passed, then open the FTIR hood and quickly but carefully push the sample holder
forward. The Sample-KBr mixture is now in place to have its spectrum collected.
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Once the sample spectrum collection is completed, remove the sample holder and
clean the metal sample cup containing the Sample-KBr powder mixture. Retain the neat
KBr cup, if there are more samples to run. Or clean both sample cups if spectra
collection is complete for all samples.
A.4.4

Transmission FTIR
Transmission FTIR is unique in that spectral information is collected from the

entire sample thickness, as opposed to sample (sub) surface as is the case in the other
FTIR collection methods described above. To use this method, light must be transmitted
completely through the sample. The transmission method is therefore most commonly
used on translucent gases, liquids, and (polymer) films. Insert the transmission accessory
and close the FTIR sample compartment hood to allow the FTIR to purge. Wait
approximately 25-30 minutes before collecting the background (open/empty sample
compartment) and sample spectra.
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For polymer films, place the sample in the sample clamp and after collecting the
background, quickly slide the sample into the grooves in the Transmission accessory, and
close the sliding door on the hood. The sample is now ready for spectra collection.
To remove the sample, open the lid to the FTIR hood and quickly and carefully
slide the sample clamp out of the accessory. Keep the lid to the hood closed between
samples.
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APPENDIX B
SURFACE ANALYSIS AND DEPTH OF PENETRATION: A COMPARISON OF
DIFFERENT SURFACE-SENSITIVE FTIR TECHNIQUES
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B.1

Introduction to Surface Chemistry Characterization Methods
Several characterization methods are available to researchers to investigate the

surface chemistry of samples. Commonly used techniques available to our laboratories
include X-ray photoelectron spectroscopy (XPS), contact angle goniometry, Fourier
transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM),
transmission electron microscopy (TEM) and atomic force microscopy (AFM). Each
technique uses a different method to collect sample data. XPS uses an X-ray beam to
irradiate samples and has a relative depth of penetration of 1 m, while FTIR uses an
infrared beam and measures the sample’s absorption of the IR beam. The FTIR depth of
penetration can range from approximately 0.1 to 2 m [Kwan 1998], depending on the
parameters used. Contact angle goniometry has no penetration abilities, and conveys
surface chemistry information using interfacial tension and contact angles, which are
impacted by the surface functional groups present. In electron microscopy techniques a
primary electron beam is passed through the sample and produce excited backscattered
secondary electrons that generate a sample image [John Innes Center 2012]. TEM
completely penetrates the sample thickness, while SEM scans the surface with the
electron beam and has an approximate depth of penetration range of 0.1 to 3 m that is
dependent on sample composition, density, atomic weight, and beam energy [Muller
2008]. TEM specimens do have a maximum thickness dependent upon instrument
capabilities. Samples with a thickness greater than the maximum thickness in their
native state must be amenable to being sliced and cryotomed.
The versatility, reliability, and speed of FTIR spectroscopy make it an ideal
characterization method. External reflectance (ER-FTIR) is an FTIR spectroscopic
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technique that does not utilize a crystal since the IR beam from the source is reflected by
the sample to the detector. Attenuated total reflectance (ATR-FTIR) does not require a
solid surface, as is the case with ER-FTIR, and is a fast and easy FTIR technique. In
addition, there are several options for crystal and ATR accessory configurations
allowing for a wide range of sample types to be examined. Characteristics that must be
considered include the ATR crystal properties, angle of incidence, sample material
properties, and depth of investigation desired.
Of the factors that must be considered when configuring an ATR-FTIR study,
one of the most important is the crystal selection. The primary consideration is, of
course, the absence of IR light absorbance in the wavelength range of interest. Selection
of the crystal is also dependent on the crystal chemical resistance for the sample and any
solvent present, durability, hardness, and refractive index. Table B.1 summarizes some
key properties of commonly used ATR-FTIR crystals.
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Table B.1

Tabulated Summary of Commonly used ATR-FTIR Crystal Properties
Important for Crystal Selection [Pike Technologies, 2011].

Crystal Material

Refractive
Index
2.4

Diamond/ZnSe

Long Wave
Length Cutoff
wavenumber (cm1
)

Hardness
(kg/mm2)

525

5700

780

550

1500

1150

525

120

4
Ge

Si
ZnSe

3.4
2.4

General Sample
and Solvent
Compatibility
Can withstand
hard, acidic or
alkaline samples;
pH range 1-14
General purpose,
or rubber or
carbon-filled
samples; pH range
1-4
Useful for far-IR
spectral ranges; pH
range 1-12
General purpose
ATR crystal; pH
range 5-9

Most commonly used ATR crystals have a refractive index between 2.4 and 4.0,
which is higher than most organic samples [Dole 2011]. Organic solvents such as
tetrahydrofuran, toluene, and acetone have refractive indices of 1.41, 1.50, and 1.37,
respectively. In calculating depth of penetration, for a given sample higher crystal
refractive indices result in lower depths of penetration. It is also important to consider
sample composition when choosing an ATR crystal. For example, zinc selenide (ZnSe)
would not be a good crystal choice for an acidic sample since it would etch the crystal
surface [Kazarian and Chan, 2010]. A primary factor in obtaining quality ATR-FTIR
data is dependent upon the sample surface since intimate contact is necessary to obtain
suitable signal-to-noise ratio suitable. However, obtaining this contact area—generally
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through use of a clamp—is an issue for hard and/or rough samples that would scratch
the surface of a soft crystal such as ZnSe. Some chemicals can react and etch the
surface of the crystal, as well as acidic solutions pH > 5 [Dole 2011, Pike Technologies
2011]. Etched or scratched crystal surfaces result in lower crystal-sample contact and
therefore lower quality spectra, lower depth of penetration, and potential accessory
contamination since the scratches cannot be cleaned easily. Lower and inconsistent
sample-crystal contact may result in spectral errors such as inaccurate peak detection,
increased noise levels, and the presence of negative peaks. Refer to Appendix A for
information on how to ensure consistent sample-crystal contact.
Crystal parameters are chosen to optimize sensitivity based on the crystal and
sample compositions. One parameter that can be controlled is incidence angle. For a
given sample-crystal combination, a higher incidence angle results in a lower depth of
penetration and so consequently lower spectral peak intensities [Kazarian and Chan,
2010]. The minimum and maximum depths of penetration are important to consider
when choosing an ATR crystal depending on whether only surface information is
desired, or you also want to interrogate a significant portion of sub-surface space to
maximize the signal or detect as functional groups that may be present in that region of
the sample. Based on sample composition and theorized reactions, the crystal must be
selected for compatibility with the sample. For example, self-assembled monolayers
(SAMs) grafted from gold wafers need a crystal that is sensitive enough to allow beam
penetration through the grafted surface chemistry, but must not penetrate completely
through the monolayer to the gold wafer, since the gold will reflect an excess of light
and overshadow the spectral peaks of the surface chemistry functional groups. For
surface-modified films, a larger depth of penetration is desired due to the ability of some
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molecules to penetrate into the film, while others are too large and restricted to the
film’s surface. A larger depth of penetration would permit the analysis of a greater
thickness of film.
Figure B.1 illustrates how the FTIR instrument collects ATR spectra. The IR
beam is transmitted through the crystal where it reflects evanescent waves off the crystal
and into the sample surface, where light is absorbed or reflected. Reflected light is
bounced back to the detector. Evanescent waves are only effective if the crystal has a
higher refractive index than the sample. The outputted spectrum contains absorbance
peaks that correspond to molecular motions of the functional groups that made contact
with the reflected light.

Figure B.1

B.2

Spectra collection using a single-bounce attenuated total reflectance
(ATR) FTIR accessory.

Depth of Penetration
There are several factors that affect the depth of penetration of the FTIR light

source and therefore the portion of the sample interrogated. Equation B.1 [Dole 2011] is
used to calculate the depth of penetration of the FTIR light source into the sample:
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dp =

l

2 p (n si n 2 q - n 22 )1/ 2
2
1

E q. B. 1

w h er e λ is t h e w a v el e n gt h of li g ht, θ is t h e a n gl e of i n ci d e n c e of t h e I R b e a m, a n d n 1 a n d
n 2 ar e t h e r efr a cti v e i n di c es of t h e cr yst al a n d s a m pl e, r es p e cti v el y.

B. 3

D e pt h of P e n et r ati o n: C o m p a ri n g A T R T e c h ni q u es
A T R e x p eri m e nts i n o ur l a b or at ori es utili z e diff er e nt cr yst als ( wit h diff er e nt

r efr a cti v e i n di c es) a n d diff er e nt i n ci d e n c e a n gl es w h e n c oll e cti n g s a m pl e s p e ctr a. W hil e
ot h er cr yst al o pti o ns ar e a v ail a bl e fr o m v e n d ors, i n o ur l a b or at ori es t h e MI R a cl e A T R
a c c ess or y is c o nfi g ur e d wit h a 4 5  Z n S e- di a m o n d cr yst al, a n d t h e V e e m a x A T R c a n b e
o utfitt e d wit h a Z n S e ( 6 0 ) or g er m a ni u m ( 6 0 or 6 5) cr yst al. T a bl e B. 1 li sts t h e
r efr a cti v e i n di c es, i n ci d e n c e a n gl es, a n d r a n g es of d e pt h of p e n etr ati o ns f or t h e cr yst als
us e d f or t his r es e ar c h. T h e d e pt h of p e n etr ati o n r a n g es s h o w n ar e c al c ul at e d f or a
p ol y( et h yl e n e c o- a cr yli c a ci d) ( E A A) s a m pl e w hi c h h as a r efr a cti v e i n d e x of 1. 4 0 8.
T h er e ar e t w o diff er e nt d et e ct ors a v ail a bl e o n t h e Ni c ol et 6 7 0 0 F TI R t h at w as us e d f or
d at a c oll e cti o n, M C T a n d D G T S. E a c h is c a p a bl e of c oll e cti n g o v er a diff er e nt
w a v e n u m b er ( 1/  ) r a n g e; t h e M C T a n d D G T S d et e ct or w a v e n u m b er r a n g es us e d i n t his
r es e ar c h ar e 4 0 0 0- 8 0 0 c m - 1 a n d 7 0 0 0- 4 0 0 c m - 1, r es p e cti v el y. Si n c e w a v el e n gt h is a
v ari a bl e i n t h e d e pt h of p e n etr ati o n c al c ul ati o n, t h e e x a ct w a v e n u m b er ( or w a v e n u m b er
r a n g e) of i nt er est i m p a cts t h e d p ( or d p r a n g e). T h er ef or e, if t h e s a m e w a v e n u m b er r a n g e
is b ei n g us e d f or b ot h d et e ct ors, t h er e is n o diff er e n c e i n t h e d p . It c a n b e s e e n fr o m
T a bl e B. 2 t h at t h e di a m o n d cr yst al, wit h its c orr es p o n di n g p ar a m et ers, gi v es t h e
MI R a cl e A T R t h e gr e at est d e pt h of p e n etr ati o n, at l e ast f or t h e E A A fil ms.
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Table B.2

Table of Refractive Indices [Kazarian and Chan, 2010], Incidence Angles,
and Calculated Depth of penetration (dp) ranges for an EAA film sample
(n2=1.408) for the four ATR crystal options available in our laboratories.
EAA dp range (m)

Crystal
Material

Crystal
Refractive
Index (n1)

Incidence
Angle (θ)

Diamond

2.4

Zinc
Selenide
Germanium

MCT detector

DTGS
detector

45

0.42-2.10

0.24-4.20

2.4

60

0.26-1.30

0.15-2.60

4.0

60

0.13-0.63

0.07-1.26

Germanium
4.0
65
0.12-0.60
0.07-0.60
Note that the available dp for each crystal option varies based upon the available
wavenumber range of each detector (MCT: 4000-800 cm-1; DGTS: 7000-400 cm-1).
B.4

Comparing spectra of ATR Techniques
Figure B.2 shows a common scale comparison of Veemax and MIRacle ATR-

FTIR spectra for an EAA-NH2 film. MIRacle ATR provides stronger (higher intensity)
peaks than the Veemax ATR. This is due to the fact that MIRacle ATR has a greater
depth of penetration during sample collection. Since more sample is being contacted by
the IR radiation, there is a strong signal. When compatible with an experiment and
sample type, the MIRacle accessory is therefore the preferred technique.
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Abs
0.010

MIRacle ATR
Veemax ATR

1800

1600

1400

1200

1000

Wavenumber (cm-1)
Figure B.2

Comparison of MIRacle and Veemax ATR spectra for an EAA-NH2 film
with absorbance presented on a common scale.
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APPENDIX C
COMPRESSION MOLDER OPERATIONAL GUIDELINES AND PRODUCTION OF
EVOH FILMS USING COMPRESSION MOLDING
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C.1

Compression Molder Operational Guidelines
A compression molder is available in the Swalm School of Chemical Engineering

at Mississippi State University for use, with approval, in the Unit Operations Laboratory.
The compression molder was manufactured by Carver, Inc. (model number
3893.4PR1A00, Wabash, Indiana). Due to the danger of using a compression molder, it is
important to understand fully how to use the compression molder prior to operating the
machine without assistance. A brief set of directions for how to use the compression
mold follows.
1. Turn on the main power supply using the large switch to the right of the
compression molder.

Figure C.1

Main power source switch.

2. Turn on the power to the compression molder using the red switch located on
the right side of the compression molder.
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Figure C.2

Picture indicating red switch for powering compression molder.

3. Power on the hydraulic pumps (right rocker) and heated plate (left rocker)
using the switches on the instrument panel.

Figure C.3

Instrument control panel.
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4. Adjust the temperatures for the upper and lower plates using up and down
arrows on the control panel. Set and confirm final use temperatures using the
right most button for each temperature controller.
5. Set the pressure by using manual mode (“man”) on right control panel, and set
pressure to pounds by pressing “set” three times. Use up and down arrows to
choose pressure and confirm by pressing “man”.
6. Wait for the plates and mold to heat to the set temperature.

Figure C.4

Carver, Inc. compression molder (model 3893.4PR1A00).

7. Place the material in mold (prior application of silicon release spray is
recommended). Press both green buttons simultaneously and hold until the
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desired pressure is reached. Leave sample in press for desired length of time.
Press the red button to release the plates. Warning: samples come out of the
compression molder at extremely high temperatures. Wearing hot gloves
remove the mold carefully and allow the mold to cool before handling the
sample.
8. To shut down the instrument, first cool mold to room temperature by opening
the water line to instrument using the water spigot on the wall to the right of
the press. Next turn off the control panel using the power button on the right
side of the instrument and finally shut off the main power source.

C.2

Using the Compression Molder to Make EVOH Films
EVOH (ethyl vinyl alcohol) pellets, produced by Dow Chemical, were molded

into films using a compression molder. The films were processed at 190 C and 4000
pounds. Prior to pressing, EVOH pellets must first be dried in a vacuum oven (no heat
applied) for 24 hours to evaporate any water that may have adsorbed onto the surface of
the pellets. Figure C.5 shows a film that was produced without first drying the pellets.
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Figure C.5

EVOH film produced at 190 C and 4000 lbf without drying pellets.

As can be seen from Figure C.5, if the pellets are not dried prior to compression
molding, a brittle, irregular film is produced. With drying, a thinner, more uniform film is
produced. Figure C.6 shows a film produced from dried EVOH pellets.

Figure C.6

EVOH film produced at 190 C 4000 lbs. with dried pellets.
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APPENDIX D
CONTACT ANGLE GONIOMETRY OPERATIONAL GUIDELINES FOR DATA
COLLECTION AND ANALYSIS
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D.1

Instrument Specifications
All contact angle and pendant drop data was collected using a Kruss EasyDrop

with a Teli CCD camera and analyzed using Drop Shape Analysis (DSA) software
(version 1.90.0.14, Kruss).

Figure D.1
D.2

Kruss EasyDrop Contact Angle Goniometer with syringe loaded.

Instrument Set-Up
1. Ensure the instrument is level using a small level placed on the sample
stage. Adjust the feet of the EasyDrop if the level needs to be adjusted.
2. Attach either a red (sessile drop) or green (pendant drop) needle to a
Hamilton syringe.
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3. Flush the needle several times using the fluid that will be used for data
collection.
4. Fill the needle, and ensure there are no bubbles in the tip.
5. Open DSA software, then go to the Device Control Panel and open the
“Dosing” tab.
6. Click the button for “Contin” to set the dosing control to continuous.
7. Note: The up arrow indicates moving the plunger of the syringe up and the
down arrow indicates moving the syringe plunger down. Using the up or
down arrows, adjust the position of the syringe plunger holder to the
proper position and insert the syringe into the holder extremely carefully
to avoid breaking the glass syringe barrel. Refer to Figure D.2 for an
illustration of proper syringe placement.

Figure D.2

Images depicting the proper syringe (left) and syringe plunger (right)
placement on the Kruss EasyDrop Contact Angle Goniometer.
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8. Using the dosing control down arrow, depress the syringe plunger until
fluid is dispensed out of the needle.

D.3

Static Contact Angle
Before running experimental samples, the static contact angle procedure should

be performed on polymer standards (EAA, PTFE, and LDPE) with HPLC water. Table
D.1 at the conclusion of this appendix summarizes the reference contact angles for these
materials.
1. Place sample on sample stage.
2. In the DSA software, go to file, menu and click “F-G window.”
3. Click on the “Live Video Feed” button (icon of video camera) and make sure the
camera and live video window are focused.
4. Increase illumination strength to 32 by going to the DSA device control panel and
“Imaging” tab.
5. Loosen the screw on the back of syringe holder to lower needle into frame. The
tip of the syringe needle should be visible on the screen within the live video feed.
Tighten the thumb screw once needle is in frame.
6. In the DSA device control panel, click the “Dosing” tab, then set the dosing
method to “Volume” and set the volume to 5 µL.
7. Press the up arrow to dispense 5 µL of fluid.
8. Using the up and down dial on the sample holder, slowly raise the sample until it
just touches the drop and the drop comes down onto the surface of the sample,
then lower the sample platform.
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9. Zoom in on the sample using the zoom dial on the camera until the drop almost
fills (~ 80%) the F-G window feed, then capture a photo of the drop using the
“Snap” button on the tool bar (icon of a camera).
10. Right click on the F-G window, go to “Drop Type”, and click on “Sessile Drop”,
then go to “Drop Subtype” and select “Normal Sessile Drop”. Also, make sure
“Auto Detect Substrate” in unchecked.
11. Right click on the F-G window, go to baseline type, and select “Linear.”
12. Click on the baseline shown in F-G window, and adjust using arrow keys. The
baseline should intersect the drop where the drop meets the substrate.
13. Go to file menu and open “Result Window”, then right click on F-G window and
select the appropriate fitting method under contact angle using.
14. Record results in lab notebook and/or data spreadsheet. Save the drop photo file.

D.4

Pendant Drop
The data collection method of pendant drop is very similar to contact angle.
1. In the DSA software, go to file, menu and click “F-G window.”
2. Click on the “Live Video Feed” button (picture of video camera) and make sure
the camera and live video window is focused.
3. Increase illumination strength to 32 by going to the DSA device control panel and
“Imaging” tab.
4. Loosen the screw on the back of syringe holder to lower needle into frame. The
tip of the syringe needle should be visible on the screen within the live video feed.
Tighten the thumb screw once needle is in frame.
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5. In the DSA device control panel, click the “Dosing” tab, then set the dosing
method to “Volume” and set the volume to 10 µL.
6. Press the up arrow to dispense 10 µL of fluid.
7. Zoom in on the sample using the zoom dial on the camera until the drop almost
fills the F-G window feed, then take a picture of the drop using the “Snap” button
on the tool bar (button has picture of a camera).
8. Right click on the FG window, go to “Drop Type”, and click on “Pendant Drop”.
Also, make sure “Auto Detect Substrate” under “Drop Subtype” is unchecked.
9. On the tool bar, select the “Baseline Detection” button (button looks like a circle
representing a sessile drop with a horizontal line through the center).
10. Click on the baseline shown in F-G window, and adjust using arrow keys. The
baseline should intersect the drop where the top of the drop meets the bottom of
the needle.
11. On the tool bar, select “Extraction” (button looks like outline of a pendant drop),
the select “FIT”.
12. Record results and save a picture of the drop.

Table D.1

Reference static contact angles for standard materials

Polymer Film
EAA

Reference Contact Angle
87-99

LDPE
PTFE

99
109-116
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Reference
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DETERMINATION OF OPTIMAL REACTION TIMES FOR PRELIMINARY EAA
SURFACE MODIFICATION STEPS
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E.1

Determination of Optimal Reaction Times for Preliminary EAA Surface
Modification Steps
Prior to grafting the light-sensitive polymers to the surface of EAA films,

preliminary chemical transformations were required to modify the surface chemistry. For
these preliminary reaction steps—conversion of carboxyl groups to acid chlorides and
then to primary amines—it was important to optimize the reactions conditions. The focus
was on identifying the shortest reaction time that allowed for complete reaction, as
assessed by FTIR, in order to streamline the synthesis steps and minimize any side
reactions or damage to the films. Figure E.1 illustrates the preliminary reaction steps: (1)
conversion of –C(=O)OH for the neat EAA film to –C(=O)Cl, and (2) subsequent
conversion of –(C=O)Cl to an amide (–(C=O)N) with a terminal NH2.

Figure E.1

Primary reaction steps for surface modification of EAA film: conversion of
carboxylic acid to acid chloride using PCl5 and subsequent conversion to
primary amines using ethylene diamine.

As seen in Figure E.1, the –OH in the EAA-Neat film was converted to –Cl using
a 0.3 g/mL phosphorous pentachloride (PCl5)/dichloromethane (CH2Cl2) solution
[Walters and Hirt, 2006]. This reaction is relatively quick, and the progression of the
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reaction was monitored using ATR-FTIR. The right side of Figure E.1 indicates the
reaction steps the films undergo after the initial primary reaction steps. These reaction
paths (“A” and “B”) are described in more detail in section 5.4.2 of Chapter 5, “Surface
Modification and Chemical Grafting of Poly (Ethylene co-acrylic acid) Films”. Figure
E.2 shows ATR-FTIR spectra of the EAA-Cl film at various reaction times.

Figure E.2

ATR-FTIR spectra of EAA-Cl films at reaction times of 0, 5, 15, 35, and
45 minutes showing progressive decrease in the acid carbonyl (at ~1700
cm-1) and increase in the acid chloride carbonyl (at ~1795 cm-1).

Evaluating the spectra, the strong peak observed in the 0 min spectrum at ~1700
cm-1 corresponds to the carbonyl stretch of carboxylic acid [Silverstein and Webster,
1998, Kupstov and Zhizhin, 1988] and the height of this peak decreases with reaction
time. The ~1795 cm-1 peak corresponds to the carbonyl stretch of acid chloride
[Silverstein and Webster, 1998, Kupstov and Zhizhin, 1988]. As expected this peak is
absent in the 0 min spectrum (EAA-Neat) but is present in all of the reacted film spectra,
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and its intensity increases progressively with reaction time. Table E.1 lists the
quantitative peak heights for the time intervals shown in Figure E.2.

Table E.1

Carbonyl peak height values for the transformation from carboxylic acid
(1700 cm-1) to acid chloride (1795 cm-1) during the reaction of EAA with
PCl5 to form EAA-Cl.
Film Reaction Time
(minutes)
0

Peak Height (Abs.),
Peak at 1700 cm-1
0.0377

Peak Height (Abs.),
Peak at 1795 cm-1
0.0000

5

0.0058

0.0258

15

0.0028

0.0286

35

0.0018

0.0269

45

0.00600

0.0269

The measured acid chloride carbonyl peak height at 35 min and 45 min are equal,
indicating the reaction is apparently complete at 35 min. To minimize any batch-to-batch
variation in yields, all EAA-PCl5 films were reacted for 45 min to ensure the reaction had
gone to completion prior to proceeding with the next step.
The second preliminary reaction that needed to be optimized was the conversion
of –(C=O)Cl to –(C=O)N with a terminal NH2. As shown in Figure E.1, the EAA-Cl to
EAA-NH2 step was achieved using a 0.0025 g/mL ethylene diamine/water solution. This
reaction progression was also monitored using ATR-FTIR. Figure E.3 shows the ATRFTIR spectra for the EAA-NH2 films at various reaction times.
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Figure E.3

ATR-FTIR spectra of EAA-NH2 films at reaction times of 0, 60, 90, and
150 min and 24 hours—with and without sonication. Sonicated films had
complete surface reaction with the ethylene diamine, while unsonicated
films contained some unreacted surface –Cl groups (presence of peak at
~1800 cm-1).

Examining the spectra, the acid chloride peak from EAA-Cl can be seen in the 0
min spectrum at ~1800 cm-1. As anticipated, this peak decreases with increasing time.
Two peaks at ~1646 cm-1 and ~1530 cm-1 are not present in the 0 minute spectrum but is
seen in all the other spectra, indicating the peak corresponds to the –NH2 reacted films.
These peaks indicate the formation of a secondary amide [Silverstein and Webster,1998,
Kupstov and Zhizhin, 1988], replacing the acid chloride of the EAA-Cl film, and
increases in intensity as time increases. The secondary amide peaks begin to appear as
early as 60 minutes, but even after 150 minutes the acid chloride peak was still present.
The films were reacted for 24 hours and still showed the acid chloride peak. After
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sonication for 24 hours, the acid chloride peak had receded and the secondary amide
peaks were fully formed, indicating the reaction had gone to completion. Table E.2 gives
numerical peak height values for the peaks of interest in the EAA-NH2 reaction series.
Table E.2

Peak height values for functional groups of interest in the reaction of EAACl to EAA-NH2.

Film Reaction Time Peak Height (Abs.), Peak Height (Abs.),
(minutes)
Peak at 1800 cm-1 Peak at 1646 cm-1

0
60
90
150
24 Hours, No
Sonication
24 Hours, With
Sonication

Peak Height
(Abs.),
Peak at 1530
cm-1

0.0269
0.0197
0.0192
0.0131
0.0054

0.0000
0.0020
0.0059
0.0078
0.0109

0.0000
0.0017
0.0037
0.0066
0.0091

0.0000

0.0182

0.0149
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GRATING OF POLY(ETHYLENE GLYCOL DIACRYLATE) TO AMINE SURFACEMODIFIED EAA FILMS

166

F.1

Introduction
The grafting of poly(ethylene glycol diacrylate) (PEGD), a difunctional polymer,

was initially going to be used to aid in the grafting of (bromomethyl)-9,9-dihexyl-9Hfluorene) (BDMF) to the amine-modified EAA films (EAA-NH2) through the terminal
acrylate groups. However, successful reaction between BDMF and EAA-NH2 was
achieved without aid from the acrylate reactive groups of PEGD. This work can be found
in section 5.4.2 of Chapter 5, “Surface Modification and Chemical Grafting of Poly
(ethylene co-acrylic acid) Films”. While the PEGD reaction was not needed to grafting of
PEGD to the EAA-NH2 films, the reaction method was successful. The procedure and
preliminary results are presented here since this reaction could be useful to another
researcher.
F.2

Results
Two different molecular weights of PEGD were investigated since it was

suspected that the additional polymer length might affect the grafting of PEGD to EAANH2 or the subsequent grafting of BDMF to the free terminal acrylate group of PEGD.
The PEGD molecular weights examined were Mn = 258 (n=4) and Mn = 575 (n=11)
(Sigma Aldrich, CAS 26570-48-9) referred to as PEGD258 and PEGD575, respectively.
The chemical structure of PEGD is shown in Figure F.1.

Figure F.1

Chemical structure of poly(ethylene glycol diacrylate) (PEGD).
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For the grafting reaction, sodium hydroxide (NaOH) was used as a base catalyst.
The molar ratio of PEGD to NaOH was 2:1, and both acetone and toluene were tested as
the solvent. PEGD was in solution with the solvent at 5 mM. The films were reacted for 5
hours at 60 C. on a hot plate. Due to the bulkiness of the PEGD chemical this reaction
takes several hours. The films were enclosed in individual vials, constantly stirred using
a magnetic stir bar, and were insulated with sand that was also heated to 60 C. The films
were all reacted concurrently. At the conclusion of the reaction time, each film was
removed with tweezers, rinsed three times with clean solvent, and then dried at room
temperature in a vacuum oven (at a pressure of 30 mmHg). A schematic of the reaction
steps in Figure F.2 shows that the terminal C=C group reduces to a single group to attach
to the terminal –NH2 of the film via the terminal carbon. The –NH2 of the EAA-NH2 film
loses an –H in order to bond with the C of the acrylate on the PEGD molecule. This is a
Michael’s addition reaction [Russell et al., 2000, Mather et al., 2006]. ATR-FTIR
spectroscopy was used to monitor the reaction progression.
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Figure F.2

Reaction scheme for the reaction of PEGD with EAA-NH2.

Figure F.3 shows the ATR-FTIR spectra for EAA-NH2 (2) and several samples of
EAA-PEGD (3a-4b) under different reaction conditions to illustrate the changes in
surface functional groups. There are several spectral differences between EAA-NH2 and
the PEGD reacted films. Three peaks in particular are of interest in the PEGD-reacted
films and located at approximately 1750 cm-1, 1240 cm-1, and 1020 cm-1. Based on the
PEGD chemical structure and the proposed reaction scheme, these peaks are associated
with the reaction of PEGD with the surface of EAA-NH2 via covalent bonding. The peak
at ~1750 cm-1 corresponds to the C=O stretching vibration of ketones present in the
PEGD structure [Bruno and Svoronos, 2006, Silverstein and Webster, 1998]. The peak at
~1240 cm-1 corresponds to the C-O stretching vibration of the esters present in the PEGD
structure [Bruno and Svoronos, 2006, Silverstein and Webster, 1998]. The vinyl
(acrylate) groups present in the PEGD structure absorb at ~1020 cm-1 [Bruno and
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Svoronos , 2006, Silverstein and Webster, 1998]. Using ATR-FTIR, the presence of
PEGD functional groups on the surface of the EAA-NH2 films confirmed the grafting of
PEGD to the EAA film surfaces.

Figure F.3

ATR-FTIR spectra of EAA-NH2 (2), EAA-PEGD575-Acetone (3a), EAAPEGD575-Toluene (3b), EAA-PEGD258-Acetone (4a) and EAAPEGD258-Toluene (4b). Spectral peaks of interest are boxed.
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NANOPARTICLES IN DRUG DIFFUSION
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G.1

Introduction
Nanoparticles have attracted increased interest in recent decades for a variety of

applications. They have been investigated for use in many applications, such as chemicals
(catalysts), biology (biosensing, bioimaging) [De et al., 2008], semiconductors, and drug
delivery [Zhang et al., 2011] and have the potential for applications in water purification,
medical diagnostics (quantum dots), and generation and conservation of energy [Card et
al., 2008]. Nanoparticles are already present in many consumer products, including
ultraviolet B radiation-protective sunscreen, topical silver nanoparticles for antimicrobial
and odor-reducing applications, and cosmetics [DeLouise, 2012; Card et al., 2008]. The
small size of nanoparticles (>100-200 nm) makes them adaptable for a multitude of
functions. Of particular interest is the use of nanoparticles in inhalation drug delivery
systems for treatment of pulmonary conditions. Some valuable properties of
nanoparticles, such as large relative surface area [Zhang et al., 2011], good solubility in
pulmonary mucus [Card et al., 2008], and surface morphology [Chow et al., 2007] make
them a promising material for inhalation drug delivery.
G.2

Characteristics of Nanoparticles
Nanoparticles have the ability to be optimally designed for particular applications.

Characteristics such as numerous particle formation techniques, narrow particle size
distribution, improved drug stability, enhanced bioavailability, continual release and
precise site targeting allow for optimization of nanoparticle systems [Chow et al., 2007].
The ability to engineer particles is advantageous for the designing of final drug products
and their precise characteristics to specific applications, the consistency of particle
properties, and development of treatment techniques for respiratory drug delivery
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systems. For example, large surface area, one of the more influential properties of
nanoparticles, results in faster drug release and shorter times to reach high drug
concentrations at the absorption site [Zhang et al., 2011]. It also increases solubility and
dissolution rate and minimizes macrophage clearance [Zhang et al., 2011].
Not all characteristics of nanoparticles positively affect the path of nanoparticles
within the respiratory system. Size-related challenges such as exhalation and mucociliary
clearance are frequently encountered. Submicron particles, such as nanoparticles, have a
higher risk of being exhaled due to their small size [Chow et al, 2007]. Holding the breath
after inhalation helps the nanoparticles deposit before being exhaled. Nanoparticles must
also be engineered with specific properties such as shape, hydrophobicity and particle
diameter [Chow et al., 2007] that are particularly advantageous for the desired quick
dissolution or sustained release drug behaviors that are pertinent to each application. By
considering these properties and designing the nanoparticle systems accordingly, the
small size challenges of nanoparticles can be overcome and even beneficial.
An additional challenge that is encountered with nanoparticles is agglomeration.
Nanoparticles can assemble into particles larger than 1 micron [Card et al., 2008]. Due to
their large surface area, nanoparticles possess high Gibbs free energy, making it
challenging to prevent agglomeration and prevent formulation instability [Zhang et al.,
2011]. Nanoparticle surface modifications can be designed to limit interactions between
particles, lessening the tendency for agglomeration and therefore increasing the
probability for inhalation and deposition in the lungs [Card et al., 2008]. In some
instances, the nanoparticle susceptibility to agglomeration may be regarded as a positive
characteristic. Controlling agglomeration in nanoparticles can result in nanoparticle
agglomerate dry powders that can be customized to the desired physicochemical
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characteristics for aerosol delivery and dissolution [El-Gendy et al., 2011]. An example
of this with asthma drugs is highlighted in Section G.4, Nanoparticles in Inhalation
Medicine.
As seen in Chapter Three with drug particles, other factors affect the deposition
and diffusion on inhaled particles. Factors such as molecular weight, pH, and charge
influence the path of the particulates in the lung. An inverse relationship between
molecular weight and diffusion coefficient has been regularly reported [Khanvilkar et al.,
2001]. It has also been found that hydrophobic particles have lower permeabilities due to
the hydrophobic nature of the mucus [Khanvilkar et al., 2001; Norris and Sinko, 1997].
Additionally, pH was found to influence the diffusion of drugs across the membrane. An
increase in pH produced an increase in diffusion coefficient and a decrease in lag time
[Shaw et al., 2005].
G.3

Fate of Nanoparticles in the Lung
The advantages of pulmonary lung delivery have previously been discussed [See

Chapters 1-3]. Using nanoparticles as a vehicle for drug delivery to the lungs presents
vast opportunities for enhanced drug efficiency. The path of nanoparticles in the lung
must be investigated so the particles can be engineered with the most essential properties
in mind. Nanoparticles, unlike larger drug particles, will deposit primarily by diffusion in
the lung after inhalation. Due to the small size of nanoparticles, convection, a critical
characteristic in micron-scale inhaled particles, is no longer a dominant factor [Zhang et
al., 2011]. It is important to note, however, that the deposition of micron-sized
agglomerates of nanoparticles is controlled by convection [Zhang et al., 2011].
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Upon landing on the pulmonary mucosal surface, the physiochemical
characteristics of the nanoparticles, particularly the size and surface chemistry, will
ultimately dictate the rate and efficiency of diffusion across the mucus layers. Ideally, the
mucus layer will enhance dissolution of the particle and help it descend further into the
mucus, first through the upper gel phase of the mucus layer and eventually through the
sol phase. Agglomerates may remain in the gel layer, or separate back into individual
nanoparticles and follow the same path of dissolution and absorption [Zhang et al., 2011].
The rate of nanoparticle absorption depends on site of deposition in the lung (varying
mucus layer and epithelial wall thicknesses) as well as nanoparticle properties such as
polarity and solubility. Polar/hydrophilic nanoparticles dissolve readily in mucus [Zhang
et al., 2011]. After absorption, the particle is uptaken by the epithelium or alveolar
macrophages [Zhang et al., 2011]. Some nanoparticles may transport across the epithelia
and into the bloodstream. From the bloodstream nanoparticles may reach organs or sites
such as lymph nodes or bone marrow [Sung et al., 2007].
G.4

Nanoparticles in Inhalation Medicine
The vast amount of research that has been published has demonstrated the

potential of nanoparticles for treatments of lung conditions. In 2007 alone over 200
scientific publications related to engineered nanoparticles were published [Card et al.,
2008], a significant increase from the late 1990s when annual publications were below
fifty for engineered nanoparticle studies. Since initial investigations into the use of
nanoparticles for drug delivery began in the 1960s [Sung et al., 2007], several methods of
delivering nanoparticles into the lung for therapeutic actions have been developed.
Nanoparticles can dissolve, entrap, or encapsulate the drug or be physically or chemically
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adsorbed to the active drug [Sung et al., 2007; Parveen et al., 2012]. Their small size
allows them to efficiently penetrate barriers and into individual cells, which reduces
negative side effects and increases the therapeutic effect [Parveen et al., 2012].
Nanoparticles used in biological systems are typically synthetic biodegradable polymeric
particles, and the degradation of these materials can be manipulated to control the drug
release rate [Sung et al., 2007]. The wide range of delivery methods have enabled
nanoparticles to be effectively designed and researched as potential methods for the
treatment of many pulmonary illnesses, including lung cancer, tuberculosis, and asthma.
The broad spectrum of diseases with nanoparticle research is a significant contribution to
the future of inhalation nanoparticle treatments. Several examples of nanoparticle-based
delivery methods currently being studied are outlined below.
Anticancer drugs are known to cause severe negative side effects in cancer
patients. Studies have been conducted for the potential uses of inhalation routes for
delivery of the chemotherapy drugs. Due to unresolved systemic side effects and toxicity
issues that limit the amount of drug that can be administered, pulmonary delivery systems
still face many challenges before they can be employed in regular cancer treatments [Roa
et al., 2011]. Nanoparticles, however, can be targeted to specific cell types and combine
the concepts of specific directed drug delivery and the benefits of using nanoparticles for
lung cancer treatment [Roa et al., 2011]. A study was conducted using doxorubicinloaded nanoparticles in H460 and A459 lung cancer cells in mice. It was determined that
inhaled doxorubicin nanoparticle powders increased survival time in affected mice
compared to intravenous administration of the same dosage of drug [Roa et al., 2011].
Nanoparticles have also been investigated in the treatment of tuberculosis (TB).
Therapeutic plasma levels of antitubercular drugs increased for up to 6 days when guinea
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pigs took a single inhaled dose of aerosolized poly (DL-lactide-co-glycolide)
nanoparticles doped with the drugs isoniazid, rifampicin, or pyrazinamide [Card et al.,
2008]. Repeated inhalation treatments had higher levels of therapeutic plasma drug levels
success than more frequent oral administration of the antitubercular drugs [Card et al.,
2008]. Another study (in vivo) on guinea pigs found that the same drugs (isoniazid,
rifampicin, or pyrazinamide) were more effective than oral drug administration when
encapsulated in alginate nanoparticles and administered through inhalation [Zahoor et al.,
2005; Card et al., 2008]. By investigating the use of nanoparticles to (1) target alveolar
macrophages that harbor TB bacilli and (2) sustain high drug concentrations in the lung
[Misra et al., 2011], the future of nanoparticle aerosol treatment for TB remains
promising.
Asthma is yet another condition that nanoparticles have been demonstrated as a
successful treatment option. Most pharmaceutical drugs used to treat asthma have particle
sizes between 1-5 μm, which is the ideal particle size to prevent exhalation or
mucociliary clearance that occurs with smaller particles [El-Gendy et al., 2011]. To avoid
the clearance of nanoparticles from the lung, nanoparticle size asthma drugs have been
purposely agglomerated and evaluated for their potential as treatments for asthma.
Suspensions containing agglomerated nanoparticles were used to develop aerosols of the
asthma medications albuterol and fluticasone. Additionally, an aerosolized blend of dried
agglomerated fluticasone and albuterol in solution was evaluated [El-Gendy et al., 2011].
Powders of the single drug agglomerates or combined therapeutics possessed desirable
aerodynamic properties, particle sizes, and also increased surface area resulting in 75%
total deposition compared to only 22-30% total deposition as has been reported for
albuterol administered through metered-dose inhaler [Dhand, 2005]. The powders of the
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single drug agglomerates or combined therapeutics also experienced increased
dissolution [El-Gendy et al., 2011] over traditional micron-sized single drug particles.
The formulation presented in this thesis presents promising data and conclusions that
immensely support further development of nanoparticles as treatments for asthma.
G.5

Toxicity of Nanoparticles
Nanoparticle toxicity is a highly debated topic in regards to patient side effects in

nanoparticle research. Much of the nanoparticle toxicity investigation stems from
negative environmental factors such as air pollution, industrial exhaust, and naturally
occurring nanoparticles (viruses or allergens [DeLouise, 2012]). The ability of these
ambient ultrafine particles (particles with an aerodynamic diameter >100 nm) to diffuse
through the pulmonary mucus and through the epithelial and endothelial cells to organs
and even the central nervous system is cause for concern and further investigation. Due to
the large surface area of nanoparticles, which as previously been discussed, nanoparticles
are biologically active and have the physiochemical properties to enter through the lungs
and other body systems. Environmental (urban and industrial) nanoparticles are generally
insoluble in the pulmonary mucus and lung and non-biodegradable materials, such as
carbon black, carbon nanotubes, ultrafine asbestos, silica, and metal-based nanoparticles
such as titanium dioxide [Card et al., 2008]. Therapeutic nanoparticles are biodegradable
[Sung et al., 2007] and therefore affect the body differently.
In light of the detrimental effects environmental nanoparticles have demonstrated,
the effects of engineered nanoparticles are also under investigation. Engineered
nanoparticles have distinctive and specifically designed properties that render them
valuable to treat lung ailments and are biologically degradable [Sung et al., 2007], unlike
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environmental nanoparticles. While engineered nanoparticles could potentially trigger
adverse pulmonary effects on the respiratory system, most engineered nanoparticles are
intended for treatment purposes and are designed to avoid any detrimental effects. There
is an extreme lack of knowledge regarding toxicity of engineered nanoparticles and a set
of guidelines needs to be established in order to have a common scale to compare
potential toxicities of multiple types of nanoparticles [Card et al., 2008].
G.6

Conclusions
From the concise summary of published studies and nanoparticle characteristics

presented here, it is clear that the exploration into nanoparticle-based pulmonary lung
drug delivery applications is only just beginning. Initial results have yielded positive
results for the ability of nanoparticle-based therapies to improve respiratory conditions,
and have provided a foundation to direct the development of future nanoparticle-based
drug delivery methods. Engineered particles can overcome obstacles of sub-micron sized
particles and existing aerosol drugs. The precise design and targeted drug delivery
potential make nanoparticulate therapy an area that deserves further investigation.
A successful, validated method for the determination of diffusion coefficients for
aerosol drugs through a representative pulmonary mucus has been previously discussed
in Chapter 6 of this thesis. This method could also be applied to other biological fluids of
interest. These diffusivities are necessary to model the transport properties of these drugs
and in turn, nanoparticles in assessing their bioavailability in the lung, regardless of
origin (environmental or engineered). Modeling the diffusion coefficients of
nanoparticles will enhance past and present studies on the potential of nanoparticles for
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drug delivery as well as studying the effects of industrial or naturally occurring
nanoparticles on the lung.
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